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Regulation of gene expression, which is essential for the unfolding of all processes taking 
place in multicellular organisms, is very complex. Gene expression is controlled at the level of 
transcription, RNA processing and localization, translation and protein modification and 
decay. Among the various post-transcriptional regulators of gene expression, microRNA 
(miRNA)s contribute to the maintenance of gene expression patterns among various cell 
types in an organism. miRNAs are small, evolutionarily conserved non-protein coding RNAs, 
whose biogenesis involves multiple steps in the nucleus and cytoplasm of the cell. So far 
35,828 miRNAs have been reported from 233 species and in humans they are present as one 
of the abundant gene families comprising over 2500 miRNAs. Mature miRNAs are loaded into 
Argonaute (AGO) proteins to form RNA induced silencing complexes (RISC), which find their 
targets via nucleotide complementarity between sites mostly present in 3’ untranslated 
region (3’UTR)s of mRNAs and miRNAs. The outcome is destabilization or translational 
repression of the miRNA targets. Although the components of miRNA biogenesis are 
relatively well characterized, the mechanisms through which miRNAs execute their functional 
activities remain less understood. In the first chapter of this thesis, we have addressed two 
important aspects of miRNA mediated gene regulation. 
Differential expression analysis based on high-throughput data sets generated upon 
modulating the expression of a given miRNA in a given model has helped to identify miRNA 
targets. Many computational target prediction models have been proposed. They are 
typically trained on high-throughput data sets, and are based on few parameters such as 
seed complementarity of targets, evolutionary conservation etc. Validation of predicted 
miRNA targets remains non-trivial and we believe that one reason could be lack of methods 
that consider the miRNA activity at multiple levels. An aspect that has been largely ignored so 
far is the time scale on which miRNAs regulate their targets. In one study we have addressed 
the kinetics aspects of miRNA regulation, and proposed a model that takes these aspects into 
account. The parameters of this model were inferred from a variety of low and high-
throughput experimental data sets and we found that the model well describes the time 
dependent changes in the level of mRNA, proteins and ribosome density levels upon miRNA 
transfection and induction. We also found that miRNAs may not generally act as fast 
regulators of gene expression due to two bottlenecks, one is the miRNA loading into 
Argonaute proteins and the other is the rate of protein decay. These influence the time-scale 
and magnitude of miRNA mediated gene regulation. 
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Several recent studies have indicated that the miRNA binding sites present in the coding 
region (CDS) of an mRNA are functional, but their implications remain unclear. Use of high-
throughput approaches such as cross-linking and immunoprecipitation (CLIP) to isolate AGO 
bound target sites indicate that there are as many sites located in CDS as in 3’UTRs. The 
second study presented in this thesis concerns itself with the function of coding region-
located miRNA binding sites. Using published high-throughput data sets of Argonaute CLIP 
and ribosome protected fragment profiles upon miRNA transfections, we have shown that 
miRNA binding sites that are located in CDS and 3’UTRs have co-evolved and have similar 
sequence and structure properties. We also found that the miRNA binding sites located in 
CDS are capable of inhibiting translation, while those located in 3’UTR are more efficient in 
triggering mRNA degradation. This particular observation was validated experimentally using 
an inducible miRNA expression cell line, and with a luciferase reporter system containing CDS 
located binding sites of the cognate miRNA. Our study therefore suggests that miRNAs may 
co-target CDS and 3’UTR to fine-tune the time scale and magnitude of the post-
transcriptional regulatory effect imposed by them. 
Recent studies reported that miRNAs from miR302/367 cluster enhance the somatic cell 
reprogramming induced with embryonic stem cell (ESC) specific transcription factors: OCT4, 
SOX2, KLF4 and c-MYC. Few other reports also claimed that miR-302/367 cluster alone is 
enough to reprogram somatic cells to induced pluripotent stem cell (iPSC)s. However, the 
mechanisms underlying the miRNA mediated reprogramming are not clear. We tried to 
establish the miR-302/367 mediated reprogramming of fibroblasts in the primary mouse 
embryonic fibroblast (MEF)s, but, similar to other labs, we were unable to reproduce the 
initial result. However, we have succeeded in enhancing the reprogramming efficiency in the 
secondary transgenic mouse embryonic fibroblasts (TNG)-MEFs that contained a 
pluripotency marker “Nanog” tagged with a green fluorescent protein, along with miR-
302/367. Apart from miRNAs, other post-transcriptional regulators we have focused in this 
thesis are tissue specific splicing factors.  Recent evidence indicated that knockdown of 
muscle blind like (MBNL) proteins enhance the reprogramming efficiency. Our own analysis 
of already published mRNA-seq data sets of iPSCs and their parental cells also showed that 
the tissue specific splicing factors are differentially expressed between iPSCs and their 
parental cells. Especially ESRP1, ESRP2 and MSI1 showed striking changes in their expression 
levels during the course of reprogramming. Based on this analysis we hypothesized that 
these factors may enhance the reprogramming efficiency. To investigate this hypothesis we 
again used secondary TNG-MEFs as a model and we have transduced them with both 
lentiviruses and retroviruses as carriers to deliver our candidate splicing factors. Our 
experiment indeed revealed an increase in the reprogramming efficiency of 1.4 fold to 2 fold, 
with ESRP2 showing highest enhancement. As a follow up of these experiments, we aim to 
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decipher the cascade of events through which miR-302/367 and splicing factors enhance the 
efficiency of reprogramming induced by the ESC set of transcription factors. Since the major 
changes involved in reprogramming occur during the early and late phases, we plan to 
perform an early and late time series of mRNA profiling upon the induction of 
reprogramming with miR-302/367 and splicing factors in secondary TNG-MEFs. 
In conclusion this thesis presents two main contributions to the field of miRNA-based 
regulation of gene expression. The first is a mathematical model that describes the kinetics of 
miRNA dependent gene regulation and the second shows that the miRNA binding sites 
located in CDS sites are functional and are more effective in inhibiting translation than the 
sites present in 3’UTR.  Besides these two studies, I have obtained evidence that tissue 
specific splicing factors, in particular ESRP1, ESRP2 and MSI1 are able to enhance 
reprogramming efficiency up to 2 fold. Experiments are under way to uncover the 
mechanisms involved in the enhancement of reprogramming efficiency by tissue specific 
factors.  
Since relatively little is known about the function of alternative splice forms in iPSC 
generation, these preliminary studies could set the ground for future research in iPSC and 
also towards clinical research. Being able to obtain iPSCs with more efficient and safer 
methods will enable studies of various diseases at the clinical level. On the other side, as 
miRNAs are currently being considered for various therapeutic approaches, a deeper 
understanding of the underlying mechanisms by which miRNAs regulate gene expression 
would help in the better design of therapeutic compounds. The work presented in this thesis 
may thus be beneficial for both the miRNA and the iPSC fields. 
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Chapter 1 
1. Fundamentals of gene regulation 
1.1 Introduction 
Life on this planet has evolved tremendous variety, from unicellular to multicellular 
organisms. They span a wide range of sizes, from the smallest microorganisms like 
parasitic bacteria to the blue whale, which is considered to be one of the largest animals 
to have existed. Nevertheless, regardless of size, all organisms are composed of 
fundamental units, which are the cells. Based on morphology, metabolism, and sub-
cellular organization, two types of cells are known, prokaryotic or eukaryotic. Most 
multicellular organisms are eukaryotic, and in general prokaryotes are unicellular, with 
few exceptions like myxobacteria [1]. There remain many unknowns about the 
evolutionary transitions from prokaryotic life to eukaryotic life and from uni-cellularity to 
multi-cellularity. However, it is likely that ability to adapt to changes in environment by 
expressing different sets of genes and thereby cellular phenotypes was an important 
factor in this process. The emergence of development is even more remarkable in this 
respect because it involves “running” coherent gene expression programs that are 
encoded in the genome, over quite long periods of time.  
1.1.1 Gene regulation 
The “expression” of the genetic material is what distinguishes different cell types within 
an individual. During embryonic stages, the pluripotent stem cells that constitute the 
embryo express the same set of specific transcription factors that are responsible for 
initiating the transcription of “pluripotency” genes, which maintain the embryonic state. 
At some point however, through mechanisms that are intensely studied currently, 
differentiation towards various lineages is initiated. The processes that underlie the 
change in gene expression at different stages of the development or in response to the 
intracellular or extracellular environments are denoted by the term “gene regulation” [2]. 
Essentially every step of gene expression is regulated, including transcription from the 
DNA template and translation of messenger RNA (mRNA)s into proteins. Cell growth, 
proliferation, apoptosis, metabolism, differentiation rely on specific regulators to establish 
the appropriate gene expression patterns. For instance, increased expression of genes 
such as the polo like kinase1 (PLK1) and BUB1 mitotic checkpoint serine/threonine kinase 
(BUB1) are associated with high proliferation, whereas cyclin (CCN)s CCNE1, CCND1 and 
CCNB1 take part in cell cycle regulation [3]. A remarkable example of how vital 
transcriptional gene regulation could be is the induction of pluripotency in somatic cells by 
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the ectopic expression of pluripotency-associated genes like OCT4, SOX2, KLF4 and c-MYC 
[4]. Another classic example is the conversion of fibroblasts to myoblasts by the ectopic 
expression of MyoD [5]. These observations (as well as many others that have emerged 
since the landmark paper of Yamanaka and colleagues [4]) make the point that 
differentiation is a reversible process, where the appropriate manipulation of gene 
expression, via a remarkably small number of transcription factors, can lead to a desired 
cellular phenotype [4-6].  
Not surprisingly, altered gene expression as a result, for instance, of mutations, can lead 
to pathological conditions [7]. For instance, spinal muscular atrophy [8] is caused by 
mutations in the SMN1 gene. Somatic mutations that cause misregulation of genes 
associated with cellular functions like cell growth, proliferation, division, migration and 
foreign tissue invasions have been observed in various types of cancers [9, 10].  
1.1.2 Transcription 
Characterizing the mechanisms by which gene expression is regulated has been a most 
active field of research ever since the central dogma of molecular biology was proposed 
[11]. As already mentioned, gene expression is regulated at virtually all major steps 
including transcription, mRNA processing, mRNA stability, transport to the cytoplasm and 
translation [12]. General transcription factors (GTFs) [13] such as TFIIA, TFIIB, TFIID TFIIE, 
TFIIF and TFIIH [14] act together with the DNA-dependent RNA polymerase II (RNAP II)  to 
form a basal transcriptional machinery and maintain the basal transcription in a cell. 
Condition-specific transcription is regulated through the binding of sequence specific 
transcription factors to cis-acting regulatory elements that are typically located upstream 
of genes, in the core promoter region, but also distally, in enhancers, silencers, insulators 
and “locus control regions”. Trans-acting transcription factors can either activate or 
repress expression of a gene [15, 16].  
Sequence specific transcription factors along with RNAP II and GTFs form a transcription 
pre-initiation complex at the core promoter region to initiate transcription. Synthesis of 
protein coding mRNAs is carried out by RNAP II in the nucleus. RNAP II is made of 12 
subunits, with Rbp1 being the largest [17]. A distinctive feature of RNAP II is the extended 
carboxyl terminal domain (CTD) residing on the Rbp1 subunit. The CTD coordinates pre-
mRNA synthesis and processing. It recruits complexes responsible for chromatin 
remodeling, histone modification to initiate the transcription. Changes in the 
phosphorylation state of the serines or threonines of the CTD is a defining factor in the 
recruitment of complexes responsible for pre-mRNA processing such as capping, splicing 
and 3’-end formation [14, 18, 19]. The mature mRNA, along with various RNA binding 
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protein (RBP) complexes is exported to the cytoplasm for translation by ribosomes [20, 
21]. 
Figure 1: Main steps of gene expression. (A) All protein-coding genes are transcribed by RNA polymerase II 
(RNAP II), which has a characteristic carboxyl terminal domain residing on the largest subunit of RNAP II. The 
phosphorylation status of the serines or threonines of CTD direct the recruitment of variety of complexes 
responsible for the processing of pre-mRNAs. (B) Pre-mRNAs transcribed in the nucleus undergo co/post-
transcriptional processes such as capping, splicing, polyadenylation to form a mature mRNA which will 
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further exported to the cytoplasm where they are subjected to translation (C) by the ribosomal machinery 
to form proteins. 
Translation is also subject to regulation, as will be described later in this thesis. The main 
steps of gene expression and the corresponding regulatory processes are briefly 
summarized in Figure 1. 
1.1.3 Co- and post-transcriptional mRNA processing and its regulation 
1.1.3.1 Five-prime capping 
The 5’ cap is the first modification to be acquired by a nascent mRNA. The cap is a 7-
methylguanosine (m7G) structure, whose function is primarily to protect the pre-mRNA 
from 5’-3’ exonucleases.  The formation of the cap structure involves a series of enzymatic 
reactions. First a triphosphatase enzyme removes a phosphate molecule from the 5’ 
terminus of the nascent mRNA, and then a guanosine monophosphate (GMP) is added by 
the enzyme guanylyltransferase to form the G(5’)ppp(5’)N cap. The cap is eventually 
methylated at the 7th position of guanosine by an RNA methyltransferase enzyme to give 
m7G cap [14, 22]. The first two capping enzymes are directly associated with activated CTD 
of RNAP II, and act on the nascent mRNA. Capping is important for the completion of 
transcript elongation by RNAP II [23]. Additionally, the cap binding protein (CBP) is 
recruited at the cap structure to form a complex that is important for further processing 
of the pre-mRNA in pre-mRNA splicing, pre-mRNA 3’end formation and for the nuclear 
export of RNA [24].  
1.1.3.2 Polyadenylation 
Protection of mRNA 3’ ends from 3’-5’ exonucleases is due to another modification, 
polyadenylation, which further assists in the nuclear export of mature mRNAs and in their 
efficient translation in the cytoplasm [24]. A complex of proteins such as the cleavage and 
polyadenylation specificity factor (CPSF) that binds to an AAUAAA element, the cleavage 
stimulatory factor (CstF) that binds to U/GU rich downstream elements and the cleavage 
factor Im (CFIm) that recognizes UGUA motifs lead to the recruitment of cleavage factor 
IIm (CFIIm) and poly (A) polymerase. The pre-mRNA is cleaved approximately 20 
nucleotides downstream of the AAUAAA polyadenylation signal and a long stretch of 
adenines is added by the poly(A) polymerase [25]. The CTD of RNAP II facilitates the 
formation of the 3’-end processing complex [26-28]. 
1.1.3.3 Pre-mRNA splicing  
Over 90% of nascent pre-mRNA is in fact noncoding sequence, in the form of introns. The 
removal of intronic sequences and joining of the remaining, largely coding sequences 
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called exons occurs by a co/post-transcriptional mechanism called splicing [14]. Most of 
the human genes undergo alternative splicing to give rise to different protein isoforms, 
which frequently differ in their biological activity [29]. For instance the Fas receptor 
undergoes alternative splicing to produce both soluble and membrane bound protein 
isoforms, with opposing effects on apoptosis [30]. In Drosophila melanogaster, the Down 
syndrome cell adhesion molecule (DSCAM) gene can theoretically give rise to more than 
38,000 variants, more than the total number of genes [31-33]. Thus, splicing contributes 
to diversity in the proteome.  
1.1.3.4 Types of alternative splicing  
The locations where the pre-mRNA cleaved to remove the introns and join the exons are 
called splice sites [34]. Most exons in an mRNA are constitutive, they will be included in 
the majority of transcripts. Other exons, also known as “cassette exons” are included in 
some but not all of the transcripts [35]. Another common splice variation consists of small 
changes in the location of the splice site, which leads to variations in the length of exons. 
The 5’ terminal exons can further vary through an alternative choice of the promoter 
followed by alternative splicing, while the 3’ terminal exons can vary due to alternative 
splicing and alternative polyadenylation [36]. Retention of introns has also been described 
[33]. These major types of splicing are depicted schematically in Figure 2. 
1.1.3.5 The splicing reaction 
From the in vitro studies of radiolabelled pre-mRNA incubated in HeLa nuclear extract, it 
became evident that removal of introns and joining of exons is carried out in two steps 
[37-39].  In the first step, a trans-esterification reaction is triggered when the 2’hydroxyl 
group of adenosine at the branch site attacks the 3’-5’ phosphodiester bond of the 5’ 
splice site to cleave the 5’ intron from the exon. The 5’ guanosine end of the intron 
becomes attached covalently to the adenosine of the branch site through a 2’-5’ 
phosphodiester bond. This generates two intermediates, the cleaved off 5’exon and the 
intron attached to the 3’ exon in a branched circular configuration. The second step also 
involves a trans-esterification reaction in which a 3’ hydroxyl group of 5’ exon attacks the 
phosphodiester bond of the 3’ splice site releasing the branched intron and joining the 
exons [40, 41]. The outline of the splicing reaction is depicted in Figure 2H. 
The 5’ splice sites are defined by a consensus sequence, GURAGU (where G: guanine U: 
uracil A: adenosine R: any purine). The 3’ splice site has three elements: a branch site with 
the consensus YNYURAY (where Y is any pyrimidine), a polypyrimidine tract, and a YAG 
splice acceptor site [42, 43]. Recognition of these elements by the spliceosome complex is 
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essential for gene expression particular in higher eukaryotes, in which the majority of 
transcripts consist of multiple exons. 
The spliceosome is composed of small nuclear RNAs (snRNAs) and several auxiliary 
proteins. Five snRNAs, U1, U2, U4, U5, and U6, form the small nuclear ribonucleoprotein 
particles (snRNPs) that are involved in the assembly of spliceosome complex on the pre-
mRNA.  Spliceosome assembly on the splice sites begins by recognition of the 5’ splice site 
by U1 snRNP, the binding of splicing factor (SF1) to the branch point, and the binding of 
U2 auxiliary factor (U2AF) to the polypyrimidine tract and 3’ terminal AG [44]. This initial 
complex undergoes extensive conformational changes; SF1 is replaced by U2 snRNP at the 
branch point, and further recruitment of U4/U6-U5 tri-snRNP complex occurs to make a 
catalytically active spliceosome complex [45].   
Figure 2: Types of alternative splicing and sketch of the splicing reaction. The simplest described splice 
variations are shown (combinations thereof can occur within a transcript).  (A) A cassette exon can be 
included or excluded from the mRNA (exon skipping). (B, C) Changes in the selection of alternative 5’ and 3’ 
splice sites leads to isoform in which the affected exons have different lengths. (D) An intron can sometimes 
be retained.  (E) Mutually exclusive exons are exons that not selected together in a transcript. (F, G) 
Selection of alternative promoters or polyadenylation sites can also lead to different choices of internal 
exons. (H) The splicing reaction involves two trans-esterification steps, wherein the first step the 5’exon is 
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detached and an intron/3’exon fragment forms a branched structure and in the second step two exons are 
ligated and branched structure is released. 
1.1.3.6 Cis and trans-acting elements of splicing 
Splice sites can be weak or strong, presumably depending on their affinity for splicing 
factors.  These differences in the strength of splice sites open the possibility for regulating 
the binding of splicing factors by other RNA-binding proteins. This involves cis-acting RNA 
sequence elements and trans-acting protein regulators. Cis-acting elements include exonic 
splicing enhancers (ESEs), exonic splicing silencers (ESSs), intronic splicing enhancers (ISEs) 
and intronic splicing silencers (ISSs) [46], whereas trans-acting factors include proteins of 
the Ser/Arg (SR) family and heterogenous nuclear RNPs (hnRNPs) [47, 48].   
Members of the SR protein family typically bind to ESEs. They recruit the U1 snRNP to 5’ 
splice site and the U2AF and U2 snRNP to the 3’ splice site [49, 50]. Studies showed that 
SR proteins also have RS (Arg-Ser) domains with which they bind to several regulatory 
factors such as transformer2 (TRA2), and SR-related nuclear matrix proteins (SSRM1 and 
SSRM2) to enhance splicing [51, 52]. Phosphorylated SR proteins act as sequence-
dependent splicing activators [53], whereas dephosphorylated SR proteins bind to a 
regulatory protein, SRp38, to act as splicing repressors [54]. . 
In contrast to ESEs, ISSs are generally known to bind to hnRNPs, a class of proteins known 
to be associated with the unspliced pre-mRNA (hnRNA- also called heterogenous nuclear 
RNA). hnRNPs have both RNA binding domains as well as protein-protein interaction 
domains [55]. Of the various hnRNPs, only few hnRNPs have well characterized roles in 
splicing. For example, hnRNPA1, hnRNPA2 and hnRNPH mostly share mechanisms to 
inhibit splicing, promote exon skipping, and participate in 5’ splice site selection. A recent 
study showed that hnRNP L binds to an ESS to inhibit the pairing of U1 and U2 snRNPs and 
promote exon skipping in the CD45 pre-mRNA [56]. In another report, a U-rich element 
present adjacent to the 5’splice site of the K-SAM exon of the FGF2 transcript was shown 
to bind to the TIA-1 protein, this binding interferes with spliceosome assembly and 
induces U1 snRNP to bind to 5’ splice site [57]. Like other steps of gene expression, 
splicing is also regulated in a combinatorial manner. For example hnRNP A1 and the SR 
proteins SF2 and SC35 have antagonistic effects on the splicing of β-tropomyosin exon 6B 
[58], whereas SR protein SFRS7 and the hnRNPs F and H compete to regulate the splicing 
of exon2 in α-tropomyosin [59]. HnRNPH and hnRNPF have also been reported to act 
positively on splicing as part of intronic splicing enhancer complexes with KSRP and PTB 
[60, 61]. 
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1.1.3.7 Tissue-specific splicing 
Alternative splicing is part of tissue-specific programs of gene expression and is based on 
the differential expression of splicing regulatory proteins between tissues. High-
throughput technologies like micro-arrays and RNA sequencing have revealed the breadth 
of alternative splicing that occurs as a consequence of combinatorial effects of various 
splicing regulatory proteins [62]. The brain appears to have the highest occurrence of 
alternative spliced isoforms which is due to the expression of a number of brain-specific 
splicing factors such as neuro-oncological ventral antigen (Nova)1, Nova2 and nuclear 
polypyrimidine tract-binding proteins (nPTB) [63]. nPTB is expressed in neural progenitor 
cells, but its expression is downregulated in the differentiated neurons [64], whereas 
Nova1 and Nova2 are differentially expressed in various regions of the nervous system, 
with Nova1 being expressed in hindbrain and spinal cord, and Nova2 being highly 
expressed in neocortex and hippocampus [65, 66].  Similarly, epithelial cells express the 
RBM35a (ESRP1) and RBM35b (ESRP2) splicing factors, which regulate the expression of 
epithelia-specific exons. Downregulation of ESRP1 leads to the loss of epithelial splicing 
during epithelial to mesenchymal transition (EMT) [67, 68].  
1.1.4 microRNAs 
A recently discovered class of post-transcriptional regulators is the small regulatory non-
coding RNAs called microRNAs (miRNAs). As the first part of my PhD dealt with regulation 
of gene expression by miRNAs, here I describe in some detail miRNA biogenesis, their 
functions and mechanisms through which miRNAs regulate gene expression.  The 
biogenesis and functions of miRNA are shown schematically in Figure 3. 
1.1.4.1 Discovery 
The first report of a miRNA (lin-4) came into light in 1993, when Victor Ambros and 
colleagues reported that lin-4 represses the heterochronic lin-14 gene, which plays a role 
in the transition of Caenorhabditis elegans (C.elegans) between larval stages [69]. 
However, it was not until Gary Ruvkun and his colleagues reported in 2000 that let-7 
miRNA is a 21-nucleotide RNA that is complementary to elements in 3’UTRs of several 
heterochronic genes, whose expression it probably regulates [70], that the field started to 
expand dramatically. A series of studies that emerged in rapid succession catalogued 
miRNAs in fly, zebrafish, mouse and human [71-73]. To date, 35,828 miRNAs have been 
reported from 233 species, many being conserved over large evolutionary distances [74]. 
MiRNAs form one of the most abundant gene families, which comprises over 2500 
miRNAs in humans [74]. Most human genes are in fact regulated by miRNAs and a protein-
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coding mRNA typically contains binding sites for one or more miRNAs in its 3’ untranslated 
region (UTR).  
Figure 3: Biogenesis and functions of miRNAs: miRNA genes are transcribed by RNA polymerase II as 
primary-miRNA (pri-miRNA), which are processed by Drosha-DGCR8 complex to make precursor-miRNA 
(pre-miRNA). Pre-miRNAs are then exported to the cytoplasm via the RanGTP-Exportin5 complex, and 
further processed there by the Dicer-TRBP complex to yield a mature miRNA-miRNA* duplex. The mature 
miRNA is loaded into an AGO protein to form an RNA-induced silencing complex (RISC) and this complex is 
guided by miRNA to an mRNA target to exert its functions. The AGO-GW182 complex induced miRNA-
dependent target degradation by recruits the CAF1-NOT1-CCR4 deadenylase complex to trigger 
deadenylation of target mRNAs. MiRNAs also repress translation of target mRNAs via AGO which competes 
with translation initiation factor eIF4E in binding to cap structure to block assembly of ribosomes. 
1.1.4.2 Transcription and nuclear processing of miRNAs 
MiRNAs are mostly located in the introns of coding and non-coding transcripts, and their 
expression is controlled by the promoters of the host transcripts.  A few studies reported 
that miRNA have independent transcription start sites [75, 76]. Thus, for most miRNAs, 
promoters can be identified by collectively analyzing the data from mRNA sequencing 
(mRNA-seq), mapping of CpG islands and chromatin-immunopreciptation sequencing 
(ChIP-seq). For instance, association of RNAP II with the promoter of miR-23a~27a~24-2 
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cluster was revealed from ChIP data [77]. Some miRNA genes are organized in 
polycistronic transcription units, from which the miRNAs are co-transcribed [78]. Although 
some miRNAs like let-7 are deeply conserved in evolution [70], the targets seem to evolve 
rapidly [79]. The activities of individual miRNAs in a polycistronic miRNA cluster may 
differ. For instance, the most conserved miRNA cluster, mir~100~let-7~mir-125 plays a 
role in the development of invertebrates. In mammals it is only let-7 and no other miRNAs 
that is downregulated during early stages of development [80]. 
Although α-amanitin (an RNAP II inhibitor) sensitivity experiments showed that mammalian 
miRNAs are transcribed by RNAP II (and not by RNA polymerase-I (RNAP I) or RNA 
polymerase-III (RNAP III) [77, 81]), some viral miRNAs are transcribed by pol-III. For 
instance, miRNAs from a mouse virus, MHV68, are encoded in tRNA-like primary 
transcripts, which are transcribed by Pol-III [82]. In animals, transcribed primary-
microRNAs (pri-miRNAs) are usually kilobases (kbs) long, have cap structures at the 5’ end, 
miRNA-encoding stems of up to 35 base pairs (bp), stem terminal loop and a poly(A) tail 
[83]. Pri-miRNAs are processed in the nucleus by the RNase III enzyme Drosha together 
with its essential co-factor DGCR8. The two proteins form the so-called microprocessor 
complex [84]. Drosha is a ~160 kDa protein which has two RNase III domains (RIIIDs) and a 
double stranded RNA binding domain (dsRBD) at its carboxy-terminal end. Cleavage of the 
pri-miRNA by Drosha defines the 5’ terminus of the so-called 5p miRNA, which is encoded 
in the 5’ arm of the pre-miRNA hairpin structure. Because the sub-sequences located at 
the 5’ end of the mature miRNA is important for function [85], Drosha can thereby 
determine the miRNA specificity. One RIIID of Drosha cuts the pri-miRNA at 11bp away 
from the junction of single and double stranded RNA and the second RIIID cuts the pri-
miRNA at 22bp away from the junction linked to the terminal loop [83, 86]. This 
processing gives rise to precursor-miRNAs (pre-miRNAs), which are exported to the 
cytoplasm by a nuclear protein called exportin5 (EXP5), encoded by XPO5 gene. EXP5 
together with pre-miRNA and Ran-GTP (Ran-guanosine triphosphate) forms a transport 
complex that translocates the pre-miRNA. This complex is dissociated by the hydrolysis of 
GTP to release the pre-miRNA into the cytosol [87]. 
1.1.4.3 Cytoplasmic processing of miRNAs 
In the cytoplasm, another type III RNase enzyme, Dicer, together with transactivation 
responsive RNA-binding protein (TRBP) cleaves off the terminal loop to release a small 
RNA duplex. Dicer recognizes a two-nucleotide 3’ overhang, generated by Drosha, and 
cleaves the precursors at a distance of 21-25 nucleotides from the 3’ end of the terminus. 
The levels of Drosha and Dicer are regulated by their binding partners, DGCR8 and TRBP, 
and vice versa [86, 88].  Dicer is a 200 kDa protein, which also has two RIIIDs which form a 
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catalytic center located as in Drosha, at its carboxyl terminus. At the amino terminus Dicer 
has a helicase domain, DUF283, which functions in the recognition of pre-miRNAs [89].  
Dicer releases a small double stranded duplex, which contains both mature miRNA or 
guide strand and its complementary strand known miRNA* or the passenger strand.  Only 
one of the two strands is generally loaded onto an Argonaute (AGO) protein to form a pre-
RNA induced silencing complex called RISC [90]. For some miRNAs, both strands of the 
duplex can be loaded with comparable efficiency into AGO, and in these cases, the mature 
miRNAs are named based on the miRNA gene name, to which the 5p or 3p suffix is 
appended [86].  
1.1.4.4 Strand selection 
Dicer and its counterpart TRBP not only cleave the pre-miRNA, but also assist in the 
loading of the small RNA onto the AGO protein [91]. The strand that is loaded into AGO, 
also called the “guide strand” is selected by AGO protein based on the thermodynamically 
stability of the two ends of the duplex. That is, the end that is least stable gives the small 
RNA whose 5’end will be anchored in the AGO protein to form the RNA-induced silencing 
complex (RISC) [92, 93]. After the guide strand selection, in an ATP-independent 
biochemical reaction, the passenger strand is released. Release of the passenger strand 
from pre-RISC is also assisted by Dicer, which takes it to the degradation machinery [94]. 
The passenger strand can also be involved in gene silencing, although typically it is less 
active compared to the guide strand [95, 96].  
1.4.5 The Argonaute proteins 
Dicer, AGO and TRBP form a RISC loading complex (RLC) or pre-RISC, which aids in the 
loading of miRNAs onto AGO protein. After guide strand selection, the miRNA guides RISC 
to its complementary mRNA targets.  RISC is the major processing machinery of the RNA 
interference (RNAi) mechanism through which silencing of genes takes place [97]. RNA 
silencing is an evolutionary conserved phenomenon, wherein miRNAs together with other 
RBPs degrade their other RNA targets or repress translation.  AGO proteins form three 
subclasses, namely AGO, PIWI and worm-specific AGO proteins (WAGOs) [98].  In humans 
there are four Argonaute proteins encoded by four Ago genes.  In humans, all AGO 
proteins have the ability to induce translation repression and mRNA degradation, but only 
AGO2 has the “slicing” activity that allows it to directly cleave miRNA targets [99]. This 
however, requires that the guide miRNA is perfectly complementary to its target mRNAs. 
AGO2 is also involved in gene silencing as AGO1, AGO3 and AGO4 [100]. AGO proteins 
have four domains: the N-terminal, PAZ, MID and PIWI [101]. The PAZ domain has a 
characteristic feature to recognize the two-nucleotide 3’ overhang, with which it binds to 
the guide RNA of the small RNA duplex. The MID domain contacts the miRNA 5’ end, 
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which frequently starts with the U nucleotide. Within MID there also lays a MC motif that 
is known to be involved in the translation control of target mRNAs [102]. Whereas the 
PIWI domain has a structure similar to RNase H, which contains active site that bears 
slicing activity, the N-domain assists in the unwinding of the duplex RNA [103].   
1.1.4.6 The miRNA “seed” sequence 
The most important part of the miRNA for its efficiency in repression is the region of 
nucleotides 2-7 at the 5’ end. This has been called the miRNA “seed” sequence [104].  The 
binding of the miRNA to the target mRNA is nucleated by the seed sequence and the 
additional binding of the miRNA 3’end to the target may also play a role in enhancing the 
target repression [105]. MiRNA binding sites that are efficient in host transcript 
degradation are located mostly in the 3’UTRs of the mRNAs [106]. Other than the seed 
sequence, factors that influence the binding of the miRNAs to targets and the efficiency of 
repression are the accessibility and the position of the binding site in the 3’UTR, as well as 
the nucleotide composition around miRNA binding sites [107]. RBPs also compete with 
miRNAs in binding or even enhance the binding of the miRNA [108]. 
1.1.4.7 MiRNA functions and mechanisms 
Several molecular mechanisms for miRNA-induced gene silencing have been proposed. 
The fact that these mechanisms emerged from experiments conducted in different models 
with different techniques, could be an underlying factor in their diversity. The mechanisms 
with the most substantial supporting evidence are discussed below. 
From the initial studies in C.elegans, wherein the first discover miRNA lin-4 repressed the 
synthesis of lin-14 protein [69], it was thought that miRNAs mainly function as 
translational repressors. In contrast, in plants miRNAs mostly act by cleaving and 
degrading their target mRNAs [109].  Translation of mRNAs occurs in three steps, 
initiation, elongation and termination. Most data indicates that miRNA repress translation 
at the level of translation initiation.  The eukaryotic translation initiation factor (eIF) eIF4F 
contains the eIF4E subunit, which is responsible for the identification of cap structure of 
the mRNA to initiate translation. Another subunit, eIF4G, conjoins eIF4E and the poly(A) 
binding protein  (PABP) to circularize mRNAs. This is thought to stimulate translation re-
initiation through the recycling of ribosomes. The interaction of PABP with translation 
initiation factors in turn increases the efficiency of translation [14, 110]. 
It has been observed that the MC motif of the MID domain of AGO has sequence 
homology to the eIF4E [102] and this lead to the hypothesis that AGO competes with 
eIF4E for cap binding, thereby preventing the initiation of translation. This interference of 
AGO also leads to the inhibition of binding of 40S or 60S subunit to the repressed mRNA, 
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which subsequently represses translation [102, 111]. In addition, co-sedimentation 
experiments in human cells yielded polysomes that contained miRNAs, AGO proteins and 
their mRNA targets suggesting that miRNAs are also able to block translation post-
initiation [112, 113]. 
Although the initial studies indicated that miRNAs only participate in translational 
repression, more recent studies found that miRNAs also destabilize their targets. 
Microarray-based measurements of transcript levels after perturbing the miRNA pathway 
or miRNA levels revealed significant changes in the levels of already validated targets 
[114-116]. General mRNA degradation is carried out either in the 3’-5’ direction by 
exosomes or by decapping, followed by 5’-3’ degradation by the endonuclease XRN1 
[117]. Isolation of miRNA and their cognate targets from the processing bodies (P-body), 
which are cytoplasmic foci where mRNA degrading and translation repression components 
are found, also support the idea of miRNA mediated mRNA degradation. Whether this is a 
consequence of other modes of repression is still disputed [118]. The P-body protein 
GW182 (with 3 isoforms in human, TNRC6A-C) interacts with AGO proteins to recruit the 
deadenylase CAF1-CCR4-NOT complex. Deadenylation is followed by decapping through 
the DCP2 enzyme, which then promotes degradation of the target mRNAs by nucleases. 
The role of miRNAs in their target degradation was elucidated when accumulation of 
mRNAs was observed upon knockdown of the components of CAF1-CCR4-NOT complex 
[115, 116].  
1.1.4.8 Methods to identify miRNA targets 
Since miRNAs are known to be involved in the regulation of many fundamental biological 
processes such as development, differentiation, immune system and many more [119-
121], it is important to establish methods to identify the expressed miRNAs and their 
targets in a given system. Classical methods of identifying miRNA targets include cloning 
of miRNA genes to elicit the functional response of their targets, with which first miRNAs 
lin-4 and let-7 [69, 70] were discovered. However, much of what we have learned about 
miRNA-dependent mRNA regulation came from computational analyses and analysis of 
high-throughput mRNA expression data generated by microarrays and later with 
sequencing. In an initial study of this type, tissue specific miRNAs, miR-1 and miR-124a, 
were transiently transfected in HeLa cells, and changes in mRNA expression were 
determined with microarray analysis [122]. Computational analysis revealed that the 
downregulated mRNAs carried in their 3’ UTRs sequences complementary to the seed of 
the transfected miRNA. Synthetic oligos complementary to miRNAs of interest have also 
been used to antagonize the miRNA activity and increased the mRNA and protein levels of 
miRNA targets [123-125]. This type of studies yielded miRNA targets that were 
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differentially expressed in response to the ectopic expression of specific miRNAs, but also 
false positive candidates. Computational methods that exploited not only the seed 
sequence complementarity but also the degree of evolutionary conservation of putative 
target sites, such as TargetScan [104] and ELMMO [126] were reported to be effective in 
defining miRNA targets [104, 127-129].  Proteomics data was generated after miR-1 
transfection using stable isotope labeling by amino acids in cell culture (SILAC) to identify 
both destabilized and translationally repressed targets [130]. Upon analysis of such data, 
12 targets for miR-1 were identified, of which 6 were validated with luciferase assays. 
Following this, other groups also used slightly modified approaches to identify the targets 
for various other miRNAs [131, 132].  
1.1.5 Next generation sequencing and CLIP 
The application of sequencing technologies helped to crack some important questions in 
molecular biology. An important landmark was the shot-gun sequencing and assembly of 
the human genome in the year 2003 which was accomplished with the first generation 
method called Sanger sequencing invented by Edward Sanger [133]. After the successful 
completion of human genome sequencing, the second generation or next generation 
sequencing methods brought new methodologies to answer complex questions such as 
determining gene expression profiles transcriptome wide. mRNA sequencing is the most 
widely used method to profile all polyadenylated mRNAs in a given population of cells 
[134]. This method has been modified to infer alternative splice forms, alternative 
promoter sites and alternative poly(A) sites [135, 136]. High-throughput sequencing 
methods are employed to infer the binding sites of the RNA binding proteins, for instance 
with Argonaute crosslinking and immunoprecipitation (CLIP) [137, 138]. CLIP relies on the 
in-vivo crosslinking using ultraviolet (UV) C light (254nm) of RNA binding proteins to their 
target RNAs intact in the cells. These complexes are pulled down with a specific antibody 
and are further processed to yield RNA fragments that are eventually sequenced.  The 
CLIP method has been used extensively to discover not only miRNA targets but also non-
coding RNAs such as small nucleolar RNAs (snoRNAs) [139] associated with snoRNPs. A 
modified protocol of CLIP called photoactivatable ribonucleoside CLIP (PAR-CLIP) [140] 
was proposed by Tuschl group wherein photoactivatable ribonucleosides such as 4-
thiouridine (4-SU) or 6-thiouridine (6-SU) are incorporated into RNAs before crosslinking 
with UV A (at 365nm) light. This induces mutations (T-to-C with 4-SU or G-to A with 6-SU) 
during the reverse transcription, which helps in the determination of binding sites at a 
nucleotide resolution level.  These mutations are further used as diagnostic markers in 
distinguishing the signal from noise in CLIP and to determine high affinity binding sites of 
miRNAs. Based on transcriptome-wide Argonaute CLIP [138, 140] our group has 
succeeded in developing a computational method to infer an empirical model called 
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MIRZA that allows one to quantify the strength of miRNA-target interactions. This model 
then enables identification of the miRNAs that most likely guided the interaction of AGO 
with each of the CLIPed mRNA sites. Moreover, this model enables one to infer both 











 2. Timescales and bottlenecks in miRNA-
dependent gene regulation 
High-throughput approaches generate huge data sets, which need to be analyzed 
computationally. Importantly, these data are generated in a limited number of conditions. 
To generalize as well to model miRNA-dependent regulation in the context of other 
processes, computational target prediction models remain useful. Currently, such models 
are based on several important aspects of miRNA target regulation such as the 
complementarity of targets to the miRNA seed sequence, their evolutionary conservation 
etc.  Importantly, the experimental validation of predicted targets may induce side effects 
that complicate the interpretation of the data. Moreover, as described above, the miRNA 
mechanisms continue to be debated, partially due to the lack of methods that allow a 
comprehensive characterization of the behavior of miRNA targets, simultaneously and at 
all levels. An aspect that has not been considered in analyzing miRNA regulation is the 
time scale on which miRNA regulation takes place. In one study, we have addressed these 
kinetics issues and showed that they need to be taken into account when designing and 
analyzing experiments aimed at characterizing the regulatory function of miRNAs by 
means of miRNA perturbation and subsequent measurements of the induced changes in 
mRNA and protein levels. In addition, we have analyzed a detailed model of miRNA action, 
investigating how different parameters such as the rate at which miRNAs load into AGO 
protein and their decay rate influence the time-scale and magnitude of miRNA-mediated 
gene regulation.  
2.1 Statement of my work 
In the study described below, I carried out the experimental work. I have constructed the 
inducible miRNA constructs and used them to establish cell lines that stably express 
miRNAs in an inducible manner. I carried out an intensive screening of clones with 
Northern blots to check the consistency and proper expression of miRNAs. After 
establishing stable inducible cell lines, I cloned putative targets of the miRNAs of interest 
in the reporter vector and validated them by luciferase assays in the inducible miRNA 
expression cell lines. I have also established a stable cell line with constitutive expression 
of the miRNA target and inducible expression of its cognate miRNA. I have tested this cell 
line for the consistency of the miRNA target downregulation by luciferase assays until 
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several days after miRNA induction. This cell line was used for the final experiments 
described in the study below. 
17
Timescales and bottlenecks inmiRNA-dependent gene
regulation
Jean Hausser1,3,*, Afzal Pasha Syed1, Nathalie Selevsek2, Erik van Nimwegen1, Lukasz Jaskiewicz1,
Ruedi Aebersold2 and Mihaela Zavolan1,*
1 Biozentrum, University of Basel and Swiss Institute of Bioinformatics, Basel, Switzerland and 2 Institute of Molecular Systems Biology, ETH Zurich, Zurich,
Switzerland
3Present address: Department of Molecular Cell Biology, Weizmann Institute of Science, Herzl Street 234, 76100 Rehovot, Israel
* Corresponding authors. J Hausser or M Zavolan, Biozentrum, University of Basel and Swiss Institute of Bioinformatics, Klingelbergstrasse 50/70, Basel, 4056,
Switzerland. Tel.: þ 972 8 934 4447; Fax: þ 972 8 934 4125; E-mail: jean.hausser@weizmann.ac.il or Tel.: þ 41 61 267 1577; Fax: þ 41 61 267 1585;
E-mail: mihaela.zavolan@unibas.ch
Received 9.5.13; accepted 30.10.13
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the implications of miRNA expression dynamics for the processes that they regulate are not well
understood. We derived a mathematical model of miRNA-mediated gene regulation, inferred its
parameters from experimental data sets, and found that the model describes well time-dependent
changes in mRNA, protein and ribosome density levels measured upon miRNA transfection and
induction. The inferred parameters indicate that the timescale of miRNA-dependent regulation is
slower than initially thought. Delays in miRNA loading into Argonaute proteins and the slow decay
of proteins relative to mRNAs can explain the typically small changes in protein levels observed
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miRNAs involved in cell-cycle regulation do, accelerated miRNA turnover is necessary.
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Introduction
The cellular abundance of proteins appears to be controlled to
a substantial extent at the level of translation (Schwanha¨usser
et al, 2011). Among post-transcriptional regulators, miRNAs
are short, evolutionarily conserved, non-protein-coding RNAs
that modulate the rates of both protein translation and mRNA
decay (Bartel, 2009; Fabian et al, 2010; Huntzinger and
Izaurralde, 2011). MiRNAs guide Argonaute (Ago) proteins to
specific elements that are located mostly in the 30 untranslated
regions (UTRs) of mRNAs and are typically complementary to
the miRNAs’ ‘seed’ region (7–8 nucleotides at the 50 end)
(Bartel, 2009). They are involved in virtually every cellular
process, from early development (Wightman et al, 1993;
Kanellopoulou et al, 2005; Song et al, 2011) to organ function,
and their perturbed expression has been associated with
numerous human diseases, such as diabetes (Trajkovski et al,
2011), cancer (Lu et al, 2005) and viral infection (Pfeffer et al,
2004). Furthermore, miRNAs appear to be able to initiate, on
their own, the complex process of reprogramming somatic
cells into pluripotent stem cells (Anokye-Danso et al, 2011).
Evidence for context-specific modulation of both miRNA
biogenesis (Heo et al, 2009) and decay (Chatterjee and
Grosshans, 2009; Krol et al, 2010; Rissland et al, 2011) has started
to emerge. Yet, the implications of a flexible modulation of miRNA
expression dynamics for the dynamics of the controlled processes
remain largely unexplored. Rather, from a kinetic stand point,
miRNAs are generally viewed as fast regulators of gene
expression, in contrast to transcription factors, whose expression
additionally requires protein synthesis (Shimoni et al, 2007;
Hobert, 2008). Here, we use a variety of low- and high-throughput
data sets to uncover the kinetics of various steps in the miRNA-
dependent regulatory cascade. Contrary to the expectation that
miRNAs are fast regulators, we find that miRNAs may not be
acting as rapidly as commonly assumed due to two bottlenecks,
one at the level of miRNA loading into Ago and the other at the
level of protein decay. The derived quantitative model enables us
to predict the effect of manipulating miRNA expression on
mRNA, protein and ribosome density levels, to uncover these
effects from experimental data sets and to make predictions about
the dynamics of miRNA-dependent gene regulation in various
physiological scenarios.
Results
Inference of a kinetic model of miRNA-dependent
regulation
A stumbling block for a quantitative description of
miRNA-dependent gene regulation is that the parameters
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of miRNA expression dynamics and of miRNA–target interac-
tion are generally unknown. The fluorescence cross-correla-
tion spectroscopy experiments of Ohrt et al (2008) offer a
possible solution. This study measured the fraction of small-
interfering RNA (siRNA) in complex with Ago as well as the
fraction of Ago in complex with siRNAs, as a function of the
time after siRNA micro-injection into cells. Because the siRNA
and miRNA pathways share many components, these data
allow us to obtain initial estimates of the dynamics of Ago
loading, which we can then use to predict the dynamics of
miRNA-induced changes in miRNA targets.
Figure 1A illustrates the structure of the Ago-loading model
that we constructed. At time t¼ 0, X0 siRNAs are micro-
injected into the cytoplasm from where they either decay at a
rate d or associate with free Ago at a rate g¼ b f0, with b being
the rate of binding and f0 the fraction of free Argonaute
proteins. Ago-complexed siRNAs dissociate at a rate u. With
reasonable assumptions supported by experimental evidence
(Khan et al, 2009), namely that the fraction of free Ago f0 is
small and that siRNAs load into Ago by competing out
endogenous miRNAs, the fraction of Ago proteins loaded with
the injected siRNA can be described by a bi-exponential
function. This form facilitates the modeling of mRNA and
protein dynamics of miRNA targets, as will be described
shortly. We obtained maximum-likelihood estimates and
confidence intervals on the model parameters g, d, u, X0 by
Markov Chain Monte Carlo (Supplementary Figure S1) and
found a good agreement between the data and the model
(Figure 1B). Therefore, Ago loading upon small RNA micro-
injection can be well approximated by a bi-exponential
function.
Does this model describe well the dynamics of Ago loading
upon miRNA transfection? The above model predicts that the
peak in Ago loading would be about 10 h after the delivery of
the small RNA (Figure 1B). However, the peak in mRNA
repression in miRNA transfection experiments, which should
occur at the peak of Ago loading with the miRNA, appears to be
considerably delayed. For example, in the experiments of
Grimson et al (2007) target mRNAs are typically more
repressed at 24 h than at 12 h after miRNA transfection
(Supplementary Figure S2A). This is likely due to a delayed
delivery of transfected miRNAs to the Ago proteins (Broderick
and Zamore, 2011; Stalder et al, 2013) compared with the
situation in which the small RNAs were directly micro-injected
into cells. To investigate the dynamics of miRNA loading into
Ago under transfection conditions, we therefore used the fine-
grained time series of mRNA expression of Wang and Wang
(2006) who transfected miR-124 in HepG2 cells. However,
because up to this point our model only describes the
dynamics of Ago loading with a small RNA, we first need to
derive the consequences of Ago-loading dynamics for the
mRNA and protein level of the small RNA targets.
The abundance of transcripts and proteins associated
with individual genes is frequently described in terms of the
rates of mRNA transcription, decay and translation and the
rate of protein decay (e.g., Hargrove and Schmidt, 1989;
Schwanha¨usser et al, 2011; and Khanin and Higham, 2009). A
large body of evidence indicates that miRNAs modulate both
the decay and translation rates of mRNAs. How these rates
respond to changes in miRNA expression is not known.
However, because the studies of Djuranovic et al (2012) and
Be´thune et al (2012) showed that once loaded in Ago, miRNAs
find their targets relatively fast, we can assume that the relative
changes in mRNA decay and translation are proportional to the
fraction of miRNA-loaded Ago. The resulting model, describ-
ing the mRNA and protein abundance of a given miRNA target,
is parametrized by two proportionality factors d and l that
relate the fraction of loaded Ago to the relative increase in
mRNA decay and decrease in translation (see Materials and
methods). l41 indicates that miRNAs predominantly affect
the translation of the message, while l between 0 and 1
corresponds to the case where miRNAs impact mostly the
mRNA decay.
We first fitted the mRNA expression dynamics in response to
miR-124 transfection measured by Wang and Wang (2006). To
do so, we fixed the Ago-loading parameters g, d, u to the values
inferred from the fluorescence cross-correlation spectroscopy

























Figure 1 The amount of siRNA-loaded Ago following siRNA micro-injection can be modeled by a bi-exponential function. (A) Cartoon illustrating the model
parameters: at time t¼ 0, X0 siRNAs are injected into the cell, after which the siRNAs X either decay with rate d or load into a free Ago f0F with rate b to form siRNA-
loaded Ago complexes A. Small RNAs dissociate from Ago at rate u. (B) Measured (dots) and fitted (lines) fractions of complexed Ago and complexed siRNAs from the
data set of Ohrt et al (2008). Error bars represent the 95% confidence interval on the mean measured fraction of Ago and siRNA in complex. Maximum-likelihood
parameter estimates also appear in the figure. g¼ bf0 is the Ago–siRNA association rate b normalized to the fraction of free Ago f0. See also Supplementary Figure S1.
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result, the fraction of loaded Ago can be described by a bi-
exponential function of time. One can show that mRNA
expression dynamics are driven by a single free parameter X0d:
the product of the initial concentration of the small RNA X0
and the maximum change in mRNA decay rate that can be
induced by the small RNA d. Alternatively, to account for the
presumed delays in Ago loading upon miRNA transfection, we
modified the Ago-loading model to include an additional
compartment (presumably the endosomes) in which V0
miRNAs are loaded at the time of transfection (Figure 2A, in
red). From this compartment, miRNAs are either degraded or
translocate to the cytoplasm where they can associate with
Ago. These assumptions lead to a tri-exponential Ago-loading
function. In this alternative model, describing the miRNA-
induced changes in mRNA abundance requires two free
parameters: ~dþ r, the experiment-specific rate with which
miRNAs are cleared from endosomes through degradation or
transfer to the cytoplasm, and rV0d, the gene-specific influence
of the transfected miRNAs on mRNA degradation.
We compared the goodness of fit of both models by fitting
their free parameters—X0d for the bi-exponential model, or
~dþ r and rV0d for the tri-exponential model i—to 1098 genes
that had a miR-124 seed match in the 30 UTR and were
repressed on average 4, 8, 16, 24 and 32 h post transfection.
This represents a total of 5490 data points. With a maximum
log-likelihood of 877.3, the tri-exponential Ago-loading model
fitted better the mRNA profiling data than the bi-exponential
model (log-likelihood of  2994.6; Figure 2B; Supplementary
Figure S2B). Replicate experiments would allow us to estimate
an upper bound on the goodness of fit that can in principle be
achieved, but unfortunately, the time series experiment did not
include replicates. Nonetheless, we used a data set of six
replicate experiments in which miR-124 was transfected into
human embryonic kidney 293 (HEK293) cells and mRNA
expression was subsequently profiled by microarrays
(Karginov et al, 2007) to estimate this upper bound. The
average standard deviation on the log2 mRNA fold change was
s¼ 0.26 (Supplementary Figure S2C), corresponding to a 20%
uncertainty on the fold change. At this cutoff, the tri-
exponential model fitted 83.8% of the genes (Figure 2C), and
the prediction error was uniform across time points




















































































Figure 2 Changes in mRNA levels in the miR-124 transfection time course of Wang and Wang (2006) can be modeled assuming a tri-exponential Ago-loading
function. (A) Cartoon illustrating two models of miRNA transfection experiments and their parameters. Free, fitted parameters appear in black, fixed parameters from
Figure 1 in gray. The bi-exponential model (in green) is the same as in Figure 1A. Also shown is a tri-exponential model of Ago loading (in red), which is identical to the bi-
exponential model, except for the addition of an extra compartment (V) in which V0 miRNAs are loaded at time t¼ 0, and two additional rates: rate of miRNA decay in this
compartment (~d) and rate of transfer to the Ago-accessible environment (r). (B) Log-likelihood profile of the clearance parameter ~dþ r given the mRNA profiling time-
course data. The log-likelihood of the tri-exponential model (red line) is compared with that of the bi-exponential model (green line). (C) Cumulative distribution of the per-
gene relative error between the model and the time-course data. The x-axis represents the per-gene relative error between the model prediction and the measurements.
For any chosen cutoff on the relative error, the fraction of genes whose regulation following miRNA transfection could be predicted at the chosen error cutoff or less can
be read on the y -axis. The dotted line marks a 20% error on the fold change typically observed in miRNA transfection experiments. (D) Boxplots of the model residual
on log2 fold changes for genes that fit the measured mRNA fold changes with less than a 20% error. Boxes span the interquartal range and whiskers extending up to
1.5 times the interquartal range. See also Supplementary Figure S2.
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accounting for delays in Ago loading is necessary to model
changes in gene expression following miRNA transfection.
Validation of the derived models of mRNA and
protein abundance changes in response to miRNA
transfection and induction
To test whether the models derived above can describe the
change in abundances of both mRNAs and proteins following
miRNA perturbation, we selected a ‘prototypical’ miRNA,
miR-199a, that is not normally expressed in HEK293 cells and
established a cell line in which the expression of miR-199a is
inducible with doxycylin from a pRTS-1 episomal vector
(Bornkamm et al, 2005). We further cloned the 30 UTR of the
kinectin (KTN1) gene, containing a miR-199a-3p binding site,
downstream of the stop codon of the renilla luciferase in a
psiCHECK-2 vector and stably integrated this construct in the
genome of cells containing the miR-199 expression vector. We
then investigated the response of the KTN1 gene at both the
mRNA and protein level upon induction of miR-199a or
transfection of miR-199-3p mimic. For Ago loading, we used
the tri-exponential model for the transfection experiment,
while for miRNA induction experiment, we changed the one-
time micro-injection represented in Figure 1A to add constant
miRNA synthesis into the Ago-accessible compartment X. The
measured and predicted mRNA and protein-level dynamics for
both miRNA transfection and induction are shown in Figure 3
and Supplementary Figure S3.
From the perspective of the measured changes, we found
that the transfection experiment had higher variability,
presumably because the transfection efficiency varied to some
extent between the replicate experiments. The changes in
mRNA expression, measured by qPCR, also showed higher
variability compared with changes in protein expression,
which were estimated based on the luciferase activity. None-
theless, the models give a reasonable fit to the mean observed
changes. Furthermore, the protein-level changes, which are
the final readout of our models’ dynamics and whose
prediction depends on all of the assumptions that our models
make, are remarkably well described by the models. These
results indicate that our models predict well mRNA and
protein-level changes in response to changes in miRNA
expression. Furthermore, as data from other groups also
suggest (Karginov et al, 2007), controlling variability in
transfection experiments is difficult, and miRNA target
identification could therefore be more accurate in experiments
in which the miRNA is induced instead of transfected.
As additional validation of our model, we further tested its
ability to explain changes in mRNA abundance and translation
efficiency (estimated through Ribosome Protected Fragment
(RPF) sequencing) measured at two time points (12 and 32 h)
after miR-155 and miR-1 transfection by Guo et al (2010).
Indeed, we found that the maximum-likelihood estimates of
both ~dþ r and rV0d were in the range of those previously
observed in Wang’s miR-124 and our miR-199 transfection
experiments (Supplementary Figure S4A). The proportion of
genes whose mRNA-level and RPF dynamics was fitted at the
expected accuracy was 67.5% and 48.3% in the miR-155 and
miR-1 transfections, respectively (Figure 4A). These numbers
are lower than those we obtained for the Wang and Wang
(2006) data, which could be due to the lower reproducibility of
translation efficiency measurements by RPF—30% variability
on the log2 fold change according to Ingolia et al (2009)—
compared with mRNA profiling. Thus, our models that link the
dynamics of the miRNA to the dynamics of its target at the
mRNA and protein level explain well kinetic data from reporter
systems as well as from high-throughput measurements.
Implications of Ago-loading kinetics and protein
turnover for miRNA-dependent gene regulation
To explore the implications of our models for miRNA-
dependent gene regulation, we investigated currently open






















Figure 3 The kinetic model fits measured changes in mRNA and protein levels following miR-199a transfection (A) or induction (B) in HEK293 cells. The 30 UTR of the
KTN1 miR-199a target was cloned downstream of the stop codon of a luciferase reporter gene. Changes in mRNA expression following miR-199a transfection or
induction were quantified by qPCR whereas changes in protein levels were determined by measuring luciferase activity. In the transfection experiment, changes in
mRNA and protein levels were then fitted assuming the previously introduced three-exponential Ago-loading model. In the induction experiment, we assumed constant
miRNA synthesis into an Ago-accessible environment. The best-fitted model appears as a continuous line and error bars represent 95% confidence intervals on the
measured changes in mRNA and protein abundance. See also Supplementary Figure S3.
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extent to which miRNAs affect the decay as opposed to the
translation rate of target mRNAs. To answer this question, a
few studies obtained direct, high-throughput measurements of
mRNA as well as protein-level changes upon miRNA transfec-
tion (Baek et al, 2008; Selbach et al, 2008). The general
conclusion was that miRNAs predominantly affect the mRNA
decay rate. If this were the case, then one would expect a strong
correlation between the changes in levels of mRNA and in
protein of individual genes, which is not what one typically
observes. Rather, changes in protein abundance appear
uncoupled from changes in mRNA abundance and miRNA
targets typically change less at the protein compared with the
mRNA level (see Section 3.4 of the Supplementary Material).
By measuring protein decay rates by Selected Reaction
Monitoring, we further found that fast-decaying proteins were
preferentially detected as miRNA targets in these experiments
(Section 3.4 of the Supplementary Material). Additionally, in
the one experiment in which mRNA and protein-level changes
were measured a week after the expression of a miRNA was
abrogated yielded a much stronger correlation. All of these
observations suggested that the mRNA and protein-level
changes were measured far from steady state, and we re-
analyzed these data in the framework of our kinetic model.
The three Stable Isotope Labeling by Amino acids in Cell
culture (SILAC) experiments of Baek et al (2008) fitted the
model very well. The dynamics of480% of genes with a seed
match to the transfected miRNA and downregulated 24 h post
transfection was perfectly described by the model (Figure 4B;
Supplementary Figure S4B). This included genes for which the
mRNA was more strongly regulated than the protein
(Supplementary Figure S4D). In addition, the values of the
fitted parameters were consistent with the values obtained
from the other data sets (Supplementary Figure S4). Applica-
tion of the model to the pulsed SILAC (pSILAC) data from the
five transfection experiments of Selbach et al (2008) revealed a
similar picture, with 50–90% of downregulated mRNAs with
seed match to the transfected miRNA fitting the model
(Figure 4C; Supplementary Figure S4C), including genes for
which protein levels were less affected than mRNA levels
(Supplementary Figure S4E). Thus, our model explains to a
large extent the measured effects of miRNA on mRNAs
and protein levels. Dissecting the relative contribution of
translational repression and mRNA decay to the miRNA-
mediated repression of individual targets (Supplementary
Figure S4A–C) we found that on averageE25% of the putative
targets on a miRNA undergo predominantly translation
repression. Thus, our analysis supports the previous asser-
tions that miRNAs have a stronger impact on mRNA decay
compared with translation (Baek et al, 2008, Guo et al, 2010). It
further indicates that the discrepancy between the measured
mRNA and protein-level responses of individual miRNA
targets was due to the expression dynamics of the transfected
miRNAs and to the confounding effect of protein decay rates
on protein levels.
The second question that we sought to address relates to the
observation that the expression of some miRNAs changes
rapidly as a function of cellular state. In particular, Krol et al
(2010) showed that the expression of miRNAs from the miR-
183/96/182 cluster (but not of other miRNAs) changes rapidly
in response to illumination and that these changes are
important for the regulation of gene expression in the retina.
Circadian changes in miRNA expression levels in the liver have
also been described (Gatfield et al, 2009) and, examining the
relative abundance of miRNAs in Ago2-immunoprecipitation
samples prepared from HeLa cells in M phase and unsynchro-
nized cells (Kishore et al, 2013) we also found that miRNAs of
the let-7 family are two-fold upregulated during the M phase
while miR-21 is 66% downregulated (Supplementary
Table S1). In all of these circumstances the targets of the
miRNAs whose expression is modulated should respond
rapidly, on the timescale of about a day. We therefore asked
under what conditions would the protein-level dynamics of
miRNA targets reflect the rapid dynamics of the miRNA itself.
We used the model for miRNA induction experiments that
was introduced in the previous section to compute the
amplitude in the oscillation of a target protein level as a
function of the protein decay rate and miRNA kinetics. To
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Figure 4 The kinetic model explains temporal changes in mRNA abundance, protein abundance and translation efficiency of most miRNA targets. Cumulative
distributions of the relative error between the model prediction and the measurements in different transfection experiments. (A) Ribosome Protected Fragment
(RPF) sequencing and mRNAseq experiments upon transfection of miR-155 and miR-1 by Guo et al (2010). (B) SILAC and microarray experiments upon miRNA
transfection of miR-124, miR-1 and miR-181a by Baek et al (2008). (C) pSILAC and microarray experiments following the transfection of let-7b, miR-155, miR-16,
miR-1 and miR-30a by Selbach et al (2008). The x-axis of each panel represents the per-gene relative error between the model prediction and the measurements. For
any chosen cutoff on the relative error, the fraction of genes whose regulation following miRNA transfection could be predicted at the chosen error cutoff or less can be
read on the y -axis. The dotted, vertical bars mark a 20% error cutoff on the fold change. This error level is typically observed in miRNA transfection experiments. See also
Supplementary Figure S4.
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regulatory scenario in which miRNA synthesis switched
between two regimes during a 24-h cycle (Supplementary
Figure S5A): the first 12 h of low miRNA expression (synthesis
rate: half of its maximum level) and the next 12 h of high
expression (maximal synthesis rate). Although it does not
come as a surprise that proteins with median half-life (48 h;
Schwanha¨usser et al, 2011) undergo oscillations of o1% in
amplitude (Figure 5A), increasing the protein turnover rate by
two orders of magnitudes still only leads to a modest increase
in the amplitude of protein oscillations (o10%; Figure 5D).
Responsible for these small changes are the slow kinetics of
Ago loading and miRNA decay. It is only when fast protein
turnover is combined with fast miRNA kinetics (rates of Ago
association, dissociation, and of miRNA decay) that substan-
tial oscillations in protein levels (60% of the baseline level
assuming no translation repression and up to 2.5-fold with
translation repression; Figure 5B) ensue.
Another highly relevant regulatory scenario is when the
synthesis of a miRNA is abrogated at the transition between
cell types or states. For example, rapid synthesis and
subsequent clearance of the dre-miR-430 miRNA is important
for proper zebrafish development (Chen et al, 2005; Giraldez
et al, 2005). We thus investigated how fast target proteins are
expected to change in response to a sudden block in miRNA
synthesis (Supplementary Figure S5B). We again used the
model introduced in the previous section for miRNA induction
experiments and computed the time necessary for proteins to
reach 90% of their steady-state level in the absence of the
miRNA—the recovery time—as a function of the protein decay
rate and of the miRNA kinetics. As expected, simulations
revealed that the main factor limiting the recovery time
is the protein decay rate (Figure 5C and D). However, they
additionally allowed us to estimate the timescale of the protein
response. Namely, proteins with a median half-life of 48 h
(Schwanha¨usser et al, 2011) would have a recovery times
larger than 140 h (6 days). This implies that miRNAs are a slow
means of regulating the levels of typical proteins. It may thus
be expected that miRNAs preferentially target proteins with
rapid turnover. We tested this hypothesis by comparing the
decay rates of top compared with weakest predicted miRNA
targets (highest and lowest, respectively, prediction scores
according to the ElMMo algorithm (Gaidatzis et al, 2007)
that estimates the strength of evolutionary selection of the
miRNA-complementary sites) measured by Cambridge et al
(2011). Indeed, we found that the highest scoring targets had
significantly higher protein decay rates than low-scoring
targets. This indicates that miRNAs preferentially target
fast-decaying proteins, on whose expression they have
a rapid regulatory impact (Supplementary Figure S5C).
Alternatively, mechanisms such as increased protein turnover
Figure 5 Parameter ranges that are compatible with a specific dynamic of protein targets. (A) Changes in protein levels induced by a miRNA whose
synthesis switches between half-induction and full induction in 24 h cycles. Simulations were performed assuming the default kinetic parameter (48 h protein half-life,
miRNA loading and decay rates estimated from biophysics data, red line) or faster kinetics (30min protein half-life, 14-fold speed-up in miRNA loading and decay,
black line). (B) Amplitude (fold change) of the oscillations in protein abundance as a function of protein decay and miRNA kinetics. The color bars correspond to the
case where miRNA only affect mRNA decay (l¼ 0) or equally regulate mRNA decay and translation (l¼ 1). (C) Changes in protein levels following a sudden
drop in miRNA synthesis given default kinetic parameter (48 h protein half-life, miRNA loading and decay rates from biophysics data, red line) or faster kinetics
(5 h protein half-life, three-fold speed-up in miRNA loading and decay, black line). (D) Protein recovery time as a function of protein decay and miRNA kinetics.
The color bars correspond to the case where miRNA only affect mRNA decay (l¼ 0) or equally regulate mRNA decay and translation (l¼ 1). See also Supplementary
Figure S5.
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or cell division would need to be recruited to diminish the
recovery time of miRNA targets. Similar considerations apply
to the situation when a miRNA is strongly induced to repress
its targets.
Discussion
By contrast to transcription factors, miRNAs are often viewed
as rapid means of regulating gene expression. Although
synthesizing a miRNA likely requires less time than synthesiz-
ing a protein, miRNAs only function as part of complexes with
Ago proteins. Some studies (Khan et al, 2009) already
suggested that Ago levels within cells are limiting, implying
that for a miRNA to exert its function, it has to displace other
miRNAs from Ago. The models we introduced here abstract
much of the molecular complexity of the miRNA pathway, but
their parameters can be fitted from presently available data
sets. As a result, it remains challenging to pinpoint the precise
steps (binding the double-stranded miRNA to Ago, expelling
the passenger/miR* strand, etc.) that are most responsible for
the inferred bottlenecks. Nevertheless, our analysis indicates
that it is the overall Ago-loading process that determines the
timescale of miRNA-dependent gene regulation. At an esti-
mated Ago-dissociation rate of u¼ 0.116 h 1, the half-life of
Ago residency isB6 h, which sets a lower bound on the time
that miRNAs need to regulate their target.
Re-analysis of data from experiments in which both mRNA
and protein levels were measured after miRNA transfection
shows that mRNAs underwent more pronounced changes than
the proteins. The underlying explanation appears to be
different in different experimental settings. In the SILAC
experiments, it is the slow rate of protein decay that does not
allow the full extent of protein downregulation to be reached
before the miRNA is degraded. In contrast, in the pSILAC
experiments the change of labeling medium, done 8 h post
transfection, occurred before the full Ago loading with the
transfected miRNA was reached (20–30 h post transfection).
Thus, the proteins were labeled before the miRNA fully exerted
its inhibitory effects and the confounding effect of protein
decay rate was only partially circumvented. This suggests that
changing the labeling medium at a later time point would
better capture the effect of miRNAs of protein synthesis
by pSILAC.
Simulating changes in mRNA and protein levels for two
biological realistic scenarios, namely circadian oscillation of
miRNA expression and a sudden change in miRNA synthesis,
we found that protein decay rates critically limit the efficiency
of miRNA regulation. Importantly, we found that oscillations
of large amplitude in protein levels in response to an oscillating
miRNA are predicted to be achievable only when the miRNA
undergoes fast turnover and when the miRNA–Ago loading
kinetics is fast, much faster than micro-injected siRNAs were
found to load and unload from Ago. This is not a reflection of
differences between siRNA and miRNA dynamics, because the
siRNA–Ago loading model allows a very good fit to mRNA and
protein-level data from a variety of experiments in which the
miRNA expression was manipulated. Rather, our results
suggest that active mechanisms increase miRNA turnover in
specific in vivo conditions. The rate of Ago loading with a
specific miRNA can be increased by activating the miRNA’s
transcription. Exonucleases such as Xrn2 (Chatterjee and
Grosshans, 2009), RRP41 (Bail et al, 2010), PNPase(old-35)
(Das et al, 2010) and Xrn1 (Chatterjee et al, 2011), which have
been implicated in active miRNA degradation as well as
destabilization by a complementary miRNA (Chen et al, 2011;
De et al, 2013) can destabilize the miRNA, thereby critically
regulating miRNA residency in Ago.
Large oscillations in protein levels in response to an
oscillating miRNA require a fast protein turnover rate. This
situation is probably exemplified by the miR-16 family of
miRNAs that regulates the cell cycle (Linsley et al, 2007),
directly targeting Cyclin D3, Cyclin E1 (Liu et al, 2008) and
likely also Cyclin D2, the latter being one of the top predicted
ElMMo (Gaidatzis et al, 2007) targets of these miRNAs with
three conserved binding sites. Indeed, cell-cycle proteins do
undergo fast decay (Schwanha¨usser et al, 2011), and these
cyclins have been shown to undergo proteolysis at different
points of the cell cycle (Russell et al, 1999; Strohmaier et al,
2001; Kida et al, 2007). Thus, miRNAs should be able to
meaningfully modulate the expression of these proteins if they
can rapidly load and unload from the Ago protein and decay. A
natural timescale for the decay of proteins is set by cell
division. In cells that undergo substantial clonal expansion,
the miRNA-induced repression can take hold on the timescale
of protein dilution by cell division. In non-dividing retinal
neurons (Krol et al, 2010) however, miRNA-based regulation of
protein levels would be slow unless the miRNA targets have a
high turnover rate.
In conclusion, we constructed a unifying mathematical
framework of the kinetics of miRNA-mediated gene regulation
starting with Ago loading, going through miRNA-dependent
change in mRNA abundance, translation efficiency and
protein abundance. We inferred the model parameters from
various types of experiments and showed that it accurately
describes regulatory dynamics in miRNA micro-injection,
induction and transfection experiments. This framework
will help in further designing miRNA target identification
experiments and in characterizing miRNA function away
from the steady state such as in development, cell cycle and
circadian rhythms.
Materials and methods
Modeling the kinetics of Ago loading
We briefly outline the models describing Ago loading with small RNAs
that we use in our study. Full derivations can be found in Section 3.2 of
the Supplementary Material.
Modeling Ago loading following siRNA micro-injection
In a micro-injection experiment, X0 siRNAs enter the cell at time
t¼ 0 h. A fraction f0 of the RAgo molecules is not bound to endogenous
miRNAs (Khan et al, 2009) and therefore available for binding to
siRNAs. If we assume that the fraction of free Ago f0 remains fairly
constant during the experiment—that is, if siRNAs load mostly by
displacing miRNAs from Ago—and that the amount of free endogen-
ous miRNAs is not significantly affected by the small RNAs micro-
injection, that siRNAs only decay if they are not bound to Ago and that
Ago–siRNA association and dissociation rates happen on a fast
timescale compared with processes such as synthesis and degradation,
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dt ¼ dX bf0RXþuA

ð1Þ
where free siRNAs X decay at rate d, associate with a free Ago at rate b
and unload from a loaded Ago A at rate u. The equation for A specifies
that the production rate of loaded Ago depends on the amount of free
X, on the amount of free Ago f0R and on the binding rate b. Loaded Ago
A is then lost by dissociation that happens at rate u. In the equation
that defines the dynamics of free siRNA X, the first term accounts for
first-order decay (at rate d), the second for the association with a free
Ago and the last for the release from a loaded Ago. For convenience
when fitting the biophysical data of Ohrt et al (2008), we can rewrite
these equations in terms of the fraction of loaded Ago a ¼ AR and




dt ¼ ðdþ gRÞXþuRa

ð2Þ
The analytical solution for the Ago-loading function a(t) can be shown
to be bi-exponential where each exponential accounts for a different
phase of the Ago-loading dynamics. The initial phase corresponds to
the displacement of endogenous miRNAs by the siRNAs, and the
second phase corresponds to the slow clearance of siRNAs from cells.
Modeling the loading of Ago with miRNAs upon miRNA
transfection
In miRNA transfection experiments, miRNAs are delivered with
liposomes as vectors as opposed to being directly injected into cells.
This likely introduces an additional delay as miRNAs need to traffic
from liposomes to endosomes and cytoplasm (Stalder et al, 2013). To
account for that delay, we introduce an additional compartment V to
our model.V0 miRNAs are delivered toVat time t¼ 0 h, and from there
they can either decay with rate ~d or transfer to the cytoplasm X with
rate r. The ordinary differential equation (ODE) system describing
these dynamics can be written as
dV









The analytical solution for the Ago-loading function is tri-exponential,
aðtÞ ¼ ~k1eb1t þ ~k2eb2t ð~k1 þ ~k2Þe ð~dþ rÞt
whose parameters ~k1; ~k2; b1;b2 can be computed from the biophysical
parameters illustrated in Figure 2A (see below).
Modeling Ago loading upon miRNA induction.
When the miRNA is induced (by doxycyclin in the case of our
experiment), there is no need to account for the endosomal
compartment. We therefore start from Equation (2) and slightly alter
the model by assuming that miRNA synthesis c(t) is inactive before 0 h
and follows 0th order kinetics upon doxycyclin induction, that is
dX






cðtÞ ¼ 0 if to0
X0d if t  0

The fraction of loaded Ago a(t) is then coupled to changes in mRNA
decay and translation as will be described below (Equation 8).
Modeling miRNA-induced changes in mRNA and
protein abundance
We modeled mRNA and protein dynamics using an ODE model along the
lines of those previously introduced by Hargrove and Schmidt (1989)
and Khanin and Higham (2009)
dm
dt ¼ c d0 þDdðtÞð Þm
dp
dt ¼ l0 þDlðtÞð Þm sp
(
ð5Þ
where m is the mRNA abundance, p the protein abundance, c the
transcription rate, d0 and l0 the mRNA decay and translation rates in
the absence of the miRNA, s the protein decay rate, and Dd(t) andDl(t)
represent the time-dependent changes in mRNA decay and translation
rates induced by the miRNA.
Assuming that mRNA and protein abundances are at steady state
before miRNA transfection, that is, mð0Þ ¼ cd0 and pð0Þ ¼ cd0
l0
s ,
Equation (5) can be rewritten in terms of the fold change in mRNA
and protein abundances fm and fp, that do not depend on the
transcription rate c:
dfm











If after transfection the miRNAwas to persist at a constant level until a
new steady state was reached, then the change in protein abundance
relative to the initial state would be given by fp ¼ 1þ DlðtÞl0
 
fm, that is
proportional to the change in mRNA abundance, the proportionality
factor being the change in translation rate of the mRNA. The timing
with which the protein abundance changes and how closely it follows
the mRNA abundance will depend on the decay rate of the protein, s;
fast-decaying proteins will reach the steady state faster in response to
the miRNA compared with slow-decaying proteins.
Of the two approaches to measure protein abundance changes upon
miRNA transfection, SILAC (Baek et al, 2008) measurements can be
described directly by Equation (6). pSILAC (Selbach et al, 2008), on the
other hand, measures newly synthesized proteins. That is, at tc¼ 8 h
after transfection, the growth medium was changed and the amount of
protein synthesized between 8 and 32 h after either miRNA or mock
transfection was estimated. The difference between the amount of
protein produced in miRNA- and mock-transfected cells between 8 and











Compared with Equation (6), the magnitude of measured changes in
protein abundance no longer depends on the protein decay rate s, but
rather on the factor s
1 e sðt tc Þ, which is larger than s, particularly
shortly after the medium change (t¼ tc). Consequently, pSILAC
amplifies changes in protein levels by a factor s
1 e sðt tc Þ that decreases
with time. In addition, at constant time t, the strongest amplification
occurs when 1 e sðt tcÞ is small, that is for stable proteins (small s).
The change of a stable protein is therefore amplified more than
that of an unstable protein, and therefore the regulatory impact
of a miRNA will be revealed whether the protein is stable or
unstable (Supplementary Figure S5D). As a consequence, for a miRNA
target to appear as a ‘non-responder’ in a pSILAC experiment, its decay
rate has to be extremely small, which we could verify experimentally
(see Supplementary Material). The similarity in the fold-change
trajectories of fast- and slow-decaying miRNA targets is of course a
main rationale of the pSILAC approach (Schwanha¨usser et al, 2009)
which by reducing the confounding effect of protein decay rates leads
to higher correlation between mRNA and protein fold changes
(average of r¼ 0.27 and r¼ 0.41 for all genes and genes with seed
match, respectively, compared to an average of r¼ 0.18, for both
categories of genes in SILAC, see Supplementary Table S2).
Assuming that the relative increase in mRNA decay and the decrease
in translation is proportional to the fraction of Ago molecules loaded
with the miRNA a(t) yields
d0 þDdðtÞ
d0
¼ 1þ daðtÞ ¼ 1þ ~aðtÞ ð8Þ
l0
l0 þDlðtÞ ¼ 1þ ldaðtÞ ¼ 1þ l
~aðtÞ: ð9Þ
where d and l are proportionality factors. Because miRNAs increase
mRNA decay and repress translation, both l and d should be positive.
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~aðtÞ :¼ daðtÞ represents the relative change in the mRNA decay rate as
a function of time.
Combining Equation (8), that relates the amount of miRNA-loaded
Ago to changes in the rate of mRNA decay with Equation (6), that
describes changes in mRNA level, we obtain a relationship between the




¼ d0 1 1þ ~aðtÞð Þfm½ : ð10Þ
Friedel et al (2009); Schwanha¨usser et al (2009), measured mRNA
decay rates in high-throughput. Although we can use the per-gene
measurements of mRNA decay rates from these studies, the data reveal
a fairly tight distribution around a median of 0.12/h (5.8 h half-life).
For simplicity, we set the mRNA decay rate d0 to 0.12/h in the above
relation to analyze the mRNA response to miRNA transfection.
Similarly, by substituting Equations (8) and (9), that relate the
amount of miRNA-loaded Ago to changes in the rates of mRNA decay





1þ l~aðtÞ  fp
 
ð11Þ
which describes the change in protein level that would be measured as
a function of time in an SILAC experiment. A similar equation can be
derived for pSILAC measurements by substituting Equation (8) into




1 e sðt tcÞ
fm
1þ l~aðtÞ  fp
 
: ð12Þ
Because the protein decay rates have a much wider distribution than
mRNA decay rates, in both models we used the measured (in HeLa
cells) decay rates s of individual proteins Cambridge et al (2011) rather
than a median decay rate.
Changes in mRNA and protein abundance fm are driven by the
relative change in mRNA decay ~aðtÞwhich depends on how the miRNA
is delivered. In the case of a transfection experiment, one can solve
Equation (3) to show that ~aðtÞ takes the form
~aðtÞ ¼ ~k1eb1t þ ~k2eb2 t ð~k1 þ ~k2Þe ~dþ rð Þt ð13Þ
with
b1;2 ¼ dþ gRþu
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
dþ gRþuð Þ2  4ud
p
2
~k1 ¼ b1 þdþ gRuR drV0b2 b1
b2 þdþ gR
b1 þ ~dþ r
~k2 ¼  b2 þdþ gRuR drV0b2 b1
b1 þdþ gR
b2 þ ~dþ r
8><
>:
The parameters d, g, R, u specify the kinetics of Ago loading and can be
fitted from the experiments of Ohrt et al (2008) (see below). As a result,
mRNA dynamics following miRNA transfection are determined by two
free parameters, drV0 and ~dþ r. Modeling changes in protein
abundance requires an additional parameter l.
In the case of an induction experiment, solving Equation (4) shows
that the function ~aðtÞ takes the form of bi-exponential

















There too, we use the values of the Ago-loading parameters d, g, R, u
inferred from the experiments of Ohrt et al (2008) (see below). From
Equation (14), we see that mRNA changes upon miRNA induction
fm(t) are driven by one free parameter X0d. As in the transfection case,
modeling protein dynamics fp(t) require an additional parameter l,
which accounts for the effect of miRNAs on translation relative to
mRNA decay.
Measuring changes in target protein and mRNA
abundance upon miR-199 transfection and
induction by luciferase assays and qPCR
Establishing a cell line stably expressing a miRNA
target as well as inducibly expressing the cognate
miRNA
We generated a stable HEK293Tcell line that simultaneously expresses
hsa-miR-199a-3p (miRBase accession MIMAT0000232) and its target
30UTR (Kinectin 1, KTN1, RefSeqID NM_004986). KTN1 was chosen
among the hsa-miR-199a-3p targets predicted by ElMMo (Gaidatzis
et al, 2007) that had at least one binding site with high probability of
being under selective pressure (P40.7) and a 30 UTR shorter than 1500
nts so that it could be cloned efficiently. The approach we took is
illustrated in Supplementary Figure S6. We PCR amplified the primary
hsa-miR-199a-3p and the target KTN1 30 UTR and cloned them into
pGEM-T Easy vector (Promega). The hsa-miR-199a-3p insert was
sequenced and subsequently cloned into an inducible pRTS-1 vector
(Bornkamm et al, 2005), replacing the luciferase gene at SfiI restriction
sites. We then transfected HEK293Tcells with the miR-199a-3p-pRTS-1
plasmid and selected colonies after 2 weeks of culture in the presence
of hygromycin B (Calbiochem, 100 mg/ml). Selected colonies were
subsequently propagated in the presence of hygromycin B.
The cell line was tested for hsa-miR-199a-3p expression after
the addition of doxycycline (1mg/ml) with northern blotting
(Supplementary Figure S7). The small RNA Northern was performed
as previously described (Pall and Hamilton, 2008), with a minor
change: we used the conventional TBE buffer instead of an MOPS-
NaOH buffer.
The KTN1 30 UTR insert from the pGEM-T Easy vector was
sequenced and subsequently cloned downstream of the open reading
frame of renilla luciferase in a psi-CHECK2 vector (Promega). The miR-
199a-3p-pRTS-1 cell line was then used for co-transfection of KTN1-
psiCHECK-2 and pPUR (Clontech) plasmids in a 3:1 ratio. Stable
colonies were isolated after 2 weeks of culture in the presence of
hygromycin B and puromycin (Sigma-Aldrich, 0.75 mg/ml). Selected
colonies were subsequently propagated in DMEM with 10% FCS,
penicillin-streptomycin (Sigma-Aldrich), hygromycin B and puromy-
cin. We confirmed the genomic integration of the KTN1 30 UTR by PCR
(see Supplementary Figure S8).
MiRNA transfections and luciferase assay
KTN1 cells were split in 12-well plates for both transfection and
induction experiments. hsa-miR-199a-3p mimic (c-300536-07-0005)
and miRNA mimic negative control (CN-002000-01-05, Thermo Fisher
Scientific) were transfected with a final concentration of 25 nM using
lipofectamine 2000 (Invitrogen) transfection reagent according to the
manufacturer’s protocol. At the same time in a different set of
experiment, hsa-miR-199a-3p expression was induced with doxycy-
cline (Sigma-Aldrich, 1 mg/ml). Cells were collected at different time
points (0, 2, 4, 8, 16, 24, 32 and 48 h). Both luciferase and qRT-PCR
were performed with cells from a single well. Renilla and firefly
activities were measured with the dual luciferase reporter assay system
(Promega) with a luminometer (Centro LB960, Berthold Technolo-
gies). Firefly luciferase was used as an internal control.
Quantitative real-time PCR
We extracted total RNA with the TRI reagent (Sigma) as per the
manufacturer’s protocol, and then applied DNase digestion with
RQ1DNase (Promega) followed by phenol-chloroform purification
and cDNA synthesis with SuperScriptIII (invitrogen) reverse trans-
criptase according to the manufacturer’s protocol. We measured mRNA
levels with the Step One Plus real-time PCR system (Applied
Biosystems) employing Power SYBR Green PCR Master Mix (Applied
Biosystems). Firefly expression was used as an internal control.
The primers for KTN1 30 UTR were forward—GGGG CTCGAG TGGG
AAACTGTTCATTTGAGG, reverse—TATT GCGGCCGC TTGCTGACGCC
ATTACAAAA. Primers for hsa-miR-199a-3p were miR-199a-
3p_1_forward—AAAAGGCCTCACTGGCCCCTCCCCCACTCTTTAGGAT,
Bottlenecks in miRNA-mediated gene regulation
J Hausser et al
& 2013 EMBO and Macmillan Publishers Limited Molecular Systems Biology 2013 9
26
miR-199a-3p_1_reverse—AAAAGGCCTCACTGGCCGTGGGGATGGCA
GACTGATA. Primers for KTN1 cell line were GAGCGCGTGCTGAA
GAACGAG (forward) and TTGCTGACGCCATTACAAAA (reverse).
qRT-PCR primers were for firefly luciferase: hFluc-RT-rev—CGGTAGAC
CCAGAGCTGTTC, hFluc-RT-for—TGCAGAAGATCCTGAACGTG, and for
renilla luciferase: hRluc-RT-rev—CTAACCTCGCCCTTCTCCTT and
hRluc-RT-for—TCGTCCATGCTGAGAGTGTC.
In the qPCR data, the standard deviation on the log2 fold change was
on average 0.31 (corresponding to a 23.8% uncertainty on the fold
change), as typically observed in miRNA transfection experiments
(Supplementary Figure S2).
Fitting kinetic parameters
We now describe the strategies we used to fit the kinetic parameters to
the different data sets. Table I provides an overview of all parameters
and documents how we determined their values.
Fitting the parameters of Ago loading from the
fluorescence cross-correlation spectroscopy siRNA
micro-injection time course
We obtained the fractions of cytoplasmic Ago in complex with the
siRNA and the cytoplasmic fractions of siRNAs in complex with Ago 0,
1, 3, 6, 12, 24 and 48 h after siTK3 micro-injection together with the
standard errors on these fractions (Ohrt et al, 2008). This experiment
was the largest of those performed by Ohrt et al (2008). We subtracted
the fraction of bound Ago and bound siRNA at 0 h from all the mea-
surements so that the fraction of bound Ago and siRNA was 0% at 0 h.
To fit the parameters, we simulated the fraction of Ago in complex
with the siRNA and the fraction of siRNA in complex with Ago using
Equation (2). Initial parameter space exploration by gradient ascent
methods on the likelihood assuming a Gaussian error model suggested
initial parameter estimates: g¼ 105, d¼ 0.12, u¼ 0.12 and
X0¼16 000. We then refined these estimates and determined their
uncertainty by Markov Chain Monte Carlo. The chain was initialized at
10% of our initial estimates. From there, we performed Gaussian
moves with standard deviation set to 33% of our initial parameter
estimates, with a uniform prior that only allowed positive parameter
values. The chain ran for 106 sampling steps and visual inspection of
the sampling traces suggested that sampling was at equilibrium
(Supplementary Figure S1). Acceptance probability was 20.8%. The
parameter set with highest likelihood was g¼ 3.0510 6/molecule/
h, d¼ 0.102/h, u¼ 0.116/h and X0¼18 661.67 molecules. Finally, we
determined the posterior probability distributions of the parameters
from the MCMC samples, excluding the first 50 000 samples to ensure
that the chain was ‘burnt-in’ (Supplementary Figure S1).
The product of the miRNA–Ago association rate b and the fraction of
free Ago f0, g¼ bf0, was in the range of 10 6/molecule/h suggesting
that the rate of small RNA binding to Ago is small or that there is
little free Ago at steady state. In contrast, small RNA dissociation from
Ago (u) appears to be about as fast as their decay (d), of the order
of 101/h. mRNA decay rates are in a similar range (Friedel et al, 2009;
Schwanha¨usser et al, 2011). Finally, we estimated that X0C19 000
molecules of small RNA were injected in the cell at time t¼ 0 h.
Fitting changes in mRNA, protein and RPF abundance
upon miRNA transfection by previous studies, and in
the present study through luciferase activity and qPCR
of a reporter gene
We fixed the baseline mRNA decay rate d0 to the average of previously
estimated values. That is, Friedel et al (2009) estimated a median
decay rate of 0.15/h in murine fibroblasts and 0.13/h in human B cells,
while Schwanha¨usser et al (2011) reported a median mRNA decay rate
of 0.08/h in murine fibroblasts. We used the average of these values,
0.12/h for d0, corresponding to a mRNA half-life of 5.8 h. For the
dynamics of miRNA loading into Ago, we assumed that the rates of
association (b)/dissociation (u) of the Ago–miRNA complex, the
miRNA decay rate d, and the fraction of free Ago at steady state f0 were
the same as in the experiment of Ohrt et al (2008). Hence, we fixed the
parameters g¼ bf0, u and d to the values mentioned in Figure 1B. The
remaining parameters X0, the initial amount of miRNA and d, the
factor that relates the fraction of loaded Ago to the relative change in
the mRNA decay rate, most certainly vary between experiments. Under
the bi-exponential Ago-loading model, d and X0 always occur as a
product in the analytical expression of ~aðtÞ (Equation 7 of the
Supplementary Material). The model has hence one free parameter
dX0 which we estimated by fitting mRNA profiling time-series data.
Similarly, the analytical expression of ~aðtÞ under the tri-exponential
Ago-loading model (Equation 13) depends on two parameters: ~dþ r,
the rate with which miRNAs are cleared from endosomes through
degradation or by transferring to the cytoplasm, and rV0d, that
quantifies the influence of the transfected miRNAs on mRNA
degradation.
For each transfection experiment (Wang and Wang, 2006; Baek et al,
2008; Selbach et al, 2008; Guo et al, 2010), we scanned 25 values of
~dþ r between 0.003/h and 0.6/h, equally spaced on a logarithmic
scale. For each of these values and for each gene, we first obtained the
rV0d parameter by maximum likelihood from the mRNA profiling data,
Table I Parameters were either obtained from previous measurements or fitted to the data
Figure 1 Figure 2 Figure 3 Figure 3 Figure 4 Figure 4 Figure 4
Ohrt Wang Transfection Induction Guo Baek Selbach
g miRNA–Ago association Fitted Fixeda Fixeda Fixeda Fixeda Fixeda Fixeda
d miRNA decay Fitted Fixeda Fixeda Fixeda Fixeda Fixeda Fixeda
u miRNA–Ago dissociation Fitted Fixeda Fixeda Fixeda Fixeda Fixeda Fixeda
X0 Amount of micro-injected miRNAs Fitted
d0 mRNA decay Fixed
b Fixedb Fixedb Fixedb Fixedb Fixedb
s Protein decay Fixedc Fixedc Fixedd Fixedd
~dþ r Clearance from endosomes Fitted Fitted Fitted Fitted Fitted
rV0d miRNA-induced change in
mRNA decay (transfection)
Fitted Fitted Fitted Fitted Fitted
X0d miRNA-induced change in
mRNA decay by miRNAs (induction)
Fitted
l Translation repression Fitted Fitted Fitted Fitted Fitted
Rows correspond to parameters and columns to data sets. Parameters were either fitted, fixed to the indicated reference. Empty cells represent cases in which a given
parameter is irrelevant to the data set. To give an overview, we briefly indicate the references used to set the parameters. The main and Supplementary Methods sections
describe how we determined them.
aThe Ago-loading parameters g, d, uwere fixed to the values inferred from the micro-injection and fluorescence cross-correlation spectroscopy experiments of Ohrt et al
(2008).
bThe mRNA decay rate d0 was fixed to 0.12/h, a value determined from the measurements of Friedel et al (2009) and Schwanha¨usser et al (2011).
cThe decay rate s of the luciferase was set to 0.14/h, (https://tinyurl.com/promegaBatesLuciferase).
dProtein decay rates were obtained from the mass-spectrometry measurements of Cambridge et al (2011).
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assuming a Gaussian error model on the measured log2 mRNA fold
change. To set the standard deviation of the error model in the case of
the data of Wang and Wang (2006); Baek et al (2008); Selbach et al
(2008); Guo et al (2010) where biological replicates were not
performed, we used the value 0.25 from the miRNA transfection data
of Karginov et al (2007) (Supplementary Figure S2C). In the case of our
luciferase and qPCR measurements, we used the standard error
computed from triplicate measurements. We focused on genes that
carried a seed match to the transfected miRNA and whose cognate
mRNA levels were downregulated following miRNA transfection,
averaging log2 fold changes when several time points were available.
When analyzing the qPCR measurements of the present study, we also
discarded data points for which changes in mRNA and protein levels
could not be determined in triplicates because the machine failed to
amplify the target. We maximized the log-likelihood with respect to
rV0d by a combination of golden section searches and successive
parabolic interpolations implemented in the optimize() function of
the R software (R Development Core Team, 2006). Finally, by repeating
this procedure for the different values of ~dþ r, we determine the value
of ~dþ r that maximized the likelihood of each transfection experiment,
as well as of the gene-specific rV0d parameters. With only one time
point of mRNA and protein measurement in the experiments of Baek
et al (2008), the parameter estimation problem is under-determined. As a
result, the experiments of Baek et al (2008) do not suggest a single, most-
likely estimate for ~dþ r but rather a range of values that are consistent
with the measurements (Supplementary Figure S4B). The values of ~dþ r
that we inferred from Wang’s miR-124 transfection, our miR-199
transfection, and Guo’s miR-155 and miR-1 transfections were within
these ranges. Fixing the value of this parameter to 0.014/h—a value
inferred from Wang’s miR-124 transfection (Figure 2)—we then estimated
the rV0d and l parameters for each gene, based on the measured change
in mRNA level at 24 h and protein change 48 h post transfection.
In experiments that also featured protein quantification or RPF
profiling data, we further obtained maximum-likelihood estimates of
the l parameter for each gene given the previously determined ~dþ r
and rV0d parameters and assuming the same Gaussian error model on
the log2 fold change as for the mRNA data. When fitting the SILAC data
of Baek et al (2008) and luciferase activities in our reporter system, we
used the protein dynamics defined by Equation (6) while Equation (7)
was used with the pSILAC data of Selbach et al (2008). In total, we
thereby analyzed 117, 154 and 106 genes with seed matches to miR-
124, miR-1 and miR-181 in Baek et al (2008) and 139, 211, 319, 197 and
157 genes in the let-7, miR-155, miR-16, miR-1 and miR-30a
transfections of Selbach et al (2008) for which protein turnover
measurements were available (Cambridge et al, 2011). In the case of
the RPF profiling experiments of Guo et al (2010), we first computed
the log2 fold change in translation efficiency ri–mi from the log2 fold
change in RPF ri and mRNA abundancemi. In the case of our qPCR and
luciferase measurements, we set the decay rate s of the luciferase to
0.14/h (see https://tinyurl.com/promegaBatesLuciferase). We then
fitted l by comparing the measured log2 fold change in translation





previously described Gaussian error model, where ~aðtÞ is the change
in the mRNA decay rate (Equation 3).
Fitting changes in luciferase activity and mRNA
abundance upon miRNA induction
We first fitted the X0d parameter from temporal changes in the mRNA
level by maximum likelihood assuming a Gaussian error model on the
measured log2 fold change. The standard deviation was set to the
standard error computed from triplicate measurements. By the same
method as in the previous paragraph, we first determined the
maximum-likelihood estimate of X0d from the qPCR data based on
the Ago-loading dynamics of Equations (14) and (10), and then
estimated l from the luciferase activities using Equation (11).
Simulations
We simulated the dynamics of miRNAs and their targets under two
regulatory scenarios using the same model as in an induction
experiment (Equations 14, 10 and 11), where a miRNA is synthesized
into an Ago accessible compartment X. We used parameter estimates
from the biophysics data of Ohrt et al (2008) for association g,
dissociation u and decay d. d was set to 7.32 (see below for the
justification). Protein decay rate s was initially set to 0.015/h (48 h
half-life).
Simulating protein recovery after a sudden block in
miRNA expression
We set X(0) to 18 000 which in the context of the other parameters
implied that 50% of Agos are loaded with the miRNA at steady state
(Supplementary Figure S5). This is representative of the case of highly
expressed miRNAs such as miR-430 in the zebrafish embryo (Chen
et al, 2005) or miR-122 in liver (Landgraf et al, 2007). We used
measurements made on the miR-223 knockout neutrophils (Baek et al,
2008) to determine d; namely, from the observations that miR-223
represents 5% of all miRNAs in neutrophils (Baek et al, 2008) and that
miR-223 targets are upregulated by 37% upon miR-223 knock-out (log2
value of 0.45 in Supplementary Table S2), we can use Equation (9) to
infer that the miRNA can change the rate of mRNA decay by a factor
d ¼ 0:370:05 ’ 7:4 when Ago is fully saturated with the miRNA. The
protein decay rate s was initially set to 0.015/h (48 h half-life). At
t¼ 0 h, miRNA synthesis stops, that is c(t)¼ 0. Initial conditions were
computed under the scenario that all variables are at steady state at
t¼ 0 h. By solving Equations (10), (11) and (4) at steady state, we
obtain að0Þ ¼ gXð0Þu , fmð0Þ ¼ 11þ ~að0Þ and fpð0Þ ¼ fmð0Þ1þ l~að0Þ. We then
simulated free miRNAs X, loaded Ago a, mRNA fm and proteins
fp according to Equations (10), (11) and (4) (see Supplementary
Figure S5). In the absence of the miRNA, the fold change in protein
level is fp¼ 1 by definition, but the value 1 is reached only as t tends
toward infinity. We defined the recovery time as the amount of time
necessary for fp(t) to exceed 0.9. We then monitored the recovery time
as a function of the protein decay rate which we varied between 0.014/
h and 0.14/h (corresponding to half-lives ranging from 5 to 48 h), and
general miRNA kinetics where we multiplied g¼bf0, u and d by a
common factor k ranging from 1 to 3. Finally, simulations were
performed under two scenarios: no translation repression l¼ 0 and
equal contribution of translation repression and mRNA decay l¼ 1.
Computing the amplitude of oscillations in protein
abundance in response to a miRNA with cyclic
expression pattern
In this simulation, we sought to reproduce the observations of Krol
et al (2010) by implementing the scenario in which miRNA synthesis
was half-activated during the first 12 h of a 24-h cycle, and then fully




2X0d if 0  t mod24o12
X0d if 12  t mod24o24

We again set X0 to 18 000 which in the context of the other parameters
implies that 50% of Agos would be loaded with the miRNA if miRNA
synthesis remained fully active long enough for steady state to be
reached. Note that defining miRNA synthesis as a function of the
miRNA decay rate d makes it possible to change the rate d without
changing the amount of free miRNA and loaded Ago. Initial conditions
were computed numerically by simulating free miRNAs X, loaded Ago
a, mRNA fold change fm and protein fold change fp according to
Equations (10), (11) and (4) for 100 cycles (2400 h). From these initial
conditions, we then simulated another three cycles (72 h) for
visualization purposes (see Supplementary Figure S5). We then
defined the amplitude of the oscillations as the ratio
maxfpðtÞ
minfpðtÞ between
the highest and smallest protein levels achieved in these three cycles.
We monitored the amplitude of protein oscillations as a function of the
protein decay rate which we varied between 0.014/h and 1.39/h
(corresponding to half-lives ranging from 30 min to 48 h). In addition,
the measurements of Krol et al (2010) suggest that miRNAs responding
to light-dark adaptation undergo fast turnover, with half-lives as short
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as 30 min, 14 times faster than the observed decay in the fluorescence
cross-correlation spectroscopy experiments of Ohrt et al (2008) and
used in our model. We therefore varied the miRNA decay rate, Ago
association rate and Ago dissociation rates between their original
values up to a 14-fold increase. Thereby, we varied the miRNA decay
rate from d¼ 0.10/h to 1.39/h, the Ago dissociation rate from u¼ 0.12/
h to 1.61/h and the normalized association rate from g¼ 3.1110 6/
molecule/h to 4.2710 5/molecule/h.
Supplementary information
Supplementary Information is available at the Molecular Systems
Biology website (www.nature.com/msb).
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2.2 Extended results 
2.2.1 Northern blot analysis of induced miRNA expression 
We used the following experimental approach to validate the kinetic models of mRNA and 
protein level changes in response to miRNA transfections or induction. Two miRNAs which 
are not usually expressed in HEK cells, hsa-miR-199a-3p and hsa-219-5p, were either 
transfected or induced in the appropriate cell lines and then the kinetics of miRNA 
dependent gene regulation (mRNA level changes or luciferase activities were followed). 
Initially, to pin down bona fide targets for these miRNAs, stable cell lines with doxycycline 
(DOX) inducible miRNA expression were established. Primary hsa-miR-199a-3p, hsa-
miR219-5p and hsa-miR-30a were cloned and sub-cloned in an inducible episomal pRTS-1 
vector [142]. Stable clones were isolated based on hygromycin selection and tested for 
miRNA expression with Northern blot upon induction with DOX.  MiR-30a clones were 
used as controls to compare the expression levels from the induction system with the 
endogenous miRNA levels from non-induced cells. To determine the dose dependency of 
the expression of inducible pRTS-1, stable cell lines of inducible miRNA-199a-3p and 
miRNA-219-5p were induced with different concentrations of DOX starting form 100ng/ml 
to 1µg/ml.  10µg of total RNA was isolated at different time intervals after induction with 
DOX. Expression of miRNA-199a-3p (Figure 4A&B) and miRNA-219-5p (Figure 4C) was 
observed to be dose dependent at the early time points. MiRNAs were expressed after 2 
hours of induction.  No leaky expression was observed in the Northern blots in the 
absence of DOX. The hsa-miR-30a expression was used to compare the expression of 
inducible system with the endogenous miRNA levels as shown in Figure 4D. 
Figure 4: Northern blot analysis of miR-199a-3p and miR-219-5p. These miRNAs were cloned in pRTS-1 
vectors and expressed upon induction with DOX. Expression from the pRTS-1 vector was induced with 
different concentrations of doxycycline and the expression of miRNAs was analyzed at different time 
intervals by Northern blot. 10µg of total RNA was isolated from stable HEK293T cells with inducible 
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expression of miRNAs for Northern blots. (A). Expression of miRNA-199a-3p was titrated with concentrations 
of doxycycline ranging from 100ng/ml to 1µg/ml. The data shows that expression is dose dependent at the 
early time points, eventually saturating after 48hrs of induction. Expression is so tightly regulated that in the 
absence of DOX no leaky expression is observed. (B) Expression of miR-199a-3p is visible on the blots 2hrs 
post induction with defined concentration of 1µg/ml. (C) Northern blot of miR-219-5p expression in 
presence and absence of DOX at different time intervals starting from 2 hrs. (D) In the cell line with inducible 
hsa-miR-30a expression, the expression upon induction with 1µg/ml of DOX was 1.5 fold higher compared to 
the expression from the endogenous locus, in absence of DOX induction. This indicates that the system was 
able to express miRNAs comparable to the endogenous levels, confirming the robustness of the system. 
2.2.3 Validation of targets by luciferase assays 
Targets for hsa-miR199a-3p and hsa-miR-219-5p were predicted using ElMMo [126]. We 
selected from predicted targets some that had one binding site in the 3’UTR with high 
probability of being under selective pressure (p>0.7) and with a length shorter than 1500 
nts enabling efficient cloning. To validate the computationally predicted targets of miR-
199a-3p and miR-219-5p, we performed luciferase assays.  The 3’UTR of predicted target 
transcripts were cloned in the multiple cloning site of a dual luciferase reporter psiCHECK-
2 vector. After transient transfections of these reporter vectors into the stable cell lines 
containing miR-219-5p or miR-199a-3p, the expression of these miRNAs was induced with 
1µg/ml of doxycycline. 48 hours after induction, we performed the luciferase assay. None 
of the predicted targets of miR-219-5p showed a substantial downregulation upon miRNA 
induction (Figure 5B), whereas upon the induction of miR-199a-3p, some of its targets 
underwent 30-50% downregulation (Figure 5A). One target KTN1 for hsa-miR199a-3p was 
significantly downregulated and chosen for subsequent experiments. The list of primers 
used to clone pri-miRNAs in pRTS-1 vector, the 3’UTRs in psiCHECK-2 vector and the 
probes used for hybridization in miRNA Northerns are listed in Tables 1 to 4. 
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Figure 5: Validation of the predicted targets with luciferase assays. 3’UTRs with single binding sites for 
miRNAs were cloned downstream of Renilla luciferase. These vectors were transfected in the cell lines with 
inducible miRNA expression. After a 48-hour induction of miRNA expression, a luciferase assay was 
performed to measure the Renilla luciferase levels. Changes in the Renilla luciferase levels for hsa-miR199a-
3p (A) and hsa-miR-219-5p (B) targets are shown here. The error bars represent ±SEM values and n=3. 
2.2.4 Establishment of a cell line expressing a miRNA target as well as 
inducibly expressing the cognate miRNA 
To establish a stable cell line constitutively expressing Renilla luciferase with KTN1 3’UTR 
and its cognate miRNA (referred hereafter as KTN1 cell line), I co-transfected the 
psiCHECK2-KTN1 vector and a mammalian selection vector carrying a puromycin gene 
pPUR (clontech) construct into the hsa-miR199a-3p stable cell line in a 3:1 ratio. Thus, 
isolated stable colonies were expanded in presence of 0.75µg/ml of puromycin (Sigma-
Aldrich). A sketch of the experiment for constructing this cell line shown in Figure 7.  The 
integration of psiCHECK2-KTN1 vector in the host genome was confirmed by PCR as shown 
in Figure 8. This cell line was further induced with DOX and the Renilla luciferase activity 
was measured every 24 hrs. for 8 days. The hsa-miR-199a-3p expression for 8 days was 
confirmed with Northern blot as shown in Figures 6A and B. The mRNA-level expression of 
Renilla luciferase upon DOX induction of miRNA expression was measured with 
quantitative real-time PCR (qRT-PCR) (Figure 6C) and the luciferase activity was assayed 
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for 8 days (Figure 6D). The expression of Renilla luciferase with KTN1 ‘3UTR was 
consistently downregulated for 8 days at both mRNA and protein levels as shown in 
Figures 6C and D.  
Figure 6: Characterization of the KTN1 cell line. (A) The expression of hsa-miR-199a-3p was detected already 
at 2 hrs. after DOX induction. Furthermore the expression was consistently detected until 8 days with 
Northern blot. The miRNA expression saturated after 24 hrs. Upon induction of miRNA expression, Renilla-
KTN1 levels were measured at mRNA level by qRT-PCR (C) and protein level by luciferase assay for 8 days 
(D). The errors bars in (C & D) represent ± standard deviation of three technical replicates, n=3. 
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Figure7: Schematic representation of the experiment for the establishment of the KTN1 cell line. The 3’ UTR 
of the kinectin 1 (KTN1) gene and the primary miR-199a-3p were PCR amplified and individually cloned into 
the multiple cloning site of a pGEM-T Easy vector. The 3’ UTR was subcloned to a reporter psiCHECK-2 
vector, whereas the primary miR-199a-3p was subcloned to an inducible episomal pRTS-1 vector through 
defined restriction sites. (A) First we constructed a stable cell line with inducible miRNA expression from a 
pRTS-1 vector. (B) Into the stable cell line with inducible miRNA expression, the reporter and pPUR vectors 
were co-transfected for stable integration. 
Figure 8: PCR confirming the genomic integration of KTN1 3’ UTR-psiCHECK2 vector in the KTN1 cell line. 
Primers were designed to specifically amplify the 3’UTR of Renilla luciferase (KTN1 3’UTR) from the KTN1 cell 
line. Lane 1 shows the genomic PCR product of KTN1 3’UTR from the integrated psiCHECK-2 vector, lane 2 
shows the standard DNA marker with the sizes of fragments labeled. Primers are listed in Table 4. 
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Table 1. List of targets of hsa-miR-199a-3p and their primers used to clone in the multiple cloning site of 
psiCHECK-2 vector. 
hsa-miR-199a-3p 














































Table 2. List of targets of hsa-miR-219-5p and their primers used to clone in the multiple cloning site of 
psiCHECK-2 vector. 
hsa-miR-219-5p 













































Table 3. Primers used to PCR-amplify primary miRNA sequences from HEK293 cells. The PCR products were sub-
cloned into pRTS-1 vector. 

















Table 4. List of DNA probes to hybridize the miRNAs on Northern blots and the genomic PCR primers for 





KTN1 cell line primers 
Forward- GAGCGCGTGCTGAAGAACGAG Reverse- TTGCTGACGCCATTACAAAA 
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3. Analysis of CDS-located miRNA target sites
suggests that they can effectively inhibit 
translation 
Most research on miRNAs is confined to miRNA binding sites located in the 3’UTRs of the 
mRNAs. Recent studies, particularly with CLIP, revealed many miRNA target sites in the 
coding region (CDS), but the function of these sites in modulating gene expression remains 
largely unexplored. Some experimental studies showed that miRNAs do target the CDS 
regions and function in the modulation of gene expression, even in the absence of seed 
complementarity. These studies proposed that repression on these sites instead depends 
on the complementarity of the region downstream of the seed [121, 143]. In another 
study it was shown that miR-519 represses the translation of RBP HuR which in turn 
reduces the levels of downstream targets of HuR involved in cell division [144]. There are 
also reports showing that the plant miRNAs are able to induce translational repression via 
imperfect complementarity interactions with target sites in CDS and 3’UTRs [145, 146]. 
Similarly, evidence showing that functional miRNA target sites are located in CDS regions 
of mammalian transcripts has been provided [147-149], with miRNAs affecting both mRNA 
and protein levels. Reanalysis of the protein and mRNA level data generated by Baek et al. 
[132] found that there is strong effect in the regulation of the genes with target sites 
present in both CDS and 3’UTR compared to genes that only have miRNA binding sites in 
3’UTR [150]. 
Application of high throughput approaches for isolating Argonaute- bound target sites 
indicates [138, 140] that CDS sites are as numerous as those located in 3' UTRs, although 
the density of Argonaute-bound sites is higher in 3' UTRs as compared to CDS. In the 
following study we analyzed putative miRNA target sites that are located in coding 
regions, with the aim of uncovering the function of such sites by comparison with sites 
that are located in 3' UTRs. The target sites that we used in our analysis were either 
predicted computationally or inferred on the basis of transcript- or protein-level changes 
following miRNA transfections. Our results indicate that CDS and 3' UTR target sites co-
evolved, have similar sequences and structure properties, and may have similar efficiency 
in inducing translational repression of the transcripts in which they reside. On the other 
hand, sites located in 3'UTR are much more effective at inducing mRNA degradation, as 
reported [132, 140, 149, 150]. Analyzing recently published data of ribosome-protected 
fragment profiles upon miRNA transfection [151] from the perspective of the location of 
miRNA-complementary sites, we additionally found that sites located in the CDS are most 
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potent in inhibiting translation, while sites located in the 3′ UTR are more efficient at 
triggering mRNA degradation. Our study suggests that miRNAs may combine targeting of 
CDS and 3′ UTR to flexibly tune the time scale and magnitude of their post-transcriptional 
regulatory effects. 
3.1 Statement of my work 
My contribution to this study was to validate the observation that CDS-located miRNA 
binding sites were efficient in inhibiting translation. For this, I have established a stable 
inducible hsa-miR124-3p HEK cell line using an episomal vector pRTS-1 and I have cloned 
CDS regions with at least one miRNA binding site just upstream of the stop codon of 
Renilla luciferase in psiCHECK-2 vectors, by the method of overlap extension PCR.  Psi-
CHECK-2 vectors were transiently transfected in inducible miR-124 cell line.  At certain 
time intervals, upon DOX induction of miRNA expression, changes in the mRNA and 
protein levels were measured by qRT-PCR and luciferase assays. 
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Analysis of CDS-located miRNA target sites suggests
that they can effectively inhibit translation
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Biozentrum, University of Basel and Swiss Institute of Bioinformatics, 4056 Basel, Switzerland
Most of what is presently known about how miRNAs regulate gene expression comes from studies that characterized the
regulatory effect of miRNA binding sites located in the 39 untranslated regions (UTR) of mRNAs. In recent years, there
has been increasing evidence that miRNAs also bind in the coding region (CDS), but the implication of these interactions
remains obscure because they have a smaller impact on mRNA stability compared with miRNA-target interactions that
involve 39 UTRs. Here we show that miRNA-complementary sites that are located in both CDS and 39-UTRs are under
selection pressure and share the same sequence and structure properties. Analyzing recently published data of ribosome-
protected fragment profiles upon miRNA transfection from the perspective of the location of miRNA-complementary
sites, we find that sites located in the CDS are most potent in inhibiting translation, while sites located in the 39 UTR are
more efficient at triggering mRNA degradation. Our study suggests that miRNAs may combine targeting of CDS and
39 UTR to flexibly tune the time scale and magnitude of their post-transcriptional regulatory effects.
[Supplemental material is available for this article.]
MicroRNAs (miRNAs) are ;21 nt (nucleotide)-long regulatory
RNAs that are encoded in the genomes of species ranging from
viruses to human. They formmiRNA-induced silencing complexes
(miRISCs) with Argonaute proteins which they guide, through
hybridization, to target mRNAs whose expression is subsequently
down-regulated (Bushati and Cohen 2007; Bartel 2009). In plants,
miRNAs typically trigger the endonucleolytic cleavage of their
targets through perfect or near-perfect complementarity interac-
tions with transcript coding regions (CDS) ( Jones-Rhoades et al.
2006). In contrast, in mammals they have been shown to interact
predominantly through their ‘‘seed region’’ (nucleotides 2–8 from
the 59 end of the miRNA) with 39 untranslated regions (39 UTRs)
of mRNAs (Lewis et al. 2005), inducing their destabilization and
translational inhibition (Filipowicz et al. 2008). In recent years,
the distinction between the mode of action of plant and animal
miRNAs has become less clear. There is growing evidence that
plant miRNAs can induce translational repression via imperfect
complementarity interactions with target sites in CDS and 39UTRs
(Brodersen et al. 2008; Lanet et al. 2009). Likewise, increasingly
many miRNA target sites are discovered in coding regions of
mammalian transcripts (Forman et al. 2008; Huang et al. 2010; Qin
et al. 2010; Ott et al. 2011). Application of high-throughput ap-
proaches for isolating Argonaute-bound target sites indicates that
CDS sites are as numerous as those located in 39 UTRs (Chi et al.
2009; Hafner et al. 2010), though the density of Argonaute-bound
sites is higher in 39 UTR compared with CDS (Hafner et al. 2010).
If CDS sites are as common as Argonaute cross-linking and
immunoprecipitation (CLIP) studies indicate (Chi et al. 2009;
Hafner et al. 2010), one wonders why there are relatively few re-
ports on their involvement in gene regulation and why the studies
that have been so far published suggest thatCDS sites aremuch less
effective in down-regulating mRNA levels upon miRNA trans-
fection (Baek et al. 2008; Hafner et al. 2010; Fang and Rajewsky
2011; Schnall-Levin et al. 2011). A reason may be that CDS sites
function in specific contexts, in which coding regions are acces-
sible to the miRNA-loaded silencing complex, while under normal
conditions the process of translation hinders miRNA binding to
these sites (Bartel 2009; Gu et al. 2009). Alternatively, it may be
that only a specific subset of miRNAs targets coding regions. For
instance, it has recently been found that hsa-miR-181a targets
multiplemembers of the C2H2 zinc finger domain family, through
multiple CDS sites that occur precisely in the regions of the tran-
scripts that encode the C2H2 domains (Schnall-Levin et al. 2011).
However, the CDS sites that have been isolated in CLIP experi-
ments do not seem to correspond to a restricted subset of miRNAs,
and they also did not require that the cells were treated in some
specific way to expose the use of CDS sites. Thus, none of the hy-
potheses mentioned above can explain the discrepancy between
the apparent abundance of CDS sites and the paucity of reports
about their function.
Evolutionary conservation has been successfully employed to
predict regulatory elements, including binding sites for miRNAs in
39 UTRs (Krek et al. 2005; Lewis et al. 2005; Gaidatzis et al. 2007).
Hurst (2006) used a limited experimentally verified data set that
was available at the time to demonstrate that miRNA target sites
located in coding regions exhibit significantly low evolutionary
rates inmammals. Evolutionary conservation-based approaches to
predict miRNA target sites in coding regions followed. Forman
et al. (2008) used alignments of CDS regions in 17 species to identify
conserved miRNA-complementary sites in 700 human genes.
Among themiRNAs with themost predicted CDS sites were hsa-let-
7a-5p, hsa-miR-9-5p, hsa-miR-125a-5p, and hsa-miR-153. These
authors further demonstrated experimentally that hsa-let-7b-5p
down-regulates the miRNA-processing enzyme Dicer, whose tran-
script carries multiple complementarities to let-7 in its coding re-
gion. Schnall-Levin et al. (2010) allowed for the possibility that sites
are not perfectly conserved among ‘‘all’’ genomes used in the in-
ference to show thatmiRNA targeting inCDS is as commonas in the
39 UTRs in Drosophila species. They further predicted 26,000 and
14,000 sites inhuman 39UTR andCDS regions, respectively. Finally,
Fang and Rajewsky (2011) found evidence that mRNAs that are si-
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more destabilized than mRNA targeted only in the 39 UTR, while
Schnall-Levin et al. (2011) showed that mRNAs with several miRNA
binding sites in the CDS can effectively be degraded.
In the present study we analyzed putative miRNA target sites
that are located in coding regions, with the aim of uncovering the
function of such sites by comparison with sites that are located in
39 UTRs. The target sites that we used in our analysis were either
predicted computationally or inferred on the basis of transcript- or
protein-level changes following miRNA transfections. Our results
indicate that CDS and 39 UTR target sites co-evolved, have similar
sequence and structure properties, andmay have similar efficiency
in inducing translational repression of the transcripts in which
they reside. On the other hand, sites located in 39 UTR are much
more effective at inducing mRNA degradation, as reported before
(Baek et al. 2008; Guo et al. 2010; Hafner et al. 2010; Fang and
Rajewsky 2011).
Results
Both CDS and 39 UTR sites are under evolutionary selection
The applicationof the ElMMomodel tomiRNA target prediction in
39 UTRs was described before (Gaidatzis et al. 2007) and recent
assessments indicate that ElMMo is among the most accurate
miRNA target prediction methods available (Alexiou et al. 2009;
Hafner et al. 2010; Sturmet al. 2010). ElMMo is parameter-free and,
by building its background model from the appropriate type of
regions, it can in principle predict miRNA target sites in transcript
or genomic regions that do not correspond to 39 UTRs. Here we
applied ElMMo to predict miRNA target sites in coding regions.
To determine whether the ElMMo-predicted CDS sites are func-
tional we analyzed eight published data sets (listed in Table 1) that
compared mRNA expression before and after transfections of in-
dividual miRNAs. In each of these experiments, we identified all
mRNAs that carried precisely one 2–8 seedmatch to the transfected
miRNA, and we selected 250 transcripts that were most down-
regulated and 250 that responded least to transfection. We sepa-
rated each of these sets in two subsets: transcripts in which the site
was located in the CDS, and transcripts in which the site was lo-
cated in the 39UTR.We then computed the t-values comparing the
ElMMo scores of the sites that induced an effect with those that did
not induce an effect and we computed the overall t-value over the
data sets. As Figure 1A (and Supplemental Fig. 1) shows, both CDS
and 39 UTR sites that are located in down-regulated transcripts
have a higher probability to be under selection comparedwith sites
that are located in transcripts that do not respond to transfection.
We further asked whether miRNA-complementary sites that are
isolated in Argonaute CLIP experiments also have higher ElMMo
scores compared with those that are not isolated (Fig. 1A). We
used the Argonaute CLIP data of Kishore et al. (2011) (Table 1) and
identified allmatches to the 2–8 seed of the top 10 expressedmiRNA
families in transcripts from which CLIP reads were obtained. In
principle, these transcripts were expressed and bound by Argonaute
proteins, so the transfected miRNAs should have had access to all
seed-matching sites in these transcripts.We separated the set of seed
matches into those that were the most enriched in CLIP and those
that were least enriched in CLIP and compared the distributions of
ElMMo scores of the two subsets of sites. As shown in Figure 1A (and
Supplemental Fig. 1), we found that CLIPed CDS sites had a signif-
icantly higher score compared with non-CLIPed sites. These results
indicate that ElMMo predicts functional sites not only in 39 UTRs
but also in CDSs.
ElMMo further estimates a miRNA-specific probability that
a site that is complementary to the miRNA in the reference species
(in this case human) is under selection in at least one other species
taken into account in the miRNA target prediction. Here we
used genome sequence data of the species Pan troglodytes, Rhesus
maccacus,Canis familiaris, Rattus norvegicus,Musmusculus, Bos taurus,
Monodelphis domestica, and Gallus gallus to predict sites that are
under evolutionary selection. This probability is high when the
miRNA-complementary motifs are strongly conserved and low
when they are weakly conserved across species, relative to motifs
that are not complementary to miRNAs. As shown in Figure 1B,
the probabilities of miRNA-complementary sites to be under selec-
tion pressure are strongly correlated between CDS- and 39 UTR-
located sites of individual miRNAs (r = 0.77). For comparison, we
estimated the average phastCons conservation score (Siepel et al.
2005) for CDS and 39 UTR occurrences of individual motifs, and
found a similar but weaker correlation (Supplemental Fig. 8).
Further supporting the functionality of miRNA-complementary
sites located in both CDS and 39 UTR, the phastCons scores of
these motifs are significantly higher compared with those of
other 7mers in both types of regions (Supplemental Fig. 8). These
results suggest that CDS and 39 UTR sites evolve in parallel and
that CDS sites must have a function that confers a selective ad-
vantage in evolution.
miRNAs that function in embryonic development co-target
the 39 UTR and the CDS
The proportion of miRNA-complementary sites estimated to be
under evolutionary selection in CDS as opposed to 39 UTRs differs
between miRNAs (Fig. 2A). We found that this is due to a combi-
nation of factors. First, the sequence composition of CDS and
39 UTR differ, with the result that some motifs are more abundant
in CDS and others in 39 UTR (Supplemental Fig. 9). Additionally,
the relative lengths of CDS and 39 UTR of the targeted transcripts
and the relative selection pressure onmiRNA-complementarymotifs
in the two types of regions (Supplemental Fig. 10) also contribute
to preferential targeting of CDS vs. 39 UTR. Interestingly, miRNAs
that contain the AGCAGC motif at the 59 end (hsa-miR-16-5p,
hsa-miR-15a/b-5p, hsa-miR-195-5p, hsa-miR-103-3p, hsa-miR-107,
hsa-miR-646, hsa-miR-424-5p, hsa-miR-497-5p) and that have been
previously shown to regulate cell cycle (Linsley et al. 2007; Fulci
et al. 2009; Forrest et al. 2010; Balatti et al. 2011) have many more
complementary sites in the CDS compared with 39 UTR (Fig. 2A).
On the other hand, motifs that are complementary to miRNAs
with embryonic expression—hsa-miR-302a-3p, hsa-miR-369-3p,
hsa-miR-372, hsa-miR-373-3p, hsa-miR-374b/c-5p (Suh et al. 2004),
thehomologs ofwhichhavebeen shown to be involved inmaternal
Table 1. The data sets that we used to identify properties
of functional miRNA binding sites in the 39 UTR and in the CDS
Data type Source
mRNA expression profiling after
miRNA transfection
Grimson et al. (2007), Karginov
et al. (2007), Linsley et al. (2007),
Baek et al. (2008), Selbach et al.
(2008), Hausser et al. (2009),
Guo et al. (2010)
EIF2C2 binding data from CLIP Kishore et al. (2011)
Evolutionary selective pressure
inferred with ElMMo
Gaidatzis et al. (2007)
Protein expression profiling upon
miRNA transfection
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mRNA clearance in zebrafish (Giraldez et al. 2006)—or to the on-
cogenic miRNAs of the miR-17 family—hsa-miR-17-5p, hsa-miR-
20a/b-5p, hsa-miR-93-5p, hsa-miR-106a/b-5p (He et al. 2005)—are
more frequent in the 39 UTRs (see also Supplemental Table 1).
Given that a large fraction of miRNAs appear to prefer tar-
geting of either the CDS or the 39 UTR, we asked whether some
miRNAs tend to simultaneously target the 39 UTR and the CDS of
the same transcript. To answer this question, we determined the
number of genes that contained both one of the 250 highest-
scoring CDS binding sites and one of the 250 highest-scoring
39 UTR sites for a given miRNA, as predicted by the ElMMo algo-
rithm. We then determined the fold enrichments in the number
of such co-targeted genes relative to what would be expected
if miRNAs targeted the CDS and the 39 UTR independently (see
section ‘‘Enrichments in the number of genes co-targeted in the
CDS and in the 39UTR’’ inMethods).We found significant evidence
of CDS and 39 UTR co-targeting for 62 human miRNAs (P < 0.05 at
Fisher’s exact test after Bonferroni correc-
tion; see Supplemental Table 2). Among
these were many miRNAs with impor-
tant functions: the epithelial cell-specific
(Gregory et al. 2008) hsa-miR-141-3p/
200a-3p (P < 1011), the embryonic stem
cell-expressed (Suh et al. 2004; Stadler
et al. 2010)hsa-miR-302/372/373-3p/520a-
3p (P < 108), the oncogenic component
of the mir-17/92 cluster hsa-miR-19a-3p
(P < 106) (Ventura et al. 2008; Olive et al.
2009), the oncogenic hsa-miR-130b-3p/
hsa-miR-301a-3p miRNAs (P < 106) (Shi
et al. 2011), and the hsa-miR-137 (P <
106), that is involved in neural matura-
tion (Smrt et al. 2010; Sun et al. 2011).
The tendency for these miRNAs to
target both the CDS and the 39 UTR of
individual mRNAs cannot be explained
by a general tendency of motif co-occur-
rence in the CDS and 39 UTR of the same
transcripts because co-targeting enrichments beyond threefold are
very rarely observed for random motifs (Supplemental Fig. 11).
Interestingly, the miRNAs for which we find evidence for CDS
and 39 UTR co-targeting are among those that preferentially target
39UTRs (P-value of the average CDS vs. 39UTR preference for these
miRNAs is significantly >0, P < 1015; see ‘‘Statistical evidence that
CDS and 39 UTR co-targeting occurs mostly for miRNAs that
preferentially target 39 UTRs’’ in Methods). This is illustrated in
Figure 2B. Each dot in the figure represents a miRNA. The x-axis
shows the preference of the miRNA for CDS vs. 39 UTR targeting
defined as the signed distance to the line representing the scaling
between the number of CDS and 39 UTR sites (Fig. 2A) for the re-
spective miRNA. The y-axis shows the co-targeting enrichment.
miRNAs that target the CDS and 39 UTR of the same transcripts
significantly more often than expected by chance appear in
red. Interestingly, overexpression ofmost of these CDS/39UTR–co-
targeting miRNAs has been linked with tumorigenesis (Voorhoeve
Figure 1. (A) CDS- and 39 UTR-located miRNA binding sites that induce mRNA degradation or are
isolated in EIF2C2 CLIP experiments are under stronger selection pressure compared with miRNA-
complementary sites that were not functional in these experiments; 2274 CDS- and 3956 39 UTR-lo-
cated sites that inducemRNA degradation are compared with 3513 CDS- and 3268 39UTR-located sites
that do not induce mRNA degradation; 751 CDS- and 786 39 UTR-located sites isolated in EIF2C2 CLIP
experiments are compared with 1059 CDS- and 956 39 UTR-located sites that do not induce EIF2C2
binding. (B) Scatter plot of the inferred probabilities that CDS- and 39 UTR-located sites complementary
to individual miRNAs are under selection. (Dashed red line) First principal component of the scatter.
Figure 2. Individual miRNAs differ in their preference for targeting the CDS and the 39 UTR as well as in their tendency to simultaneously target the CDS
and the 39 UTR of individual genes. (A) Number of complementary motifs, weighted by their respective ElMMo posteriors, of individual miRNAs in CDS vs.
39 UTRs. (Red dashed line) Scaling between the number of CDS and 39 UTR sites, defined as the line that goes through the origin and maximizes the
projected variance. (B) Scatter plot of the CDS vs. 39 UTR targeting preference of individual miRNAs against the fold enrichment in transcripts that are
targeted in both the CDS and 39 UTR relative to what would be expected if the sites were independently distributed. (Red dots) miRNAs with statistically
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et al. 2006; Huang et al. 2008; Olive et al.
2009; Mateescu et al. 2011; Shi et al.
2011).
Functional CDS and 39 UTR binding
sites have similar sequence
and structure properties
Previously, we found that miRNA binding
sites that are located in 39 UTRs and are
effective in mRNA degradation have spe-
cific properties such as structural accessi-
bility and a U-rich sequence context
(Hausser et al. 2009). We further found
that highly conserved miRNA target sites
share these properties, suggesting that
miRNA target sites in 39 UTRs have been
selected in evolution based on their ability
to induce mRNA degradation. We there-
fore asked whether target sites that are lo-
cated in the CDS and are functional
according to the criteria we defined for
39 UTR sites also share these properties. As
before (Hausser et al. 2009), we took a sys-
tematic approach, making use of micro-
array, CLIP, pSILAC, and SILAC measure-
ments as well as the predicted target sites
that we obtained above, with their asso-
ciated posterior probabilities (Table 1).
Functional target sites were defined as
those that had a high posterior probability
of being under evolutionary selection or
those whose associated transcripts or pro-
teins responded in miRNA transfection
experiments (see Methods). Nonfunc-
tional target sites were defined as those
that had a low posterior probability of
being under evolutionary selection or
whose associated transcripts or proteins did not respond in miRNA
transfection experiments. For each target site, we computed 32
properties that quantify the structure and sequence context of
miRNA binding sites (listed in section 1.2 of the Supplemental
Material). We then calculated the t-value quantifying the difference
between the mean values taken by the properties among the func-
tional and nonfunctional target sites. A summary of the obtained
t-values is shown in Figure 3 and indicates that CDS- and 39 UTR-
located miRNA binding sites have largely similar properties (see
also Supplemental Figs. 1–7, 12). In particular, U-rich and structur-
ally accessible environments characterize functional miRNA tar-
get sites, irrespective of their location in CDS or 39 UTRs. The
correlation is considerably smaller for sites obtained based on
measurement of protein expression changes for reasons that are
presently unknown (Hausser et al. 2009). These results again
suggest that both types of sites experience similar selective con-
straints and should be equally functional.
mRNA destabilization occurs mainly when miRNAs bind
to sites in 39 UTRs
To investigate the possible function of CDS-located miRNA target
sites, we first compiled, from the miRNA transfection experiments
of Linsley et al. (2007) and Grimson et al. (2007), transcripts that
satisfied one of the following four mutually exclusive constraints.
They had either no seed match to the transfected miRNA in either
CDS or 39UTR, or precisely one seedmatch in the CDS, or precisely
one seed match located in the 39 UTR, or precisely two seed
matches, one in the CDS and the other in the 39UTR. A seedmatch
was again defined as a match to positions 2–8 of the transfected
miRNA. Figure 4 shows that compared with 39UTR sites, CDS sites
have a smaller, though still significant effect in inducing the deg-
radation of the host transcripts. At least in some data sets, tran-
scripts that carry both types of sites are down-regulated to a sig-
nificantly lower level compared with transcripts that have only
one type of site (not shown), consistent with what Fang and
Rajewsky (2011) reported based on the analysis of the Baek et al.
(2008) and Selbach et al. (2008) data sets.
CDS binding sites can effectively inhibit translation
Although miRNAs significantly reduce the mRNA levels of their
targets (Bagga et al. 2005; Lewis et al. 2005), the initial paradigm
was that miRNAs inhibit translation without affectingmRNA levels
(Lee et al. 1993; Wightman et al. 1993), and the relative contri-
bution of these mechanisms is still a matter of debate (Eulalio
et al. 2008; Filipowicz et al. 2008; Be´thune et al. 2012; David 2012).
Recently, as a way to assess the extent of translation inhibition, Guo
et al. (2010)measured changes in ribosomeoccupancyuponmiRNA
transfection transcriptome-wide. They found that at 32 h post-
Figure 3. CDS and 39 UTR sites share common sequence and structure properties. Sets of functional
and nonfunctional binding sites were defined according to four different criteria—selective pressure,
efficacy in mRNA degradation, efficacy in reducing protein levels, and binding to EIF2C2—each cor-
responding to a different panel. We then compared t-values obtained in comparing functional and
nonfunctional sites from CDS (x-axis) and 39 UTR (y-axis) regions. Each property is represented in each
plot as a dot. Positive and negative values denote positive and negative predictors of functional miRNA
binding sites, respectively.
Function of CDS-located miRNA binding sites
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transfection, the reduction in ribosome occupancy of transcripts
with miRNA binding sites in 39 UTRs could be attributed in very
large measure (84%) to the reduction in mRNA levels.
We asked whether this observation holds equally true for
transcripts with miRNA-complementary sites that are located not
in the 39 UTR but rather in the CDS. We therefore analyzed the
behavior of transcripts carrying a single miRNA seed match in the
CDS and transcripts in which the single miRNA seed match oc-
curred in the 39 UTRs in the data of Guo et al. (2010). The data set
included mRNA and ribosome occupancy levels at 12 and at 32 h
post-transfection, which we analyzed as described in ‘‘Processing
of quantitative proteomics, microarrays and deep sequencing
data’’ inMethods. As shown in Figure 5 and previously reported by
Guo et al. (2010), transcripts that are targeted in the 39 UTR are
strongly down-regulated at 32 h after transfection, and their ri-
bosome occupancy at this time largely reflects the mRNA level.
Transcripts in which the single miRNA seed match occurred in the
CDS exhibit a similar behavior, though the reduction in their
mRNA levels ismore limited. Surprisingly, we found that transcripts
with a single miRNA seed match in the CDS exhibited a significant
reduction in ribosome occupancy at 12 h post-transfection that was
not due to a corresponding reduction in
mRNA levels (’’translation, 12 h’’ bars in
Fig. 5). In addition, the reduction in ribo-
some occupancywas increased formRNAs
with twomiRNA seedmatches in theCDS,
corresponding to an estimated 18% re-
duction in the translation rate (Supple-
mental Fig. 13). This suggests that miRNA
binding sites that are located in CDS are
effective in inducing translational in-
hibition immediately after miRNA trans-
fection while sites located in the 39 UTR
sites are effective in down-regulating the
mRNA levels.
To assess the generality of these
findings we revisited the data from a
very recent study that investigated the
miRNA-induced translational inhibition
and mRNA degradation during maternal-
zygotic transition in zebrafish (Bazzini
et al. 2012). In contrast to Guo et al.
(2010), who concluded that miRNAs have
very limited effects on translation, Bazzini
et al. (2012) identified a kinetic aspect of
the miRNA-induced response. Namely,
expression of the dre-miR-430 miRNAs
caused an initial, transient, translational
repression of the targets that was followed
by the degradation of their corresponding
mRNAs. Both CDS and 39UTR sites were
found to have a qualitatively similar ef-
fect, though CDS sites were much less
effective than 39UTR site (Bazzini et al.
2012). Reanalyzing the data of Bazzini
et al. (2012) we found, as before, that CDS-
located sites appear to induce translational
repression at the early time points but are
not effective in mRNA degradation (Sup-
plemental Fig. 14). In contrast, 39 UTR-
located sites induce transient translational
repression followed by mRNA degrada-
tion.We further analyzed transcriptomics and proteomics data that
were obtained a week after the induction of miR-223 deletion in
mouse (Baek et al. 2008). As shown in Supplemental Figure 15, the
expression levels of mRNAs with CDS sites change very little upon
knockout of miR-223 whereas their translation increases in the ab-
sence of the miRNA to a degree comparable to the translation of
transcripts with binding sites in 39 UTRs. Finally, we constructed
reporters to measure the effect of a miRNA on the protein and
mRNA level of miRNA targets with CDS-located target sites. First,
we generated a HEK293T stable cell line containing an episomal
pRTS-1 vector fromwhich the expression of hsa-miR-124-3p can be
induced with doxycyclin. We then selected two conserved CDS
miR-124 target sites that were represented with a relatively high
number of reads in the EIF2C2 (also known as Ago2) CLIP data of
Hafner et al. (2010). These are likely to be functional hsa-miR-124-
3p target sites. We inserted these sites in-frame, in their native se-
quence context, at the end of the Renilla-encoding coding region
of the dual luciferase psiCHECK2 vector. We also constructed
variants of these constructs that contained mutations in the
miRNA seed-complementary region (see Supplemental Methods
and Supplemental Fig. 16). We then estimated the protein ex-
Figure 4. mRNA destabilization occurs mainly through sites located in the 39 UTR. Shown are log2
fold changes inmRNA levels uponmiRNA transfection in the experiments of (A) Linsley et al. (2007) and
(B) Grimson et al. (2007). mRNAs with binding sites located in the CDS only, in the 39 UTR only, and in
both CDS and in 39 UTR were analyzed separately. Fold changes were normalized to the average fold
change of mRNAs that did not contain canonical binding sites to the transfected miRNA.
Figure 5. CDS-located binding sites transiently inhibit translation in miRNA transfection experiments.
The figure shows log2 fold changes in mRNA levels (mRNA-seq), and ribosome-protected fragments (rpf)
12 and 32h after hsa-miR-155-5p and hsa-miR-1 transfection. Changes in translationwere estimated from
the difference between changes in rpf and changes inmRNA levels. mRNAswith precisely one seedmatch
to the transfected miRNA in the CDS and no seed match in the 39 UTR were analyzed separately from
mRNAs with precisely one seed match in the 39 UTR and no seed match in the CDS. Fold changes were
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pression change (through luciferase assays) and the mRNA ex-
pression change (by qPCR) 24 h after the induction of hsa-miR-
124 expression. As shown in Supplemental Figure 17, wild-type
constructs exhibit a reduction in protein expression relative to
the mutant constructs that cannot be explained by a corre-
sponding decrease in mRNA levels. Thus, in human, mouse and
zebrafish, CDS-located miRNA binding sites appear to be more ef-
fective in translational inhibition than in mRNA degradation.
Discussion
In spite of much research, the mechanisms of action and the
function ofmiRNAs are insufficiently understood. An aspect that is
still highly debated is whether miRNAs inhibit translation, induce
mRNA degradation, or both. Recent high-throughput studies con-
cluded that the reduction in protein levels uponmiRNA expression
is largely a consequence of the mRNA degradation induced by
miRNAs (Baek et al. 2008; Selbach et al. 2008; Guo et al. 2010),
though these initial experiments may have missed an important
kinetic aspect (Bazzini et al. 2012). Another recurrent finding is
that changes in target mRNA level upon miRNA transfection or
overexpression are small. How these small effects can confer a
selective advantage that is reflected in the strong evolutionary
conservation of the target sites remains a puzzle. This applies
especially to target sites located in coding regions, whose effects
appear to be substantially smaller comparedwith those in 39UTRs
(Gu et al. 2009; Hafner et al. 2010; Schnall-Levin et al. 2010, 2011;
Fang and Rajewsky 2011). What then could the function of
miRNA-complementary CDS sites be?
Through an appropriate choice of a background set of se-
quences, the ElMMomodel that we previously developed (Gaidatzis
et al. 2007) allows us to predict miRNA binding sites in regions
other than 39 UTRs. We thus predicted miRNA binding sites in
CDS and used them to comparatively investigate the properties
and effects of miRNA-complementary sites that are located in the
coding domain or in the 39 UTR. We found that the sites that are
effective at various steps of the miRNA-induced cascade are under
evolutionary selection pressure. Furthermore, properties that we
previously found to characterize functional 39 UTR sites also char-
acterize the functional CDS sites. These findings suggest that CDS
and 39 UTR sites function through similar mechanisms and have a
comparable impact on gene expression.
Simultaneous measurement of mRNA and protein levels is
nontrivial for a variety of reasons.Obtaining a good coverage of the
proteome is difficult. Furthermore, proteomics measurements re-
quire that the proteins are labeled and this imposes constraints on
the timing of miRNA transfection (or induction of expression).
Sequencing of ribosome-protected fragments (rpf) circumvents
some of these problems. For the first time, our analysis of such data
reveals an effect that CDS-located miRNA binding sites are capable
of inducing more effectively than 39 UTR-located sites, namely
a rapid reduction inmRNA translation. In some of the data sets, the
effect appears to be transient. Why on longer time scales the re-
duction in rpf can be largely explained by the reduction of the
mRNA level is at the moment unclear. Some experiments involve
miRNA transfection,which is transient by nature. However, the dre-
miR-430 miRNA in zebrafish persists beyond 6 h post-fertilization
(hpf) when the translation inhibition is apparently relieved. Thus,
transient expression of the miRNA is probably not an explanation
in this case, although it cannot be entirely ruled out because dre-
miR-430 may be displaced from the RNA-induced silencing com-
plex by other miRNAs at later time points.
Interestingly, in both the zebrafish system and our reporter
system, some mRNAs with miRNA binding sites in coding regions
appear to be up-regulated upon miRNA expression. This may re-
flect another unsuspected complexity of the kinetics of miRNA-
dependent gene regulation (Bazzini et al. 2012; Be´thune et al.
2012; Djuranovic et al. 2012). In zebrafish, one could hypothesize
that the abundance of polyadenylated mRNAs, which are isolated
for mRNA expression profiling, differs between Dicer-deficient
and wild-type embryos. It is well known that polyadenylation is a
common means of regulation of mRNA stability and translation
(Telford et al. 1990; Audic et al. 1997; Henrion et al. 2000), with
deadenylation being reported to be sufficient for mRNA degrada-
tion (Audic et al. 1997). In the Bazzini et al. (2012) data, however,
what is observed is preferential stabilization of knowndre-miR-430
targets, which suggests either a direct involvement of miRNA-de-
pendent regulation or an indirect correlation caused by the overlap
between the set of mRNAs that undergo polyadenylation changes
in development and the set of dre-miR-430 targets. At this point
it is difficult to imagine how miRNAs would be directly involved.
miRNAs have been reported to induce deadenylation, particularly
miR-430 during maternal-zygotic transition in zebrafish (Giraldez
et al. 2006). However, at 2 hpf there should be no difference in the
mRNA level of miR-430 targets in Dicer-deficient and wild-type
cells, both of which lackmiR-430. InXenopus, it has been reported
that siRNAs impair the accumulation of the embryonically ex-
pressedmiR-427, restricting RNAi during early development (Lund
et al. 2011). If this effect were present in zebrafish as well and the
efficiency of the siRNAs were enhanced in Dicer-negative cells, it
could contribute to the observed stabilization ofmiR-430 targets at
2 hpf. These considerations, however, do not apply to our reporter
system. Because the effect appears to be reporter-specific, addi-
tional interplays with other regulators of mRNA stability and
translation rate may be at work. A few examples of crosstalk be-
tween RNA-binding proteins and the miRNA pathway have been
described (Bhattacharyya et al. 2006; Kedde et al. 2007; Kedde and
Agami 2008; Kim et al. 2009) and more are likely to emerge in the
future.
Finally, different families ofmiRNAs that are broadly expressed
but are active in different contexts show distinct preferences for the
CDS or 39 UTR. On one side of the spectrum are miRNAs expressed
in the embryonic cells and miRNAs of the miR-17-92 cluster, that
target predominantly 39 UTRs, but also show the strongest enrich-
ment in CDS–39 UTR co-targeting. This suggests that these miRNAs
strongly and robustly down-regulate target genes, for example at
developmental transitions. On the other side of the spectrum are
miRNAs of themiR-16 family,whichhavebeenpreviously shown to
regulate cell cycle (Linsley et al. 2007). These miRNAs appear to
preferentially bind to CDS-located sites, which we found to be ef-
fective in rapid inhibition of translation. This type of response may
be better suited on the time scale of the cell cycle. Future work will
determine themagnitude and timing of gene repression induced by
miRNAs binding to the coding regions to uncover new aspects of
miRNA biology.
Methods
Estimation of the selection pressure on CDS and 39 UTR
target sites
In a previous study, we introduced the ElMMomodel for inferring
miRNA target sites based on comparative genomics data (Gaidatzis
et al. 2007). ElMMo is parameter-free, requiring only a set of
Function of CDS-located miRNA binding sites
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miRNA-complementary, putative sites in a reference species and
pairwise genome alignments between the reference species and
other species. We only considered regions that were comple-
mentary to positions 1–7, 2–8, or 1–8 of the miRNA as putative
miRNA binding sites. Thus, miRNAs which are identical at po-
sitions 1–8 defined a miRNA family whose members have in-
distinguishable target sites according to our model. ElMMo pre-
dicts miRNA target site by estimating the selection pressure on
motifs that are complementary to specific miRNAs, relative to
a ‘‘background’’ set of motifs that do not correspond to miRNAs.
By simply changing the type of sequences in the input data set
(coding regions or 39 UTRs), ElMMo thus allows us to inde-
pendently estimate the selection pressure on binding sites for
individual miRNAs in CDS and 39 UTRs, respectively. We used
human as the reference species, and the RefSeq data set of human
transcripts downloaded from theNationalCenter for Biotechnology
Information (NCBI) as the set of transcripts in which we predicted
target sites.
Processing of quantitative proteomics, microarrays, and deep
sequencing data
mRNA sequences, gene to mRNA mappings, mRNA to protein mappings,
representative mRNA
We used the RefSeq mRNA database that we downloaded from
NCBI (www.ncbi.nlm.nih.gov) on Jan 18th 2011 for all analyses
described in this manuscript. The Entrez database provides us with
mappings ofmRNAs-to-genes and protein-to-genes. For each gene,
we defined a representative mRNA as the longest mRNA in RefSeq
featuring 59 UTR, coding domain, and 39 UTR annotation.
Computational analysis of quantitative proteomics and microarray data
We followed the methods previously described in Hausser et al.
(2009), except for minor changes in the analysis pipeline and for
the use of updated genomic, mRNA, and protein sequence data-
bases. The corresponding methods are described in the Supple-
mental Material.
Computational analysis of ribosome protected fragment sequencing
and mRNA profiling data from Guo et al. (2010)
Guo et al. (2010) analyzed mRNAs and ribosome-protected frag-
ments (rpf) in HeLa cells that weremock-transfected or transfected
with hsa-miR-1 or hsa-miR-155-5p. The deep sequencing data
was downloaded from the Sequence Reads Archive (accession:
GSE22004) and analyzed on the CLIPZ server (Khorshid et al.
2011). To obtain per-gene expression levels, we first computed the
number of readsmapping to representativemRNAs (longestmRNA
having annotated 59 UTR, CDS, and 39 UTR among those associ-
atedwith the gene according to the EntrezGene database ofNCBI).
The number of readswas subsequently normalized by the length of
the CDS in the case of rpf samples, or the length of the represen-
tativemRNA in the case of themRNA-seq samples. For the analysis,
we only considered 10,222 genes with nonzero expression levels
in all experimental conditions (mock, hsa-miR-155-5p, and hsa-
miR-1 transfections/mRNA and rpf sequencing/0, 12, and 32 h
after transfection).
To investigate the effect of the transfected miRNAs on mRNA
stability and translation, we first computed the log2 fold change in
rpf and mRNA expression upon miRNA transfection compared
with mock transfection. mRNAs were then divided into four sub-
sets: those with no binding sites to the transfected miRNA, those
with exactly one binding site located in the 39 UTR, those with
exactly one binding site located in the CDS, and mRNAs with two
binding sites in the CDS. Binding sites were defined as canonical
seedmatches—7mer-A1, 7mer-m8, 8mer (Bartel 2009). The overall
effect of the transfected miRNA on rpf and mRNA levels was esti-
mated by subtracting the log2 fold change of mRNAs without
binding sites from that of mRNAs with binding sites (defined as
above). Finally, the log2 fold change in translation induced by the
transfectedmiRNAswas estimated from the difference between the
log2 fold changes in rpf and mRNA levels.
EIF2C2 CLIP from Kishore et al. (2011)
We started from the raw CLIP and mRNA-seq reads (deposited in
NCBI GEO under the accession GSE28865) of the 6 EIF2C2 CLIP
experiments performed by Kishore et al. (2011). CLIP and mRNA-
seq data were processed on the CLIPZ server (Khorshid et al. 2011).
Only reads annotated asmRNA,mapping to a single genomic locus
and to a single representative mRNA were used. CLIPed sites were
defined as nonoverlapping 40-nt windows. For each mRNA, the
first window was centered on the position of the mRNA that ac-
cumulated most reads. Additional windows were extracted simi-
larly, under the constraint that they did not overlap with any
previously extracted window. For each window, we computed the
posterior probability that the number of CLIP reads associated to
the window was larger than expected in a statistical model that
only takes mRNA abundance into account (see ‘‘mRNA site ex-
traction from CLIP reads’’ below). Finally, we determined which
miRNAwasmost likely to be bound to thewindowby searching for
2–8 seed matches to the top 10 miRNA families expressed in
HEK293 cells. In case severalmiRNAsmapped to a binding site, the
site was assigned tomost highly expressedmiRNA. HEK293miRNA
profiles were determined from the two mild MNase digestion
EIF2C2 CLIP samples of Kishore et al. (2011), using the methodol-
ogy described in that paper.
mRNA site extraction from the EIF2C2 CLIP experiments
of Kishore et al. (2011)
Outline of the statistical model
For each of the c sites yielded by the CLIP experiment, we compare
the observed number of CLIP reads ri with the number of reads
expected under a backgroundmodel in which the number of reads
per CLIP site depends only on the abundance of the corresponding
mRNA.We neglect biases related to sequence accessibility, sequence
composition, etc. Instead, we will focus on how CLIP sites located
on mRNAs of different abundance are sampled in a thought ex-
periment in which all CLIP sites are equally prone to bind the RNA-
binding protein of interest and generate reads.
Estimating mRNA frequencies from mRNAseq data
Let us assume there are m genes, expressing different mRNAs. Al-
though a gene typically expresses multiple mRNA isoforms, we as-
sume for simplicity that each gene is represented by a single mRNA,
defined as the longest isoformwith59UTR,CDS, and39UTR thatwe
find in the RefSeq database of NCBI. Thus, having m genes repre-
sented bymmRNAs, we would like to compute the probability that
mRNA mi has relative abundance fi from the number of reads ni
corresponding to mRNA mi that we observe in a sample.
If n is the total number of mRNA-seq reads and qi is the (un-
known) probability that a read comes from mRNA mi, then the
number of mRNA-seq reads that map to mRNAmi can be modeled
to follow a binomial distribution:
P nijqi;n
  ¼ G nþ 1ð Þ







Cold Spring Harbor Laboratory Press on June 29, 2016 - Published by genome.cshlp.orgDownloaded from 
47
Using Bayes’s theorem, we can now compute the probability
of qi:
P qi jni;n





0 P nijq;nð ÞP qjnð Þdq
:
Assuming a uniform prior on qi, we obtain
P qi jni;n




G nniþ1ð ÞG niþ1ð Þ q
ni 1 qð Þnni dq
:
Setting a = ni + 1 and b = n ni + 1 and using the beta function
to compute the denominator yields the distribution on the prob-
ability qi for a read to come from mRNA mi:
P qi jni;n
  ¼ G aþ bð Þ





where n is total number of mRNA-seq reads and ni is the number of
reads mapping to mRNA mi.
The probability qi to obtain reads from mRNA mi is pro-
portional to both the relative abundance fi of mRNA mi, and the





where Z is a normalizing constant Z =+mi= ifi li. If the number of
distinct mRNAsm is large and if the relative abundance of mRNAs








What we are interested in is the relative abundance of mRNA
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This further yields
P fi
  ¼ li
Z
G nþ 2ð Þ









Finally, one can compute the expected relative abundance hfii
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Similarly, the deviation around the expected value hfii can be
obtained from the following fundamental property of the beta
distribution:
var qi
  ¼ ni þ 1ð Þ n ni þ 1ð Þ
nþ 2ð Þ2 nþ 3ð Þ :
Since var fi
 








, the standard devia-
tion around the expected value hfii becomes
sfi ¼
Z
li nþ 2ð Þ
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The number n of reads mapping to mRNA is typically in the
order of 106, with <1% of these reads mapping to the single most
abundant mRNA. As a result, sfi is <10
4.
Computing the distribution of the number of reads that is expected to fall into
CLIP sites based on the abundance of the mRNA in the mRNA-seq data
Let r be the total number of reads produced by the CLIP experi-
ment, ri of which map to CLIP site i, and let m(i) be the mRNA on
which CLIP site i is located. Let c be the number of CLIP sites ob-
served in the experiment. Because we only sample a finite number
of reads, CLIP sites competewith eachother for yielding sequenced
reads. In our thought experiment, all CLIP sites are equally prone
to be bound by the RNA-binding protein of interest and generate
reads. This implies that CLIP sites are sampled according to the
abundance of the mRNAs on which they reside. In that case,
the probability that a read maps to CLIP site i is
fm ið Þ
Q , where Q is the
normalizing constant +ci=1fm ið Þ.
And so, we can write the distribution of the number of reads
ri for site i as
P rijr; fm ið Þ

 
¼ G r þ 1ð Þ








However, we do not know the relative mRNA abundance fm(i),
only its distribution P(fm(i)). Ideally, we would like to integrate fm(i)
out to compute
P rijr;nm ið Þ; lm ið Þ
  ¼ ð1
0
P rijr; fm ið Þ
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nm ið Þ
Z  fm ið Þlm ið Þ

 nnm ið Þ







G r þ 1ð Þ
G ri þ 1ð ÞG r  ri þ 1ð Þ
G nþ 2ð Þ
G ni þ 1ð ÞG n ni þ 1ð Þ :
Since this integral cannot be solved analytically, we make the
approximation that all the probability density is concentrated at
hfm(i)i. Because mRNA-seq libraries are typically large (n > 106)
compared with the number of genes (m < 25,000), and because the
single most abundant mRNA usually represents <1% of the total
mRNA pool, this is a reasonable approximation to make, as shown
by Equation 2 and illustrated by Supplemental Figure 18. Ap-
proximating P( fm(i)) by its expected value
Z
lm ið Þ
nm ið Þ +1
n +2 (see Equation 1)
as opposed to the maximum likelihood estimate Zlm ið Þ
nmi
n has the ad-
vantage that the relative abundance of any mRNA is always non-
zero. This makes it possible to compute a probability of enrichment
using a simple formula, even for sites located on mRNAs with no
mRNAseq reads, as we will show now.
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The expected value approximation of P(fm(i) ) yields
P rijrð Þ ¼ G r þ 1ð Þ








where fm ið Þ =
Z
lm ið Þ
nm ið Þ +1
n+2 (see Equation 1) and Q =+
c









f m ið Þ
Q back in Equation 3 leads to
P rijrð Þ ¼ G r þ 1ð Þ













Ranking and selecting significantly enriched CLIP sites
Weuse the probabilisticmodel of Equation 4 as the basis for testing
whether site i is significantly enriched over the expected number
of CLIP read given the abundance of mRNA m(i).
Let r be the fraction of the rCLIP reads thatmap to site i. Note
that this fraction r is unknown, but can be estimated from the
number of CLIP reads rimapping to site i. Under theH0 hypothesis
that the site i is not enriched comparedwithwhat is expected given
the abundance of themRNAm(i), wewould have r# pi, pi being the
fraction of CLIP reads expected to map to site i given the abun-
dance of mRNA m(i). In contrast, under the H1 hypothesis that the
site i is significantly enriched over the number of reads expected
from the abundance of mRNA m(i) alone, we would have r > pi.
Note that P(H0) + P(H1) = 1.
Using Bayes’s theorem, we can compute the posterior proba-
bility of H1 from
P H1jr; rið Þ ¼ P rijr;H1ð ÞP H1ð Þ
P rið Þ ð5Þ
¼ P rijr;H1ð ÞP H1ð Þ
P rijr;H0ð ÞP H0ð Þ þ P rijr;H1ð ÞP H1ð Þ ð6Þ
¼ P rijr;H1ð Þ
P rijr;H0ð Þ þ P rijr;H1ð Þ ; ð7Þ
where we assumed that both hypotheses H0 and H1 have equal
prior probability P(H0) = P(H1). P(ri|r, H1) can be obtained from the
likelihood function introduced in Equation 4:









G r þ 1ð Þ
G ri þ 1ð ÞG r  ri þ 1ð Þ r
ri 1 rð Þrri dr ð10Þ
assuming a uniform prior on r (P(r) = 1, "r 2 [0, 1]). By applying
the same reasoning to P(ri|r,H0), one can show the denominator of
Equation 7 to be
P rijr;H0ð Þ + P rijr;H1ð Þ ¼
ð1
0
G r þ 1ð Þ
G ri þ 1ð ÞG r  ri þ 1ð Þ r
ri 1 rð Þrri dr:
ð11Þ
Finally, substituting Equations 10 and 11 into Equation 7
gives a simple expression for the posterior probability P(H1|r, ri)
that the number of CLIP reads ri mapping to site i is larger than
what would be expected given the abundance of the mRNA alone:
P H1jr; rið Þ ¼
Ð 1
pi
rri 1 rð Þrri drÐ 1
0 r




G r þ 2ð Þ
G ri þ 1ð ÞG r  ri þ 1ð Þ r
ri 1 rð Þrri dr; ð12Þ
which is the reverse cumulative probability of a Beta distribution.
To obtain binding sites, 40-nt windows are ranked by de-
creasing posterior probability first, and in the case of ties, by de-
creasing enrichment ratios rirpi
.
Extraction of functional and nonfunctional miRNA
binding sites
Data sets used in the analysis
The microarray and deep-sequencing data for the following refer-
ences were obtained from the Gene Expression Omnibus (http://
www.ncbi.nlm.nih.gov/geo/) under the accessions GSE6838 and
GSE8501 for Linsley et al. (2007), GSE14537 for Hausser et al.
(2009), GSE11968 for Baek et al. (2008), GDS1858 for Grimson
et al. (2007), GSE22004 for Guo et al. (2010), and GSE28865 for
Kishore et al. (2011). Themicroarray data fromSelbach et al. (2008)
were downloaded from http://psilac.mdc-berlin.de/download/.
Protein profiling data from Selbach et al. (2008) and Baek et al.
(2008) were retrieved from http://psilac.mdc-berlin.de/download/
and http://dx.doi.org/10.1038/nature07242, respectively. Finally,
predictions of miRNA binding sites under selection pressure are
available as flat files from http://www.mirz.unibas.ch/miRNA
targetPredictionBulk.php.
Extraction of functional and nonfunctional miRNA binding sites
from combined miRNA perturbation and microarray experiments
Among the mRNA profiling data sets that we reanalyzed, the ex-
periments performed by Grimson et al. (2007), Baek et al. (2008),
Selbach et al. (2008), and Guo et al. (2010) did not feature bi-
ological replicates. For these data sets, we considered the top 250
down-regulated mRNAs that carried precisely one canonical seed
match (7mer-A1, 7mer-m8, or 8mer [Bartel 2009]) to the trans-
fected miRNA. After discarding mRNAs with seed matches located
in the 59 UTRs, we ended up with a set of ‘‘positive’’ (functional in
mRNA down-regulation) seed matches. The negatives were ob-
tained from the 250 mRNAs whose log2 expression fold changes
were closest to 0 when comparing the miRNA-transfected samples
to the mock-transfected samples. After discarding all seed matches
located in the 59 UTRs, we ended up with a set of ‘‘negative’’ seed
matches.
For the experiments performed by Karginov et al. (2007),
Linsley et al. (2007), and Hausser et al. (2009), which featured bi-
ological replicates, we applied a method that we designed for
selecting transcripts that, with high probability, are affected in
expression by the miRNA across all experiments in which the ex-
pression of the given miRNA was perturbed. The method was de-
scribed previously (see the Supplemental Material of Hausser et al.
2009). Briefly, we first calculated, for each pairwise microarray
comparison (referred to as contrast) k, the probability Pk(f | ) that
a transcript that is not a target will have a log fold change of f.
To estimate the distributions Pk( f | ) we assumed that they are
Gaussian with means mk and standard deviation sk. Further as-
suming that transcripts that do not carry at least a heptameric seed-
complementary site are unlikely to be real targets, we estimated mk
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out such seedmatches.We similarly calculated, for each contrast k,
a distribution Pk(f | +) that a transcript which is a true target of the
miRNA will have a fold change f. Not knowing the distribution of
the severity of the effect that miRNAs have on the expression of
their targets we assumed as little as possible about the distribution
Pk(f | +), namely that a true target must change expression in the
right direction, i.e., f < 0 for a miRNA overexpression experiment,
and that expression changes are limited to a finite range over
which the expression change has a ‘‘uniform’’ distribution. Finally,
based on these distributions, we estimated the posterior probabil-
ity that a transcript with fold change f was a functional target in
a given experiment.
To obtain nonfunctional binding sites, we selected those
transcripts with the smallest sum of squared log2 fold changes in
the biological replicates. Finally, for the purpose of comparing the
properties of functional and nonfunctional sites, we proceeded as
with experiments where no replicates were performed:We selected
250 functional sites and 250 nonfunctional sites according to the
criteria defined above and we discarded those cases in which the
seed match was in the 59 UTR.
Extraction of functional and nonfunctional sites from ElMMo predictions
From our predictions of miRNA target sites under evolutionary
selection (Gaidatzis et al. 2007) and for each of the experimentally
tested and evolutionarily conserved miRNAs (hsa-miR-30a-5p,
hsa-let-7c, hsa-miR-155-5p, hsa-miR-1, hsa-miR-103-3p, hsa-miR-
15a-5p, hsa-miR-16-5p, hsa-miR-106b-5p, hsa-miR-20a-5p, hsa-
miR-141-3p, hsa-miR-200a-3p, hsa-miR-181a-5p, hsa-miR-124-3p
and hsa-miR-17-5p), we selected the top 250 target sites in the
order of their posterior probability of being under selection. We
also selected an equal number of sites least likely to be under se-
lection, i.e., that had the smallest posterior probability of being
under selection. This procedurewas applied to the 39UTR andCDS
ElMMo miRNA target site predictions separately.
Extraction of functional and nonfunctional sites from CLIP experiments
of Kishore et al. (2011)
The 40-ntwindowswere sorted by decreasing posterior probability,
and, in the case of ties, by decreasing enrichment in CLIP reads
(see ‘‘mRNA site extraction from EIF2C2 CLIP experiments’’ in
Methods). We only kept windows with exactly one canonical seed
match (7mer-U1, 7mer-m8, or 8mer [Bartel 2009]) to one of the top
10 expressed miRNA families in HEK293 cells. These top 10 fami-
lies were determined from readsmapping tomiRNAs in the EIF2C2
MNase CLIP experiments, as described in Kishore et al. (2011) and
were hsa-let-7a-5p, hsa-miR-103-3p, hsa-miR-106a-5p, hsa-miR-
10a-5p, hsa-miR-15a-5p, hsa-miR-19a-3p, hsa-miR-25-3p, hsa-miR-
30a-5p, hsa-miR-320a, hsa-miR-7-5p. Functional 39 UTR binding
sites were obtained from the top 250windows located in the 39UTR
while nonfunctionalmiRNA binding sites were defined as the 250
windows with weakest enrichment. Finally, CDS binding sites
were obtained in a similar fashion from windows located in coding
domains.
Properties definition and computation
For data sets in which the effect could not be unambiguously at-
tributed to a single site (all data sets other than those derived by
CLIP and comparative genomic analysis), we only analyzedmRNAs
that had precisely one canonical miRNA seed match (7mer-A1,
7mer-m8, or 8mer). In addition, we only considered sites that were
at least 100 nt away from the 59 and 39 ends of the mRNA. For each
individual putative target site we then computed 32 sequence and
structure properties, described indetail in the SupplementalMethods
and Hausser et al. (2009).
Enrichments in the number of genes co-targeted in the CDS
and in the 39 UTR
To determine whether individual miRNAs tend to target the same
genes in the CDS and in the 39UTRmore than expected by chance,
we determined, for each miRNA, the number c11 of genes con-
taining at least one of the top 250 CDS and at least one of the 250
top 39 UTR binding sites predicted by ElMMo. These numbers are
reported in the ‘‘genes targeted both inCDS and39UTR’’ columnof
Supplemental Table 2. In addition, we also determined the number
c10 of genes containing at least one of the top 250 CDS binding
sites, but not any of the 250 predicted 39 UTR binding sites. Simi-
larly, we determined the number c01 of genes containing at least
one of the top 250 predicted 39 UTR binding sites but none of the
top 250 predicted CDS binding sites.
Under the hypothesis thatmiRNAs target the CDS and 39UTR
independently, we expect a fraction c11 + c01n
c11 + c10
n of all mRNAs to be
co-targeted in the CDS and in the 39 UTR, where n = 18,430 is the
number of representative mRNAs used in the analysis. We define
the fold enrichment in the number of co-targeted mRNAs as the
ratio between the observed fraction of co-targeted mRNAs c11n and
the expected fraction of co-targeted mRNAs under the model that
miRNAs independently target the CDS and the 39UTR c11 + c01n
c11 + c10
n .
The ‘‘co-targeting fold enrichment’’ reported in Supplemental
Table 2 is defined as
nc11
c11 þ c10ð Þ c11 þ c01ð Þ
and we use Fisher’s test to assess whether the obtained ratio is
significantly different from 1. The Bonferroni-corrected P-values
are reported in the last column of Supplemental Table 2.
Statistical evidence that CDS and 39 UTR co-targeting occurs
mostly for miRNAs that preferentially target 39 UTRs
To test for a statistical link between the tendency of individual
miRNAs to co-target the CDS and 39 UTRs of the samemRNAs and
their preference for CDS vs. 39 UTR targeting, we first selected n =
62 miRNAs that showed significant enrichment in the number of
co-targeted mRNAs, as described in the previous section. These
miRNAs had an average excess of m = 585.7 predicted binding sites
in the 39 UTR. From the standard deviation s = 589.5 between the
individual 62 miRNAs, we can compute a Z-score for the tendency






which indicates a strong preference for 39 UTR targeting. Further
assuming that the preferences for CDS vs. 39 UTR targeting are
Gaussian distributed, we can compute the P-value (P < 1015) that
miRNAs that co-target mRNAs in the CDS and in the 39 UTR are
mostly found among miRNAs that preferentially target 39 UTRs.
Acknowledgments
We thank Nitish Mittal for valuable input in the design and anal-
ysis of the reporter experiments as well as members of the Zavolan
and Filipowicz lab for comments and discussions. We also thank
Antonio Giraldez andMiler Lee for sharing the processedmRNAseq
and RPF zebrafish sequencing data. Work on this project was
supported by the Swiss National Science Foundation Grant
#31003A_127307 to M.Z. B.B. was supported by aWerner Siemens
fellowship.
Author contributions:M.Z. and J.H. designed the research, J.H.
and B.B. performed analyses, A.P.S. performed the experiments,
Function of CDS-located miRNA binding sites
Genome Research 613
www.genome.org
Cold Spring Harbor Laboratory Press on June 29, 2016 - Published by genome.cshlp.orgDownloaded from 
50
A.P.S. and J.H. analyzed the data, J.H. and M.Z. wrote the paper
with the help of B.B. and A.P.S.
References
Alexiou P, Maragkakis M, Papadopoulos GL, Reczko M, Hatzigeorgiou AG.
2009. Lost in translation: An assessment and perspective for
computational microRNA target identification. Bioinformatics 25:
3049–3055.
Audic Y, Omilli F, Osborne HB. 1997. Postfertilization deadenylation of
mRNAs inXenopus laevis embryos is sufficient to cause their degradation
at the blastula stage. Mol Cell Biol 17: 209–218.
Baek D, Ville´n J, Shin C, Camargo F, Gygi S, Bartel DP. 2008. The impact of
microRNAs on protein output. Nature 455: 64–71.
Bagga S, Bracht J, Hunter S, Massirer K, Holtz J, Eachus R, Pasquinelli AE.
2005. Regulation by let-7 and lin-4 miRNAs results in target mRNA
degradation. Cell 122: 553–563.
Balatti V, Maniero S, Ferracin M, Veronese A, Negrini M, Ferrocci G, Martini
F, Tognon MG. 2011. MicroRNAs dysregulation in human malignant
pleural mesothelioma. J Thorac Oncol 6: 844–851.
Bartel DP. 2009. MicroRNAs: Target recognition and regulatory functions.
Cell 136: 215–233.
Bazzini AA, Lee MT, Giraldez AJ. 2012. Ribosome profiling shows that miR-
430 reduces translation before causing mRNA decay in zebrafish. Science
336: 233–237.
Be´thune J, Artus-Revel CG, Filipowicz W. 2012. Kinetic analysis reveals
successive steps leading to miRNA-mediated silencing in mammalian
cells. EMBO Rep 13: 716–723.
Bhattacharyya SN, Habermacher R, Martine U, Closs EI, FilipowiczW. 2006.
Relief of microRNA-mediated translational repression in human cells
subjected to stress. Cell 125: 1111–1124.
Brodersen P, Sakvarelidze-Achard L, Bruun-Rasmussen M, Dunoyer P,
Yamamoto YY, Sieburth L, Voinnet O. 2008. Widespread translational
inhibition by plant miRNAs and siRNAs. Science 320: 1185–1190.
Bushati N, Cohen SM. 2007.microRNA functions.Annu Rev Cell Dev Biol 23:
175–205.
Chi SW, Zang JB, Mele A, Darnell RB. 2009. Argonaute HITS-CLIP decodes
microRNA-mRNA interaction maps. Nature 460: 479–486.
David R. 2012. miRNAs’ strict schedule. Nat Rev Mol Cell Biol 13: 340–341.
Djuranovic S, Nahvi A, Green R. 2012. miRNA-mediated gene silencing by
translational repression followed by mRNA deadenylation and decay.
Science 336: 237–240.
Eulalio A, Huntzinger E, Izaurralde E. 2008. Getting to the root of miRNA-
mediated gene silencing. Cell 132: 9–14.
Fang Z, Rajewsky N. 2011. The impact of miRNA target sites in coding
sequences and in 39UTRs. PLoS ONE 6: e18067.
Filipowicz W, Bhattacharyya S, Sonenberg N. 2008. Mechanisms of post-
transcriptional regulation by microRNAs: Are the answers in sight? Nat
Rev Genet 9: 102–114.
Forman JJ, Legesse-Miller A, Coller HA. 2008. A search for conserved
sequences in coding regions reveals that the let-7 microRNA targets
Dicer within its coding sequence. Proc Natl Acad Sci 105: 14879–14884.
Forrest ARR, Kanamori-Katayama M, Tomaru Y, Lassmann T, Ninomiya N,
Takahashi Y, de Hoon MJL, Kubosaki A, Kaiho A, Suzuki M, et al. 2010.
Induction of microRNAs, mir-155, mir-222, mir-424 and mir-503,
promotes monocytic differentiation through combinatorial regulation.
Leukemia 24: 460–466.
Fulci V, Colombo T, Chiaretti S,MessinaM, Citarella F, Tavolaro S, Guarini A,
Foa` R, Macino G. 2009. Characterization of B- and T-lineage acute
lymphoblastic leukemia by integrated analysis of MicroRNA and mRNA
expression profiles. Genes Chromosomes Cancer 48: 1069–1082.
Gaidatzis D, van Nimwegen E, Hausser J, Zavolan M. 2007. Inference of
miRNA targets using evolutionary conservation and pathway analysis.
BMC Bioinformatics 8: 69.
Giraldez AJ, Mishima Y, Rihel J, Grocock RJ, Van Dongen S, Inoue K, Enright
AJ, Schier AF. 2006. Zebrafish miR-430 promotes deadenylation and
clearance of maternal mRNAs. Science 312: 75–79.
Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G, Vadas MA,
Khew-Goodall Y, Goodall GJ. 2008. The miR-200 family and miR-205
regulate epithelial to mesenchymal transition by targeting ZEB1 and
SIP1. Nat Cell Biol 10: 593–601.
Grimson A, Farh K, Johnston W, Garrett-Engele P, Lim LP, Bartel DP. 2007.
MicroRNA targeting specificity inmammals: Determinants beyond seed
pairing. Mol Cell 27: 91–105.
Gu S, Jin L, Zhang F, Sarnow P, KayM. 2009. Biological basis for restriction of
microRNA targets to the 39 untranslated region in mammalian mRNAs.
Nat Struct Mol Biol 16: 144–150.
Guo H, Ingolia NT, Weissman JS, Bartel DP. 2010. Mammalian microRNAs
predominantly act to decrease targetmRNA levels.Nature 466: 835–840.
Hafner M, Landthaler M, Burger L, Khorshid M, Hausser J, Berninger P,
Rothballer A, Ascano M, Jungkamp A-c, Munschauer M, et al. 2010.
Transcriptome-wide identification of RNA-binding protein and
microRNA target sites by PAR-CLIP. Cell 141: 129–141.
Hausser J, Landthaler M, Jaskiewicz L, Gaidatzis D, Zavolan M. 2009.
Relative contribution of sequence and structure features to the mRNA
binding of Argonaute/EIF2C-miRNA complexes and the degradation
of miRNA targets. Genome Res 19: 2009–2020.
He L, Thomson JM, Hemann MT, Hernando-Monge E, Mu D, Goodson S,
Powers S, Cordon-Cardo C, Lowe SW, Hannon GJ, et al. 2005. A
microRNA polycistron as a potential human oncogene. Nature 435:
828–833.
Henrion G, Renard JP, Chesne´ P, Oudin JF, Maniey D, Brunet A, Osborne HB,
Duranthon V. 2000. Differential regulation of the translation and the
stability of twomaternal transcripts in preimplantation rabbit embryos.
Mol Reprod Dev 56: 12–25.
Huang Q, Gumireddy K, Schrier M, le Sage C, Nagel R, Nair S, Egan DA, Li A,
Huang G, Klein-Szanto AJ, et al. 2008. The microRNAs miR-373 and
miR-520c promote tumour invasion and metastasis. Nat Cell Biol 10:
202–210.
Huang FWD, Qin J, Reidys CM, Stadler PF. 2010. Target prediction and
a statistical sampling algorithm for RNA-RNA interaction. Bioinformatics
26: 175–181.
Hurst LD. 2006. Preliminary assessment of the impact of microRNA-
mediated regulation on coding sequence evolution in mammals. J Mol
Evol 63: 174–182.
Jones-Rhoades MW, Bartel DP, Bartel B. 2006. MicroRNAS and their
regulatory roles in plants. Annu Rev Plant Biol 57: 19–53.
Karginov FV, Conaco C, Xuan Z, Schmidt BH, Parker JS, Mandel G, Hannon
GJ. 2007. A biochemical approach to identifying microRNA targets. Proc
Natl Acad Sci 104: 19291–19296.
Kedde M, Agami R. 2008. Interplay between microRNAs and RNA-binding
proteins determines developmental processes. Cell Cycle 7: 899–903.
KeddeM, StrasserMJ, Boldajipour B, Oude Vrielink JA, Slanchev K, le Sage C,
Nagel R, Voorhoeve PM, van Duijse J, Ørom UA, et al. 2007. RNA-
binding protein Dnd1 inhibits microRNA access to target mRNA. Cell
131: 1273–1286.
Khorshid M, Rodak C, Zavolan M. 2011. CLIPZ: A database and analysis
environment for experimentally determined binding sites of
RNA-binding proteins. Nucleic Acids Res 39: D245–D252.
Kim HD, Shay T, O’Shea EK, Regev A. 2009. Transcriptional regulatory
circuits: Predicting numbers from alphabets. Science 325: 429–432.
Kishore S, Jaskiewicz L, Burger L, Hausser J, Khorshid M, Zavolan M. 2011.
A quantitative analysis of CLIP methods for identifying binding sites of
RNA-binding proteins. Nat Methods 8: 559–564.
Krek A, Gru¨n D, Poy MN, Wolf R, Rosenberg L, Epstein EJ, MacMenamin P,
da Piedade I, Gunsalus KC, Stoffel M, et al. 2005. Combinatorial
microRNA target predictions. Nat Genet 37: 495–500.
Lanet E, Delannoy E, Sormani R, Floris M, Brodersen P, Cre´te´ P, Voinnet O,
Robaglia C. 2009. Biochemical evidence for translational repression by
Arabidopsis microRNAs. Plant Cell 21: 1762–1768.
Lee RC, Feinbaum RL, Ambros V. 1993. The C. elegans heterochronic gene
lin-4 encodes small RNAs with antisense complementarity to lin-14.
Cell 75: 843–854.
Lewis BP, Burge CB, Bartel DP. 2005. Conserved seed pairing, often flanked
by adenosines, indicates that thousands of human genes are microRNA
targets. Cell 120: 15–20.
Linsley P, Schelter JM, Burchard J, KibukawaM,MartinM, Bartz S, Johnson J,
Cummins J, Raymond C, Dai H, et al. 2007. Transcripts targeted by the
microRNA-16 family cooperatively regulate cell cycle progression. Mol
Cell Biol 27: 2240–2252.
Lund E, Sheets MD, Imboden SB, Dahlberg JE. 2011. Limiting Ago protein
restricts RNAi and microRNA biogenesis during early development in
Xenopus laevis. Genes Dev 25: 1121–1131.
Mateescu B, Batista L, Cardon M, Gruosso T, de Feraudy Y, Mariani O,
Nicolas A, Meyniel J-P, Cottu P, Sastre-Garau X, et al. 2011. miR-141
and miR-200a act on ovarian tumorigenesis by controlling oxidative
stress response. Nat Med 17: 1627–1635.
Olive V, Bennett MJ,Walker JC, Ma C, Jiang I, Cordon-Cardo C, Li Q-J, Lowe
SW, Hannon GJ, He L, et al. 2009. miR-19 is a key oncogenic component
of mir-17-92. Genes Dev 23: 2839–2849.
Ott CE, Gru¨nhagen J, Ja¨ger M, Horbelt D, Schwill S, Kallenbach K, Guo G,
Manke T, Knaus P, Mundlos S, et al. 2011. MicroRNAs differentially
expressed in postnatal aortic development downregulate elastin via
39 UTR and coding-sequence binding sites. PLoS ONE 6: e16250.
Qin W, Shi Y, Zhao B, Yao C, Jin L, Ma J, Jin Y. 2010. miR-24 regulates
apoptosis by targeting the open reading frame (ORF) region of FAF1 in
cancer cells. PLoS ONE 5: e9429.
Schnall-LevinM, Zhao Y, Perrimon N, Berger B. 2010. ConservedmicroRNA
targeting in Drosophila is as widespread in coding regions as in 39 UTRs.




Cold Spring Harbor Laboratory Press on June 29, 2016 - Published by genome.cshlp.orgDownloaded from 
51
Schnall-Levin M, Rissland OS, Johnston W, Perrimon N, Bartel DP,
Berger B. 2011. Unusually effective microRNA targeting within
repeat-rich coding regions of mammalian mRNAs. Genome Res 21:
1395–1403.
Selbach M, Schwanha¨usser B, Thierfelder N, Fang Z, Khanin R, Rajewsky N.
2008. Widespread changes in protein synthesis induced by microRNAs.
Nature 455: 58–63.
Shi W, Gerster K, Alajez NM, Tsang J, Waldron L, Pintilie M, Hui AB, Sykes J,
P’ng C, Miller N, et al. 2011. MicroRNA-301 mediates proliferation and
invasion in human breast cancer. Cancer Res 71: 2926–2937.
Siepel A, Bejerano G, Pedersen JS, Hinrichs AS, Hou M, Rosenbloom K,
Clawson H, Spieth J, Hillier LW, Richards S, et al. 2005. Evolutionarily
conserved elements in vertebrate, insect, worm, and yeast genomes.
Genome Res 15: 1034–1050.
Smrt RD, Szulwach KE, Pfeiffer RL, Li X, GuoW, Pathania M, Teng Z-Q, Luo
Y, Peng J, Bordey A, et al. 2010. MicroRNA miR-137 regulates neuronal
maturation by targeting ubiquitin ligase mind bomb-1. Stem Cells 28:
1060–1070.
Stadler B, Ivanovska I, Mehta K, Song S, Nelson A, Tan Y,Mathieu J, Darby C,
Blau CA,Ware C, et al. 2010. Characterization ofmicroRNAs involved in
embryonic stem cell states. Stem Cells Dev 19: 935–950.
Sturm M, Hackenberg M, Langenberger D, Frishman D. 2010. TargetSpy:
A supervised machine learning approach for microRNA target
prediction. BMC Bioinformatics 11: 292.
Suh M-R, Lee Y, Kim JY, Kim S-K, Moon S-H, Lee JY, Cha K-Y, Chung HM,
Yoon HS, Moon SY, et al. 2004. Human embryonic stem cells express
a unique set of microRNAs. Dev Biol 270: 488–498.
SunG, Ye P,Murai K, LangM-F, Li S, ZhangH, LiW, Fu C, Yin J,Wang A, et al.
2011. miR-137 forms a regulatory loop with nuclear receptor TLX and
LSD1 in neural stem cells. Nat Commun 2: 529.
Telford NA, Watson AJ, Schultz GA. 1990. Transition from maternal to
embryonic control in early mammalian development: A comparison of
several species. Mol Reprod Dev 26: 90–100.
Ventura A, Young AG, Winslow MM, Lintault L, Meissner A, Erkeland SJ,
Newman J, Bronson RT, Crowley D, Stone JR, et al. 2008. Targeted
deletion reveals essential and overlapping functions of the miR-17
through 92 family of miRNA clusters. Cell 132: 875–886.
Voorhoeve PM, le Sage C, Schrier M, Gillis AJM, Stoop H, Nagel R, Liu Y-P,
van Duijse J, Drost J, Griekspoor A, et al. 2006. A genetic screen
implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ
cell tumors. Cell 124: 1169–1181.
Wightman B, Ha I, Ruvkun G. 1993. Posttranscriptional regulation of the
heterochronic gene lin-14 by lin-4mediates temporal pattern formation
in C. elegans. Cell 75: 855–862.
Received February 28, 2012; accepted in revised form January 16, 2013.
Function of CDS-located miRNA binding sites
Genome Research 615
www.genome.org
Cold Spring Harbor Laboratory Press on June 29, 2016 - Published by genome.cshlp.orgDownloaded from 
52
3.2 Extended results 
To measure the effect of miRNA on mRNA and protein levels of its target with CDS-located 
binding site, a stable HEK293 cell line with inducible miR-124-3p expression was 
constructed using an episomal pRTS-1 vector. Two conserved CDS target sites (LPCAT3 and 
PSEN1) of miR-124, that showed a relatively high number of reads in AGO2-CLIP [140], 
were cloned in their native sequence context just before the stop codon of the Renilla 
luciferase in the psiCHECK-2 vector (WT) (Figure 9B & Figure 11A). As negative controls, 
constructs with mutations in the miRNA seed complementarity region were also 
generated (Mut). Mutations were generated such that the amino acid sequence was not 
changed (Figures 9C & D). Overlap extension PCR (Figure 11B) was used to clone these 
inserts at the end of the Renilla luciferase-encoding sequence. LPCAT3-psiCHEK-2 and 
PSEN1-psiCHEK-2 reporter vectors were transiently transfected in the miR124-3p stable 
cell line. miR-124-3p expression was induced with 1μg/mL DOX, and the expression was 
confirmed with  small RNA Northern blots (Figure 9A). After 24hrs, mRNA and protein 
levels were measured by qRT-PCR and luciferase assay, respectively, and compared to 
those of non-induced cells (Figure 10). The mRNA levels of the Firefly luciferase were used 
an internal control in the qRT-PCR assay. The final readout of the protein levels is the 
activity of luciferase, which was downregulated in in the cells with WT constructs, but not 
in the cells with Mut constructs. Changes in the mRNA levels were not observed except for 
the WT LPCAT3 construct, which was upregulated two-fold. We computed the change in 
translation from the difference between the change in luciferase activity and the change 
in mRNA level upon miRNA induction.  With both WT constructs translation was 
repressed, whereas with Mut constructs no translational repression was observed. The 
primers used for WT and Mut constructs, hsa-miR124-3p, DNA probe for hsa-miR124-3p, 
and qRT-PCR primers for Renilla and Firefly luciferase are listed in Tables 5 and 6. 
Figure 9: Design of the experiment to measure the effect of miR-124 on protein and mRNA levels. (A) Cells 
with an episomal hsa-miR-124 expression vector were split in a 24-well plate and induced with DOX 
53
(1μg/mL). After 24 hrs., cells were collected and small RNA Northern blot was performed. The same blot was 
hybridized with U6 snRNA probe as an internal control. (B) Short inserts containing hsa-miR-124 binding 
sites from the LPCAT3 or PSEN1 genes were cloned upstream of the STOP codon of the Renilla luciferase. (C) 
Mutant constructs were generated from the wildtype (WT) sequence of the hsa-miR-124- complementary 
site in LPCAT3 by mutating 4 positions in the seed complementary region. The mutations were designed 
such that they did not change the encoded amino acid sequence. (D) Idem for PSEN1. 
Figure 10: Translation of mRNAs with CDS-located binding sites is significantly repressed following induction 
of the cognate miRNA. We constructed a stable HEK293 cell line containing an episomal hsa-miR-124 
expression vector that can be induced with doxycycline. We also constructed two reporter psiCHECK-2 
plasmids in which wildtype (WT) miR-124 binding sites from the LPCAT3 or PSEN1 genes were inserted 























































































with 3-4 point mutations in the binding site (Mut). At time t=0h, cells were transfected with one of the 
plasmids and doxycycline was added to the medium to induce hsa-miR-124 expression. The Figure shows 
log2 fold changes in luciferase activity measurements and mRNA levels (quantified by qRT-PCR) 24h post-
transfection in DOX-induced cells vs non-induced cells. Changes in translation were estimated from the 
difference between changes in protein levels and changes in mRNA levels. Error bars represent Standard 
Errors of the Mean (SEM) from three independent experiments with three technical replicates each. The 
luciferase activities of cells transfected with WT plasmids were repressed for both constructs (p < 10−8, one-
sided t-test) while cells transfected with Mut plasmids were not (p > 0.18). Furthermore, mRNA levels were 
unaffected (p > 0.60) except in the WT LPCAT3 construct whose expression was upregulated approximately 
two fold. In both WT constructs, translation appears to be repressed (p < 10−11 for LPCAT3, p = 0.036 for 
PSEN1) while repression is lost with both Mut plasmids (p > 0.26). 
Figure 11: Methodology for cloning CDS-located miRNA binding sites in the Renilla luciferase gene just 
before stop codon. (A) psiCHECK-2 vector backbone showing its essential elements and the point where the 
CDS inserts were cloned. (B) Schematic representation of overlap extension PCR method with the primers 
used.  4 different PCRs were carried out to amplify various fragments from the vector and the CDS insert. 
Then, in the subsequent two PCRs (PCR4 and PCR5), all the fragments amplified from PCRs1 to 3 were 
joined, and restriction digestion of the final PCR product and psiCHECK-2 vector followed, ligation of the 
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digested fragments, transformation and screening of the clones to isolate the one with the insert at the right 
spot were carried out. 
Table 5. List of primers used to amplify the primary-miR-124-3p sequence, which was eventually sub-cloned in 
pRTS-1 vector. DNA probe used for the hybridization of hsa-miR124-3p on the Northern blot. Primers used for qRT-
PCR to detect Renilla luciferase (hRluc) and Firefly luciferase levels (hFluc). 
hsa-miR124-3p PCR primers 








hFluc-RT-for TGCAGAAGATCCTGAACGTG hFluc-RT-rev  
CGGTAGACCCAGAGCTGTTC 
hRluc-RT-for   TCGTCCATGCTGAGAGTGTC hRluc-RT-rev   
CTAACCTCGCCCTTCTCCTT 
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Table 6. The List of primers used in the construction of wild type and mutant reporters with CDS-located miRNA 






For1 ins GCGTGCTGAAGAACGAGCAGCTTGGCCACATCTTCTTCCTG 




Mutant for AGCCTACTATTCATACTACCGTACATTCACAAAGCAATGGTGCC 






For1 ins GCGTGCTGAAGAACGAGCAGACCATAGCCTGTTTCGTAGCCA 




Mutant For TAGCCATATTAATTGGT TTG TGT TTG ACATTATTACTCCTTGCCA 
Mutant Rev TGGCAAGGAGTAATAATGTCAAACACAAACCAATTAATATGGCTA 
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4. General Methods
The experiments in the above-mentioned studies mainly focused on DOX-inducible, stable 
miRNA-expressing HEK293T cell lines and luciferase reporter systems. The establishment 
of inducible miRNA cell lines was based on the pRTS-1 vector [142] (reverse transactivator 
silencer-1), which is an episomal vector with a size of 18.4kb that harbors a Tet regulatory 
system. It has a reverse tetracycline controlled transactivator (rtTA2s-M2) and a Tet 
repressor (tTSKRAB). The presence of both repressor and activator makes this vector more 
robust with low background and high inducibility with doxycycline. A bi-directional 
promoter Ptetbi-1 allows simultaneous expression of an enhanced green fluorescence 
protein (eGFP) and a luciferase gene. In the absence of doxycycline, tTSKRAB repressor 
downregulates the expression of both genes by binding to Ptetbi-1, whereas doxycycline 
relieves this repression and facilitates the binding of rtTA2s-M2, which in turn activates 
Ptetbi-1promoter, leading to the expression of the two genes flanking the promoter. pRTS-
1 contains the hygromycinB gene as a mammalian selection marker and ampicillin as a 
bacterial resistance marker. SfiI restriction enzyme sites flank the luciferase gene, allowing 
generation of non-cohesive ends [142, 152]. In our pRTS-1 construct, the luciferase 
cassette was replaced by the pri-miRNA of interest through SfiI restriction sites. The pri-
miRNA sequence was initially PCR amplified and cloned into the pGEMT-Easy cloning 
vector (Promega). The insert was sequenced and subsequently sub-cloned into the pRTS-1 
expression vector. The HEK293T cell line was transfected with pRTS-1 construct using 
liopfectamine 2000 (Invitrogen). 24 hours post-transfection, 100µg/ml of hygromycinB 
(Calbiochem) was added to allow selective propagation of pRTS-1 positive clones. Several 
distinct foci of positive clones were grown separately in 24 well culture plates until 
confluent enough to be seeded in a 6 well plate. These were subsequently transferred to 
10cm dishes and maintained in 50µg/ml of hygromycinB as required or cryopreserved. 
The whole process of establishing a stable cell line took 8-10 weeks. Clones were tested 
for the miRNA expression by Northern blots upon induction with doxycycline (Sigma-
Aldrich) as shown in Figure 4.  
On the other side, to study the effect of these miRNAs on its targets, a dual luciferase 
vector psiCHECK-2 (Promega) was used. psiCHECK-2 vector (Promega) expresses both 
Firefly and Renilla luciferase from two different loci. miRNA-regulated 3’UTRs of interest 
were cloned downstream of the Renilla luciferase, while the Firefly luciferase serves as a 
normalization control. To study the kinetics of miRNA mediated gene regulation, 3' UTR 
sequences with binding sites for miRNAs of interest were cloned in the multiple cloning 
site of the psiCHECK-2 reporter vector. The optimal amount of plasmid DNA to be used in 
the transfection for the luciferase assay was determined. Furthermore, a stable HEK293T 
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cell line has been generated that simultaneously expresses a miRNA and its target using 
these vector systems. Since the psiCHECK-2 vector lacks a mammalian selection marker, 
the psiCHECK-2 vector with cloned 3'UTRs was co-transfected with the mammalian 
selection vector pPUR (Clontech) with puromycin (0.75µg/ml) as a selection marker. This 
co-transfection was done in stable cell lines of pRTS-1 expressing miRNAs and allowed the 
psi-CHECK-2 reporter vectors to integrate stably within the HEK293T genome. Selection of 
clones stably hosting pRTS-1 and pSICHECK-2 was done exactly as described above. 
To study the functional properties of CDS-located miRNA binding sites a stable HEK293 cell 
line with inducible hsa-miR-124-3p was established using the same methodology as 
described above.  The cloning of CDS targets with miRNA binding sites just before the stop 
codon of Renilla luciferase in psiCHECK-2 vector was based on the overlap extension PCR 
method (Figure 11).  All plasmid DNA transfections were performed with lipofectamine 
2000 reagent as per the manufacturer’s protocol, whereas the miRNA mimics were 
reverse transfected with lipofectamine RNAi max as per the manufacturer’s protocol. 
Standard molecular cloning methods were followed [153]. The small RNA Northern was 
performed as previously described [154], with a minor change: we used the conventional 
TBE buffer instead of an MOPS- NaOH buffer.
5. General conclusions
In general, miRNAs are essential post-transcriptional regulators, which influence biological 
processes from cellular differentiation to the development of the various tissues [119-
121]. However, the mechanisms through which miRNAs regulate gene expression remain 
insufficiently understood. So far, focus in the field has been on canonical targets, that 
match perfectly the miRNA 5’ end, but recent technological advances revealed many 
functional targets with non-canonical sites, which typically show modest changes in their 
mRNA and protein levels when miRNA expression is perturbed, albeit more modest [155]. 
A relatively un-appreciated aspect has been that miRNA kinetics is important in the 
interpreting experimental results, and that the mode of miRNA delivery, transfection of 
miRNA mimics, microinjections of siRNAs and induction of miRNA expression plays an 
appreciable role. Proper experimental design is essential, because, as we have shown, the 
interpretation of the data is not trivial, and should take into account the time scale of 
miRNA kinetics. Such variations add another layer of complexity in understanding the 
miRNA mediated gene regulation. Compared to transcription factors, miRNAs were 
regarded as fast regulators of gene expression. This is because the activity of transcription 
factors requires additionally protein synthesis [156]. In the study “ timescales and 
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bottlenecks in miRNA dependent gene regulation”, using a variety of both high and low-
throughput experiments, that involved transfection of miRNA mimics, microinjection of 
siRNAs and induction of miRNA expression from inducible stable cell lines, we have 
inferred several parameters of miRNA kinetics and formulated a mathematical model of 
miRNA dependent gene regulation.  Based on the analyses derived from this model, we 
propose that miRNAs may not be acting so rapidly due to major bottlenecks of the miRNA 
pathway.  From recent studies it appears that the kinetics of miRNA action is mainly 
dependent on the levels of AGO, which is a limiting factor in cells [157], and as miRNAs 
function as part of complexes with AGO proteins, displacement of miRNAs from AGO 
should occur for other miRNAs to come into action. Therefore our analysis indicates that it 
is the overall AGO loading process that plays a main role in setting the time scale of 
miRNA-dependent gene regulation. The other bottleneck derived from this model is the 
rate with which target proteins are degraded. From the analysis of the experimental data 
in which both levels of mRNA and protein were measured after miRNA transfections, we 
observed that changes in the mRNA levels were more profound than changes in proteins. 
This indicates that on the time scale of miRNA activity (miRNAs being typically transfected 
in these experiments) and the slow rate of protein decay buffers the effect of the miRNA. 
Thus, the full extent of protein downregulation is not reached before the transfected 
miRNAs are degraded. The model that we derived will further help in designing 
experiments to identify miRNA targets and characterize miRNA function.  
Studies based on the data generated from high-throughput approaches like CLIP indicate 
that CDS sites are as many as those of 3’UTRs [138, 140]. Yet the functionality of these 
sites is still questioned because at least at the mRNA level, their impact seems to be small. 
In our study “Analysis of CDS-located sites miRNA targets sites suggests that they can 
effectively inhibit translation”, we have analyzed a variety of data sets that included 
mRNA [131, 132, 158-160] and protein expression profiling [131, 132] after miRNA 
transfections, and AGO-CLIPs [161] to characterize putative miRNA target sites in CDS 
regions. We have employed the ElMMo model [126], which was described before and is 
considered to be one of the most accurate methods for predicting miRNA target sites to 
identify putative target sites in both CDS and 3’UTR regions. A subsequent comparative 
analysis revealed that both 3’UTR and CDS sites are under evolutionary selection pressure, 
and the properties that were found to characterize functional 3’UTR sites also 
characterized the functional CDS sites. Furthermore, target sites in CDS and 3’UTR regions 
possess similar properties. In particular, they are both located preferentially in U-rich and 
structurally accessible environments characterize functional miRNA sites irrespective of 
their location in 3’UTR or CDS. We also proposed that several miRNA families, including 
those expressed in embryonic context, induce strong effects by acting both on 3’UTRs and 
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CDS sites. Among these are miRNA families that are expressed highly in embryonic cells. 
Our comparative analysis based on the number of genes containing high-scoring 3’UTR 
and CDS sites revealed a significant number of genes that were co-targeted in 3’UTR and 
CDS regions suggesting that miRNAs can functionally co-target 3’UTR and CDS sites.  Upon 
analysis of mRNA and ribosome profiling data, for the first time our analysis revealed that 
CDS-located miRNA binding sites are more effective in inducing translational repression 
than the sites in 3’UTRs. We validated this observation with other data sets as well as 
using psiCHECK2 dual luciferase reporter system. Although more work is needed to 
understand the role that the position of miRNA-complementary sites has in their function, 




6. Tissue specific splicing regulators promote
somatic cell reprogramming 
6.1 Introduction 
Mammalian development starts with fertilization that involves the fusion of two 
transcriptionally silent and morphologically distinct gametes to form a totipotent zygote. 
The term “totipotent” denotes the competence to give rise to an entire organism 
including the extra-embryonic tissues. The single cell zygote undergoes several divisions to 
form a 8-16-cell morula [162, 163]. It is at this stage when the first lineage restriction 
occurs: the morula compacts, polarizes and transforms into a blastocyst that consists of 
two distinct cell populations: the trophectoderm (TE), an outer layer of epithelium 
surrounding the blastocyst, and the inner cell mass (ICM). Just before the implantation of 
the embryo, the ICM undergoes another lineage segregation giving rise to a primitive 
endoderm (PE) cells and epiblast cells. The PE separates the fluid-filled cavity called 
blastocoel from epiblast, which forms as a cluster of cells at one side of the blastocyst. 
Cells of this ICM-derived cluster are competent to give rise to cells of all three germ layers 
(mesoderm, ectoderm and endoderm) and hence called pluripotent or embryonic stem 
cell (ESC)s [164].  
The lineage segregation during the formation of blastocyst arises from robust 
transcriptional regulatory events, which are themselves due to specific transcription 
factors (TFs).  Both in vivo and in vitro studies showed that the octamer binding 
transcription factor 4 (OCT4, encoded by Pou5f1 gene) is essential in the maintenance of 
ESC pluripotency, whereas the caudal type homeobox protein 2 (CDX2) is essential for the 
maintenance of the TE cell lineages [165-167]. Just before the formation of the blastocyst, 
these two TFs act upon each other through a positive feedback mechanism whereby the 
expression of CDX2 terminates the expression of OCT4 and vice versa. From gene 
expression and lineage-tracing experiments it has become apparent that early ICM cells 
are in fact two distinct population, expressing the homeobox TF NANOG and GATA binding 
factor 6 (GATA6) [168], respectively. GATA6-expressing cells form PE [169] and NANOG 
acts to maintain the pluripotency of ICM [170].  Studies of the TEA-domain family member 
4 (TEAD4) null mutant embryos have shown that Tead4 TF is associated with upstream 
mechanisms driving CDX2 expression [171, 172].  A schematic representation of the early 
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lineage segregations during the blastocyst formation and origin of ESCs is shown in Figure 
12. 
Figure 12: Early lineage differentiation during the embryogenesis under the control of transcription factors. 
(A) During the 8 to 16 cell morula stage of the embryogenesis, the overlap of the transcription factors CDX2 
and OCT4 is seen, (B) which later together determine the first lineage restriction of the cells into either 
trophectoderm or inner cell mass respectively. This is followed by the formation of the blastocyst with 
trophectoderm forming the outer layer of cells and ICM residing at one side of the blastocyst. (C) During the 
early blastocyst, a second lineage restriction results in the formation of epiblast and primitive endoderm, 
with the activation of NANOG and GATA6 transcription factors. (D) During the late blastocyst stage, GATA6 
positive cells form the surface layer of the ICM called primitive endoderm and NANOG cells facilitate in the 
maintenance of pluripotent epiblast cells. Concept of the image is adapted from Arnold et al. [164].
6.1.1 Pluripotent stem cells - Origins and properties 
It was in the year 1970 that a striking observation was reported from two different groups. 
Namely, that early mouse embryos, when grafted in extrauterine or ectopic sites such as 
under kidney produced malignant teratocarcinomas or benign teratomas [173, 174]. 
Teratocarcinomas are multidifferentiated tumors with substantial populations of 
undifferentiated stem cells called embryonal carcinoma (EC) cells. Spontaneous 
occurrence of teratocarcinomas originating from germ cells, such as testicular 
teratocarcinoma was much more common in strain 129 mice. 
When isolated clonally and propagated in cultures, EC cells retained their differentiation 
potential, and they were also involved in the formation of embryos when implanted in the 
ICM of the blastocyst, being capable of producing the derivatives of ectoderm, mesoderm 
and endoderm [60]. However, because EC cells showed some chromosomal aberrations, 
possessed poor differential potential or could only differentiate under certain 
circumstances and, most importantly, due to their incompetence to undergo meiosis to 
produce mature gametes, they were less amenable for experimental analyses [175]. 
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Eventually, by culturing EC cells on feeders of mitotically inactivated mouse embryonic 
fibroblasts (MEF), researchers were successful in maintain these cells in culture for longer 
time periods [176]. It was in the year 1981 when Evans and Martin, with different 
approaches, succeeded in establishing ESC lines directly from the ICM of the early 
blastocyst without the need to produce teratocarcinomas [177, 178].   
Evans’s laboratory further demonstrated that ESCs are more consistent and competent in 
producing viable mice when injected in the blastocysts [179]. ESCs are also able to 
differentiate into various somatic cell types in vitro [180] and Nagy and colleagues showed 
in 1991 with a tetraploid complementation assay that ESCs alone are sufficient to 
generate entire fetus. In this assay ESCs are injected in a tetraploid embryo, in which 
tetraploid cells only contribute to the extra embryonic tissue, whereas ESCs contribute to 
the development of the embryo eventually giving rise to a viable mouse [181, 182]. The 
co-culture of ESCs on feeder layers was long considered essential for indefinite expansion 
and for the maintenance of the undifferentiated phenotype. However, it was later shown 
that feeders could be replaced by the addition of a single cytokine, leukemia inhibiting 
factor (LIF) in the media.  LIF is a member of interleukin (IL)-6 family of cytokines that acts 
through a membrane-bound gp130 receptor to activate a downstream signaling process, 
in which tyrosine kinase janus (JAK) activates and recruits the latent transcription factor 
signal transducer and activator of transcription3 (STAT3) [183]. Other molecular signals 
triggered by LIF lead to the activation of two other signaling pathways: the 
phosphatidylinositol 3-kinase (PI3K) mediated pathway and the mitogen activated protein 
kinase (MAPK) pathway. These converge on the activation of the core pluripotency 
regulating TFs OCT4, SOX2 and NANOG through different mechanisms.  STAT3 activates 
Kruppel like factor 4 (KLF4), a positive regulator of Sox2 gene and the concurrent 
activation of PI3K pathway lead to the activation of a gene, which encodes a TF TBX3, 
which further activates the Nanog gene. The MAPK pathway activated by LIF-signaling is 
known to act on Tbx3 and Nanog genes [184]. The serum that is required during ES cell 
derivation and clonal expansions can be replaced by a growth factor called bone 
morphogenetic protein (BMP)4, which is functional in the presence of LIF [185] . Cell 
surface markers such as stage specific embryonic antigen (SSEA)-1 in mouse or SSEA4 in 
human ESCs, membrane bound receptor gp130, as well as enzymatic activities such as 
alkaline phosphatase (AP) and telomerase, define the molecular basis of ESCs [186].  In 
vitro culture of mouse primordial germ cells in presence of fibroblast growth factor 
(FGF)2, lead to the conversion of these cells into cells that were largely indistinguishable 
from ESCs known as embryonic germ (EG)cells. One important characteristic of EG cells is 
that they retain the capacity of parental germ cells to erase imprints [187].  
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Induction of pluripotency in somatic cells constituted a big landmark in both 
understanding the principles of pluripotency and the use of this technique towards 
therapeutics. Somatic cell reprogramming was first achieved through a technique called 
somatic cell nuclear transfer (SCNT). The technique, introduced by John Gurdon in 1962, 
involved the transfer of an adult nucleus from an intestinal cell to an enucleated oocyte. 
This generated a swimming tadpole, although it was not clear that the organism indeed 
developed from the adult nucleus [188]. This was proven later, by the transfer of the 
nucleus from an antibody producing lymphocyte [189].  This technique was successfully 
used by Ian Wilmut to clone a sheep in 1997 [190]. Other landmark discoveries of 
reprogramming were generated by the work on Drosophila, wherein overexpression of 
the Antennapedia (ANTP) TF induced the formation of legs instead of antennae [191]. In 
the same year, another work showed the transformation of fibroblasts to myoblasts when 
a muscle specific TF MyoD was overexpressed in fibroblasts [5].   A more recent and 
practical method of inducing pluripotency was introduced by Shinya Yamanaka in the year 
2006 and is considered to be a groundbreaking discovery of the recent times [4]. The 
method involves ectopic expression of four embryonic stem cell transcription factors 
(OCT4, SOX2, KLF4 and c-MYC) in somatic cells. This reprogramming method was first 
employed in mouse fibroblasts, thus reprogrammed cells resembled mouse ESCs. They 
were called induced pluripotent stem cell (iPSC)s. A year later Yamanaka and colleagues 
reported the same phenomenon in human somatic cells [192]. At the same time James 
Thomson came up with a different set of factors (OCT4, SOX2 NANOG and LIN28), which 
were also able to induce pluripotency in human dermal fibroblasts [193]. 
6.1.2 Induced pluripotent stem cells 
Based on the previous studies based on SCNT, Yamanaka hypothesized that it is a 
combination of transcriptional regulators that is expressed in oocytes or ESCs, and is 
responsible for the reprogramming of somatic nuclei or somatic cells. Searching for such 
combinations, Yamanaka and colleagues ended with a set of four embryo-specific TFs: 
OCT4, SOX2, KLF4 and c-MYC. This combination is now known as OSKM or Yamanaka 
cocktail. Overexpression of these TFs reprogrammed mouse embryonic and adult 
fibroblasts to cells that resembled ESCs and were called induced pluripotent stem cell 
(iPSC)s [4, 192, 193]. Compared to other approaches for obtaining pluripotent cells, the 
iPSC approach is relatively simple and reproducible. However, its efficiency is relatively 
low. iPSCs are also not hampered by the same ethical barrier as embryonic tissues, 
enabling studies of developmental processes and holds great potential for translational 
research. At the beginning, iPSC induction involved retroviruses or lentiviruses. This is a 
problem for translational applications because there is the risk of insertional mutagenesis. 
Nonetheless, the approach can be used in studies that will lead to a thorough 
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understanding of the mechanisms underlying pluripotency induction, which in turn will 
enable the development of safer and more efficient methods. This part of the thesis 
describes my work towards understanding the role of splicing factors and miRNAs in 
increasing the efficiency of pluripotency induction in somatic cells. I will first review the 
current state of knowledge concerning the molecular mechanism of pluripotency 
induction. 
6.1.3 Transcription factors OCT4, SOX2, KLF4, MYC, and NANOG 
The TFs OCT4, SOX2 and NANOG play a central role in sustaining the pluripotency of both 
human ESCs (hESCs) and mouse ESCs (mESCs) cells. They regulate transcription of a broad 
spectrum of pluripotency-related target genes and by auto regulating their own 
expression. The genomic organization of Oct4, Sox2 and Nanog and the structural domains 
of these proteins are conserved between mouse and human. OCT4, encoded by Pou5f1 
gene, is a homeodomain transcriptional regulator of the POU (Pit, Oct, Unc) family that 
regulates expression of its targets by binding to an octameric sequence motif 
“ATGCAAAT”.  The OCT4 protein consists of three domains: N-terminal domain, POU 
domain, and a C-terminal domain. The POU domain consists of two structurally 
independent subdomains, an amino terminal POU specific (POUS) domain and a carboxyl 
terminal homeodomain (POUHD), which both bind to DNA in a helix-turn-helix structure 
connected by a linker [194].   Inhibition of OCT4 expression by RNAi in both human and 
mouse ESCs resulted in the differentiation toward trophoblast and endoderm cells [195, 
196].  Although expression of OCT4 is important in the lineage commitment of epiblast, its 
expression is not sufficient for the maintenance of pluripotency phenotype of ESCs.  
Rather, it has been shown that ESCs expressing constitutive Oct4 are dependent on LIF 
and tend to differentiate as normal ESCs do [167], thus suggesting that there are other 
intrinsic and extrinsic factors required in the maintenance of pluripotency. 
Along with OCT4, the Sex determining region Y-box2 (SOX2) TF is considered a defining 
factor for ESCs. SOX2 contains the DNA-binding high mobility group (HMG) domain. SOX2 
mutant embryos die at the implantation stage, and a normal expression of SOX2 gene is 
necessary for the self-renewal of both human and mice ESCs. Knockdown or 
overexpression of SOX2 results in hESC differentiation [197]. NANOG is also one of the TFs 
to play an important role in maintaining ESC pluripotency. NANOG is a homeodomain 
protein, whose expression is one of the characteristic markers of ESCs. NANOG has several 
functional elements, which help in transactivation: the centrally located homeodomain, 
and the three C-terminal elements C-terminal domains (CD)1, CD2 and a tryptophan (W) 
repeat [198]. Overexpression of Nanog enables ESCs to maintain their ES cell phenotype 
even in the absence of LIF.  It is the W-repeat localized in between CD1 and CD2 involved 
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in NANOG protein dimerization, which helps in the maintenance of ESCs pluripotency in 
the absence of LIF [199]. The CD2 transactivation element is necessary for the 
maintenance of self-renewal property of ESCs [200]. 
Kruppel like factor 4(KLF4), a member of the Kruppel-like family of zinc finger transcription 
factors, is expressed in a variety of tissues and plays an important role in processes like 
proliferation, terminal differentiation, apoptosis and development. KLF4 can act as an 
activator or repressor of gene expression, depending on the cellular context, and it acts as 
well as an oncogene or tumor suppressor [201]. The expression of Klf4 is high in 
undifferentiated ESCs, and decreases dramatically during differentiation. Because over 
expression of Klf4 is sufficient for ESC to maintain their undifferentiated phenotype in the 
absence of LIF, Klf4 is considered a direct target of LIF [202]. Similar to KLF4, the 
Myelocytomatosis oncogene (c-MYC) also has context-dependent, acting as an activator 
or repressor of the transcription and playing important role in proliferation, cell growth, 
differentiation and apoptosis [203]. Knockout of c-MYC leads to malformation of different 
organs and reduced embryo size [204]. Although it was shown that KLF4 and c-MYC were 
important in the self-renewal of ESCs, they do not seem to be uniformly required. For 
example KLF4 could be replaced with ESSRB, an orphan nuclear receptor, in the 
reprogramming of mouse embryonic fibroblast [205] and NANOG and LIN28 were used 
along with OCT4 and SOX2 to reprogram human fibroblast to iPS cells [193].  
The transcription factor trio OCT4, SOX2, and NANOG is the core pluripotency network, 
which maintains the expression of a broad spectrum of targets including TFs, genes 
involved in signaling pathways and miRNAs responsible for self-renewal and pluripotency. 
To identify these targets, a recent study used biotinylated chromatin immunopreciptation 
(ChIP) to identify target genes whose promoters were occupied by more than one TF. This 
study also concluded that the genes with binding sites for 5 different TFs have a tendency 
to be active and the genes bound by only few TFs are repressed in ESCs [206]. In addition, 
OCT4 and SOX2 have been shown to act in conjunction on several targets that are 
involved in ES cell pluripotency. OCT4 binds to SOX2 to form a heterodimer that activates 
Sox2, Pou5f1 and Nanog transcription, while NANOG regulates the transcription of Pou5f1 
and Sox2 genes [207-210].  In another key study using ChiP-sequencing, mapping of 13 
different TF’s binding sites involved in ESC pluripotency maintenance and somatic cell 
reprogramming revealed two major clusters: OCT4-SOX2-NANOG cluster and MYC- 
specific cluster, wherein each TF from one cluster occupied their own and each other’s 
genomic targets forming a complex regulatory network.  For instance OCT4-SOX2-NANOG 
co-occupy regulatory elements in the Stat3 and Smad1 genes, which are the downstream 
targets of LIF and BMP4 signaling. The latter two factors regulate in turn Oct4, Sox2 and 
Nanog. Several groups used both expression and TF footprinting to define the interactions 
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that are important for pluripotency. For example, by knocking down the expression of 
POU5F1, generating microarray data, and comparing them with already available 
knockdown of POU5F1 data, a study revealed 137 orthologous genes which were 
downregulated in both human and mouse ESCs, with about half of these targets being 
conserved and possessing binding sites for either OCT4 or NANOG [211]. Through ChIP 
coupled with DNA microarrays a study revealed that OCT4-SOX2-NANOG form feed-
forward loops which include at least 353-protein coding and 2 miRNA genes. Feed-forward 
loops are gene expression regulator networks with a regulator controlling the expression 
of another regulator, as well as of targets that are jointly targeted by the tow regulators. 
When the two regulators have the same effect on their common targets, the loops are 
called consistent, while when the regulators have opposite effect, the loops are called 
incoherent [210]. OCT4-SOX2-NANOG TFs form pluripotency regulatory networks with 
miRNAs by occupying the promoters of 55 miRNA transcription units, including three 
polycistronic clusters [212].  
6.1.4 Methods to generate iPSCs 
In their initial iPSC study [4], Takahashi and Yamanaka found an efficiency of 0.02% of iPSC 
formation, 14-21 days post transduction with retroviruses individually expressing OSKM. 
In the following year, Yamanaka’s lab reported a similar efficiency of 0.02% after 30 days 
post transduction in human dermal fibroblasts [192]. James Thomson and colleagues 
reported similar efficiencies of 0.03-0.05 in fetal fibroblasts and 0.01% in the newborn 
foreskin fibroblasts at 20 days post-lentiviral transduction with a different set of genes, 
OCT4 SOX2, NANOG and LIN28 [193].  
One of the major concerns from the initial experimental designs was the use of four 
individual viral vectors that may have lead to suboptimal results. Thus, a single 
reprogramming cassette containing the four reprogramming factors separated by self-
cleaving peptides was introduced [213]. To overcome the problem of stable viral 
integration in the host genome, a Cre-Lox system was used. In this system the 
reprogramming factors are flanked by loxP sites, which lead, upon Cre expression, to the 
excision of the transgene cassette. This method was first successfully used in cells from 
patients with the Parkinson’s disease, at an efficiency of 0.5% [214]. Other approaches 
included the use of adenoviruses, which are non-integrating, but this method further 
dropped the efficiency of the technique to 0.001-0.0001% in mouse and to 0.0002% in 
human cells [215]. RNA viruses such as the Sendai virus, which does not enter the nucleus, 
were also used at an efficiency of 1%. However, but this approach has the disadvantage of 
lengthy passaging (10 passages) needed to dilute the viruses in cells, Furthermore cells 
have to be grown at high temperatures [216].  Use of reprogramming factors as purified 
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proteins was also reported but with an efficiency of 0.006% in mouse and 0.001% in 
human. This was technically challenging, because it required purification of large amounts 
of bioactive proteins, able to cross the plasma membrane [217]. Other reprogramming 
methods that do not involve viruses used instead episomal plasmids [218] and mini circles 
[219] but they were both reported to have relatively low efficiency, ranging from 0.001 to 
0.005%. 
With mature mRNAs of the reprogramming factors in human fibroblasts, an efficiency of 
1.4% was achieved. The further addition of LIN28 in presence of valproic acid (VPA) gave 
an efficiency of 4.4% but the method was considered to be labor intensive [220].  PiggyBac 
vectors, which can be integrated and excised with the expression of transposase enzyme 
and doxycycline inducible promoters, were also proposed [221]. Small molecules, which 
act on different signaling pathways involved in the reprogramming process or epigenetic 
modifications, were also used to enhance the efficiency of the method. For example, VPA 
and sodium butyrate inhibit the activity of histone deacetylase, while vitamin C enhances 
the activity of epigenetic modifiers such as histone demethylases Jhdm1a/1b [222]. 
Addition of several embryo-specific miRNAs to OSKM factors enhanced reprogramming 10 
to 15 fold. Mimics of miR-302b and miR-372 were transfected along with lentiviruses 
expressing OSKM to enhance reprogramming efficiency in human fibroblast cells [223]. 
Recently, it has also been reported that the miR302/367 cluster is sufficient to reprogram 
the fibroblasts without the addition of OSKM factors.  This study further claimed an 
increase in efficiency by two orders of magnitude [224].  
One of the major concerns in these experiments is that large variations are expected, 
because the expression of the reprogramming factors is difficult to control. Thus, to 
facilitate studies in the field, secondary systems were developed. The secondary 
reprogramming systems evolved from individual OSKM vectors [225] to polycistronic 
OSKM vectors [213]. Rudolf Jaenisch’s group pioneered this type of systems and proposed 
various approaches to generate them. In this type of systems, a polycistronic-
reprogramming cassette with a doxycycline-inducible promoter is introduced by gene 
targeting in ESCs that constitutively express other components required for the induction 
such as rtTA (reverse tetracycline transactivators) or iPSCs are obtained with inducible 
viral vector systems. The transgenic ESCs or iPSCs thus generated, with integrated 
inducible OSKM cassettes, are further used to obtain chimeric animals from which 
secondary somatic cells are isolated. Upon the addition of doxycycline, reprogramming 
factors are expressed in the transgenic cells to eventually reprogram these cells [213].  A 
recent study published a new transgenic mouse line wherein a doxycycline inducible Cre-
recombinase and inducible polycistronic OSKM transgene is inserted in Rosa26 locus 
[226]. Use of such systems strongly reduced heterogeneity and lead to 25- 50-fold 
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increase in the efficiency of pluripotency induction compared to primary reprogramming 
systems [227].  
6.1.5 Phases of somatic cell reprogramming 
Reprogramming is a dedifferentiation process, in which the ectopic expression of OSKM in 
the right stoichiometry leads to changes in the transcriptional and epigenetic status of the 
somatic cells and eventual acquisition of the undifferentiated state and self-renewing 
ability. Studies of gene expression along the time course of reprogramming revealed three 
phases of reprogramming and two major transcriptional waves [228, 229]. The first 
transcriptional wave is driven by c-MYC/KLF4 and the second transcriptional wave is 
driven by OCT4/SOX2/KLF4. Cells that do not reprogram fail to initiate second 
transcriptional wave, but an elevated expression of OSKM can direct these cells towards 
pluripotency. In the initial transcriptional wave the bivalent domains of gene expression 
are also gradually established [229].  Studies of the initial transcriptional phase revealed 
that cells assume stochastically one of the possible cell fates: apoptosis, senescence, 
transdifferentiation or reprograming [230].  The cells that initiated reprogramming 
undergo increased proliferation, changes in histone marks, activation of DNA repair, and 
initiate mesenchymal to epithelial transition (MET). OCT4 downregulates the epithelial to 
mesenchymal transition (EMT) regulator Snai1/2 via TGFβ2 and TGFβR3, whereas OCT4 
and SOX2 activate the miR-200 cluster of miRNAs, which in turn represses another EMT 
regulator Zeb2 subsequently facilitating MET. The MET process is assessed based on the 
expression of cadherin 1 (Cdh1) and epithelial cell adhesion molecule (Epcam) [231]. 
Besides MET, ESC-like proliferation is also acquired during the early phase of 
reprogramming [232]. In general, c-MYC enhances the transcription of proliferation-
related genes, and a recent study showed that c-MYC acts as a general amplifier of the 
gene expression contributing to the first transcriptional wave [233]. On the other hand 
KLF4 is known to assist c-MYC in enhancing transcription by jointly binding to promoter 
regions [228]. OCT4 and SOX2 are mostly known to bind to distal elements of both active 
and repressed genes. OSK factors also known to open chromatin regions to activate the 
genes responsible for the maintenance of pluripotent state whereas c-MYC only facilitates 
this process [234]. To look for further changes occurring in the early phase of 
reprograming, several groups also proposed to follow the loss of cell surface markers such 
Thy1 and CD44 and gain of SSEA1 and alkaline phosphatase [229, 235].  
The second phase of reprogramming is less understood, but it is believed that during this 
phase, pluripotency related genes are activated to facilitate the activation of core 
pluripotency network. KLF4 assists OCT4 and SOX2 in the activation of glycolysis and 
transient activation of developmental genes [229].  This phase has less transcriptional 
70
changes, but some of the pluripotency genes detected during this phase are Fbxo15, Sall4, 
endogenous Oct4, embryonic cell transcription factor (Utf1), followed by Nanog and 
oestrogen related receptor beta (Essrb) [228]. In general single cell transcriptomics and 
other techniques like clonal analysis indicate that the pluripotency associated genes are 
activated in a sequential way, some during the second phase as mentioned above, and 
others like Sox2 and surface marker ICAM1 in the late, maturation phase [230, 235]. At 
the end of this phase, expression of Sox2 and developmental pluripotency associated 2 
(Dppa2) genes are stabilized and changes in the DNA methylation occurs [229, 236]. After 
the activation of Sox2, the events involved are more deterministic. Other major changes at 
the end of this phase include the silencing of the transgenes. The cells then transit into the 
final phase, with little dependence on the transgene expression [236]. 
The final stabilization phase denotes changes in iPSCs after the acquisition of pluripotency. 
The iPSCs are then further expanded and tested by blastocyst injection or other in vitro 
differentiation assays. Stabilization also involves epigenetic changes such as telomere 
elongation and resetting of the epigenetic memory, but some bias towards the somatic 
cell type of origin remains [237, 238]. In support of these different phases of 
reprogramming, a quantitative proteomics analysis of fibroblast reprogramming revealed 
that proteome changes occur mainly at early 3 days and last 3 days of reprogramming. In 
the early phase, proteins related to cell cycle, metabolism, RNA processing and chromatin 
organization were strongly induced, whereas the EMT-associated protein were oppositely 
regulated between early and late phases of reprogramming [239]. Figure 13 shows the 
representation of the different phases observed during somatic cell reprogramming. 
6.1.6 Epigenetic changes during reprogramming 
During reprogramming, the epigenome of the cells has to change as well to reach a state 
similar to that characteristic of ES cells. Epigenetic changes occur at the level of chromatin 
remodeling, histone modifications and DNA methylation. Chromatin structure plays an 
important role in the establishment of specific expression patterns responsible for a 
specific cellular identity.  Essential structural changes in chromatin state make biding sites 
accessible for OSK factors, which act in a cooperative manner, binding of one factor 
destabilizing nucleosomes, thereby allowing other transcription factor to access sites 
which were hindered earlier [240]. Although OSK factors individually can target sites in the 
closed chromatin as well, the ability of c-MYC to access sites in closed chromatin is 
dependent on OSK occupancy. In turn, MYC facilitates the binding of OSK to the target 
sites present in closed chromatin [234]. Depletion of Mbd3, a core member of the 
Mbd3/NuRD (nucleosome remodeling and deacetylation) complex in concert with OSKM 
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transduction results in synchronized and deterministic reprogramming of both mouse and 
human cells [241].   
Figure 13:  Phases of somatic cell reprogramming. In general, major changes during reprogramming are 
observed during the initiation phase where a first transcriptional wave occurs and at the late maturation 
phase, with a second transcriptional wave. In the initiation phase, high proliferation of cells, accompanied by 
the activation of mesenchymal to epithelial transition occurs. Changes in the histone marks of the 
differentiation genes begins, which prepare them to become silent, and de novo changes in the chromatin 
marks of the pluripotency genes, prepares them to get activated during the later phases of reprogramming. 
Upon the overexpression of reprogramming genes, stochastic activation of gene expression leads a cell to 
adapt any of the various phenotypes such as apoptotic, senescent, transformed, and induced towards 
epithelial phenotype. Several pluripotency specific surface markers such as SSEA1 and CD44 are also 
detected in the early phase. The cells that engage on the reprogramming path pass through a long latent 
intermediate phase, wherein the stochastic activation of pluripotency and developmental genes occurs. In 
the late maturation phase, more deterministic changes occur in the pluripotency network after the 
activation of Sox2 and developmental gene DPPA2. These lead to the activation of the endogenous core 
pluripotency network. Changes in the chromatin marks of pluripotency genes facilitate the transcriptional 
activation of these genes. In the last phase, expression of pluripotency genes is stabilized, the epigenetic 
status is reset to the pluripotent state which can be maintained independent of transgene expression. 
Concept of the image is adapted from Buganim et al. [242]. 
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Covalent modifications of histone proteins also alter the chromatin structure. Various 
histone-modifying enzymes such as histone methyltransferases, histone 
acetyltransferases, histone demethylases and histone deacetylases regulate different 
histone marks. The expression changes in the early phase of reprogramming are confined 
to genes with active chromatin marks such as H3K4me3, and H3K4me2. These chromatin 
marks appears de novo during early phase in many promoter regions of the pluripotency 
genes such as Sall4 and fibroblast growth factor 4 (Fgf4), which are enriched for OCT4 and 
SOX2 binding sites [243]. The gain of H3K4me2 mark occurs on the nucleosome that 
covers the transcriptional start site, blocking the assembly of the transcriptional 
machinery. The depletion of the nucleosome after the acquisition of the active mark 
allows the transactivation of these genes later in reprogramming [234]. Chromatin 
changes at enhancers are considered to be more prominent in the early stages of the 
reprogramming and the active marks H3K4me1/2 and H3K27Ac surround both the 
promoters and enhancers of the pluripotency related genes [243]. H3K4 methylation is 
catalyzed by a complex involving the histone methyltransferase Set/M11, which is a 
homologue of Trithorax group (TrxG) proteins [244]. Removal H3K4 methylation perturbs 
reprogramming, whereas knockdown of a demethylase Kdm5b, which is responsible for 
the demethylation of active H3K4me1/2/3 enhances reprogramming efficiency [245]. 
Other active histone marks include H3K36me1/2, and H3K79. Global reduction of these 
marks also enhances reprogramming and a study showed that overexpression of the 
H3K36me2 demethylase Jhdm1b along with OCT4 is sufficient to reprogram somatic cells 
[222]. H3K27me3 is associated with gene silencing, but when co-localized with H3K4me3, 
it marks bivalent domains. Bivalent domains are observed at elevated levels in the 
pluripotent stem cells and the genes with these domains can be quickly turned on when 
H3K27me3 is erased, whereas can be silenced upon the erasure of H3K4me3. 
Downregulation of somatic genes during early stages of reprogramming is mediated by 
the Polycomb repressive complex (PRC)2 that trimethylates H3K27. Loss of PRC2 
components diminishes reprogramming efficiency [230]. H3K9 is another repressive 
chromatin mark that is associated with reprogramming via PRCs. Knockdown of H3K9 
methyltransferases such Ehmt2, Setdb1, Suv39h1/2 enhances reprogramming efficiency 
[234].  
DNA methylation patterns also restrict early reprogramming. DNA demethylation starts in 
the second phase and continues until the stabilization phase of reprogramming. DNA 
demethylation occurs by two mechanisms: passive demethylation takes place during DNA 
replication and active demethylation is mediated by the oxidative activity of ten eleven 
translocation methylcytosine dioxygenase (TET) enzymes. Tet1/2/3 enzymes catalyze the 
hydroxylation of 5-methylcytosine  (5mC) to 5-hydroxymethylcytosine (5hmC), which is 
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converted to unmethylated cytosine by base-excision repair [246]. DNA demethylation 
leads to open chromatin regions, which are further accessed by TFs binding to the 
promoters of the genes involved in pluripotency. In the early phase of reprogramming 
Tet1 induces DNA hydroxylation of pluripotency related genes, leading to their 
transcriptional activation at the later phases of reprogramming [229, 243].  Tet1/2, when 
overexpressed with Nanog, promotes iPSC formation, while knockdown of DNA 
methyltransferase (DNMT)3a promotes human iPSC formation [247], suggesting that 
erasure of DNA methylation promotes the expression of pluripotency genes, which were 
silenced through hypermethylation by DNA methyltransferases in somatic  cells. 
6.1.7 miroRNAs and reprogramming 
The importance of miRNAs during development was underscored by observations that 
knock out of genes encoding proteins that are necessary for miRNA biogenesis leads to 
the embryonic lethality in mice [248]. Knock out of these factors in ESCs makes the cells 
less able to proliferate and upon induction, they cannot differentiate [119]. Small RNA 
sequencing and microarrays studies revealed that several microRNA families are 
differentially expressed in human ESCs compared to differentiated cells. The microRNA 
families that are highly expressed in human ESCs include miR-302, miR-106, miR-372, 
miR17, miR-200, and miR-195 families [249, 250]. These miRNA families have homologues 
in mice with the same nomenclature except for the miR-372 family, which corresponds to 
the miR-290 family in mice. In human ESCs the let-7 family is expressed at low level and is 
upregulated upon differentiation [250]. miRNAs can either silence or stabilize the 
pluripotency genes of the ESCs. For example, miR-134, miR-296, and miR-470 can repress 
the core pluripotency genes Oct4, Sox2, and Nanog by binding to the coding regions of 
these genes [251] and miR-145 was shown to repress the expression of Oct4, Sox2 and 
Klf4 by binding to the 3’UTRs of these genes [252]. The EMT associated miR-200 family, 
which contains 5 members, is transcriptionally regulated by c-Myc. Overexpression of this 
family of miRNAs opposes the downregulation of pluripotency factors in ESCs grown 
without LIF [253].  
The most abundantly expressed miRNA family in mouse ESCs is the miR-290 family. 
MiRNAs of this family, miR-291-3p, miR-294, and miR-295 and miR-302d, are associated 
with stem cell cycling and called embryonic stem cell cycle (ESCC) miRNAs. The Blelloch 
group has shown that this subset of miRNAs can enhance the generation of iPSCs along 
with OCT4, SOX2 and KLF4, but not in the presence of c-MYC. c-MYC binds to the 
promoters of these miRNAs which suggests that these miRNAs are the downstream 
targets of c-MYC [254]. The same microRNAs were also shown to promote the generation 
of human iPSCs [223]. The reprogramming process has to cross various roadblocks and 
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this subset of miR-290/302 family targets various pathways such as EMT, cell cycle, cell 
death and mitochondrial function at both early and later stages of reprogramming. [255].  
One such pathway is the p53 pathway, which triggers cell cycle arrest, senescence or cell 
death. During reprogramming, p53 expression is upregulated by Klf4 and c-Myc, 
presumably as an attempt of the cells to maintain their genomic stability under stress. It 
was shown that miR-138 can fine-tune the expression of p53 and promote OSKM 
mediated iPSC generation [256]. Another early pathway observed during the 
reprogramming process is MET, which is controlled by TGF beta signaling and TFs like 
Zeb1/2, Snai 1/2, and Twist 1/2 [257]. MiRNAs of the miR-200 family downregulate the 
mesenchymal specific Zeb 1/2 to promote iPSCs formation [228]. It was further 
demonstrated that the miR-290/302 family and the miR-17~92 cluster significantly 
increase the reprogramming efficiency by negatively regulating the TGF beta pathway 
[223, 258]. A study from Blelloch’s group screened 570 mouse miRNAs for their ability to 
promote iPSC generation and identified several other miRNAs such as miR-181, miR-19*, 
miR-34, miR-324, miR-451 and miR-677 that are able to promote reprogramming [255]. 
In 2011, three independent groups reported that microRNAs alone could reprogram the 
somatic cells to pluripotency. One group transiently transfected a combination of mature, 
double-stranded miR-200c, miR-302s and miR-369 miRNAs in mouse adipose stromal cells 
and after 15 days observed iPSC colonies with similar efficiency reported in the original 
article on OSKM mediated reprogramming. The same set of microRNAs also induced 
pluripotency in human adipose stromal cells and dermal fibroblasts cells 20 days after the 
first transfection [259]. The second study used only miR-302s family of miRNAs to induce 
pluripotency in human hair follicle cells. They stated that miR-302’s mediated 
reprogramming in a dose dependent system wherein an inducible system was used to 
achieve 1.3-fold higher expression than it is normally expressed in human ES cell lines. It 
was also proposed that miR-302’s suppressed four epigenetic regulators, among which 
repression of histone demethylase AOF2 lead to decreased levels DNMT1 which further 
enhanced global demethylation [260]. The same group previously reported that miR-302’s 
can induce ES cell properties in human skin cancer cells and that 86% of the gene 
expression patterns were similar to the ES cell lines [261]. 
The third study reported that the miR-302/367 cluster could alone reprogram both human 
and mouse dermal fibroblasts with an efficiency of two orders of magnitude higher 
compared to the OSKM mediated reprogramming [224]. The miR-302/367 cluster is 
located in the intron 8 of the Larp7 gene on chromosome 3 in mouse and on chromosome 
4 in human. The polycistronic cluster is transcribes to lead to expression of 5 miRNA: miR-
302a/b/c/d and miR-367. MiR-302a/b/c/d have similar 5’ end (‘seed sequence’) and only 
differ in the hexanucleotides located at the 3’end of the miRNAs [249]. This cluster was 
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initially cloned from mouse ESCs and was not detectable in adult cell lines. Quantitative 
PCR methods later supported the high expression of miR-302/367 in mouse and human 
ESCs [262].  In mouse ESCs it was shown that Oct4, Sox2 and Nanog bind to the promoter 
regions of miR-302/367, miR-290 and miR-160a/363, whereas OCT4 is bound to the same 
conserved promoter region of miR-302/367 in human ESCs [212]. It is also shown that 
OCT4 and SOX2 transactivate the miR-302/367 cluster in human ESCs and that the levels 
of miR-302/367 and OCT4 are downregulated upon differentiation [263]. In the 
reprogramming context, miR-302/367 activation by OCT4 and SOX2 occurs in different 
pathways involved in reprogramming. For example, it is shown that hsa-miR-302/367 
targets BMP inhibitors like transducer of ERBB2 (TOB2), DAZ associated proteins 
2(DAZAP2) and SLAIN motif family member 1 (SLAIN1) to promote BMP signaling which 
supports the growth of human ESCs [264]. miR-302 also promotes MET by acting on 
TGFβR2 and the Ras homologue family member RHOC, which are known to reverse the 
process of EMT [223]. In the reprogramming study of Anokye-Danso et al., it was noted 
that miR-367 and VPA are necessary for the higher efficiency of miR-302/367-mediated 
reprograming of mouse fibroblasts, whereas VPA, which target histone deacetylase Hdac2 
is not necessary and did not affect the reprogramming efficiency of human fibroblasts 
cells, which have low levels of Hdac2. However, a study failed to reprogram mouse 
fibroblasts with miR-302/367 [265] alone and also human adipose stem cells with miR-
302s [266]. Since no other reports recapitulated miRNA-only mediated reprogramming, 
one cannot yet consider miRNAs as a robust tool of reprogramming. 
6.1.8 Small molecules and reprogramming 
Several small molecules are also shown to enhance reprogramming of mouse and human 
cells. For example vitamin C (L-ascorbic acid), is an essential nutrient with antioxidant 
properties in humans, its deficiency leading to scurvy [267]. Vitamin C promotes cell 
proliferation and fibroblasts show an increase in their lifespan when vitamin C is present 
in the cell culture medium [268].  Vitamin C prevents the activation of INK4/ARF locus, 
which is an important tumor suppressor locus. Induction of this locus leads to the 
activation of the p53 pathway, which is known to be a roadblock in the somatic cell 
reprogramming [269].  This study also showed that vitamin C induces H3K36 me2/me3 
chromatin marks by regulating two histone demethylases, Jhdm1a and Jhd1mb and that 
Jhd1mb and OCT4 are sufficient to induce pluripotency in fibroblasts.  This reprogramming 
process also strongly induces expression of the miR-302/367 cluster. Jhd1mb decreases 
methylation levels of histone encompassing OCT4 binding sites in the miR-302/367 gene 
and facilitates gene expression [222]. In another study it was shown that vitamin C also 
regulates histone-demethylating dioxygenase Tet1 hydroxylase that is implicated in DNA 
demethylation. In the presence of vitamin C, Tet1 negatively regulates somatic cell 
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reprogramming by modulating MET [270]. Another molecule, TGB receptorI/activin like 
kinase 5 (Alk5) inhibitor, enhances reprogramming efficiency by acting as a cooperative 
factor to inhibit TGF beta signaling pathway and also acts as a replacement factor, which 
bypasses the use of c-MYC and SOX2 to reprogram mouse fibroblasts [271].  
6.1.9 Splicing and reprogramming 
Although alternative splicing was not extensively studied in the context of reprogramming, 
differences in isoform content between ESCs and differentiated cells have been recently 
reported. For instance OCT4, an important pluripotency factor has two isoforms, OCT4A, 
the canonical transcription factor known for its major role in the maintenance of 
pluripotency and OCT4B, which is expressed in the cytoplasm of differentiated cells and 
has unknown functions [272]. Other pluripotency factors such as Sall4 with its two 
isoforms collaborate with other factors to maintain pluripotency [273] and NANOG has 
three different isoforms that also assist in the maintenance of pluripotency with different 
efficiencies [274]. A very interesting example has been reported in the study of FOXP1 
transcripts [275] FOXP1 is part of one of the four subfamilies of forkhead box (FOX) 
transcription factors and is known to regulate the genes involved in proliferation, 
development and differentiation. In this study a highly conserved alternative splicing 
event in FOXP1 transcript was identified. The transcript, named it as FOXP1-ES, contains 
an exon variant specifically expressed in ESCs and silenced during differentiation. This 
particular exon selection modifies the sequence of amino acids in the forkhead domain 
and changes the DNA binding specificity of the transcription factor. In ESCs this spliced 
isoform of canonical FOXP1 switches the transcriptional output that stimulates several 
pluripotency genes like OCT4, NANONG, GDF3, and NR5A2, concurrently silencing the 
genes involved in the differentiation. Overexpression of this isoform promoted self-
renewal and its silencing inhibited iPSC formation. Thus alternative splicing may critically 
modify the specificity of pluripotency or differentiation-related transcription factors with 
very broad consequences for the expression profile of the cells.  
In a follow up study by the Blencowe group [276], involving an analysis of RNA-seq data 
from ESCs, iPSCs, and from differentiated tissues, revealed that the muscle blind like 
(MBNL) 1 and 2 RNA binding proteins are expressed at low level in ES and iPS cells 
compared to other cells and tissues. These proteins were hypothesized to repress ES cell-
specific exons in non-ESCs. Knockdown of these proteins in differentiated cells switched 
~half of alternative splicing pattern to ES-cell like and promoted the OSKM-mediated 
reprogramming. Conversely, overexpression of these proteins in ESCs promoted a 
differentiated cell-like alternative splicing pattern. These proteins act in part by repressing 
ESC specific FOXP1 isoform, which enhances the expression of pluripotency genes and 
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represses the genes related to differentiation. Using high-throughput RT-PCR technology, 
splicing changes that occurred upon induction of fibroblasts to pluripotency and their 
redifferentiation revealed that MBNL1 and RBFOX2 act in concert to bring about 
alternative splicing changes associated with differentiation into late mesoderm [277]. In a 
very recent report [278] it was shown that SFSR2 is the most enriched splicing factor in 
ESCs and that MBD2 is most differentially spliced with three isoforms (MBD2a and 
MBD2c). MBD2c is enriched in pluripotent cells and MBD2a in fibroblasts cells. The study 
also found that overexpression of MBD2c enhanced the reprogramming of fibroblasts. 
Furthermore, miR-302 specifically targets MBD2a in promoting reprogramming of the 
fibroblasts, which suggests that the effect of MBD2 on pluripotency is isoform specific. 
6.2. Hypothesis 
Recently, our group analyzed an extensive data set of mRNA-seq reads that were obtained 
from a somatic cell reprogramming system [279]. Strikingly, we found that splicing factors 
form one of the most significantly differentially expressed category of genes (Figure 14A). 
The majority of splicing factors are expressed at higher levels in iPSCs compared to 
fibroblasts. In particular, the expression of epithelial splicing regulatory proteins (Esrp)1, 
Esrp2 and musashi(Msi)1 was strongly upregulated during reprogramming (Figure 14B). 
Figure 14: (A) Differential gene expression analysis of mRNA-seq data sets of iPSCs and parental fibroblasts 
revealed that splicing factors are preferentially upregulated upon pluripotency induction. Note that only 
differentially expressed genes (false discovery rate ≤ 0.05) are plotted.  (B) Expression fold changes of Esrp1, 
Esrp2 and Msi1 in iPSCs compared to fibroblasts. Analysis performed by Alexander Kanitz (Zavolan lab, 
Biozentrum, University of Basel) 
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6.2.1 Esrp1/2 and Msi1 
Esrp1/2 are epithelial cell-specific splicing regulators, which were first identified from a 
high-throughput cDNA expression screen [67]. Espr1/2 are highly conserved paralogs that 
contain three RNA recognition motif (RRM) domains. Upon of induction of EMT in a 
mammary epithelial cell line ESRP1/2 expression was downregulated, which subsequently 
switched the splicing pattern in the FGFR2, CD44, CTNND1, and ENAH from epithelial to 
mesenchymal. The same switch of splicing pattern in these four transcripts was observed 
when ESRP1/2 were downregulated using siRNAs. When Esrp1 was overexpressed in 
mouse mesenchymal cells it induced the opposing changes in these four transcripts, 
leading to an epithelial phenotype [67].  Since these four transcripts have well 
documented roles in EMT [67, 280], the regulation of their isoforms by Esrp1/2 suggests 
that Esrp1/2 have a major role in the EMT process. Moreover, knockdown of Esrp1 in 
mouse ESCs increases the expression levels of core pluripotency TFs, eventually enhancing 
the self-renewal property of ESCs, while the Esrp1 knockout ESCs showed impaired ability 
in early differentiation. Interestingly, ESRP1 was found to bind to the Oct4 and Sox2 mRNA 
[281].  
MSI1 belongs to the family of musashi proteins, which are highly conserved proteins that 
are highly expressed in stem cells and cancer cells and are considered to be neural stem 
cell markers [282]. Msi1 is known to regulate a large number of targets involved in 
apoptosis, proliferation, and cell cycle. It is also a stem cell marker, which regulated the 
balance between self-renewal and differentiation status of the stem cells [283]. In a 
recent study it was shown that overexpression of Msi1 repressed the EMT process by 
inhibiting translation of an EMT factor, Jagged1.  Knockdown of Msi1 in epithelial cancer 
cells supported the loss of epithelial phenotype, suggesting that Msi1 is contributes to the 
epithelial phenotype [284]. In breast cancer cells Msi1 maintains the expression of ES cell 
specific markers c-MYC, NANOG, SOX2, BMi1, and OCT4 [285]. Finally, overexpression of c-
MYC in human breast epithelial cells lead to an increased expressed of MSI1 [283]. 
This body of evidence supported our hypothesis that splicing factors, particularly those 
with epithelial pattern of expression (Esrp1/2 and Msi1) are major players in the EMT 
process, which is part of the early phase of reprogramming. Thus, we sought to determine 
whether Esrp1/2 and Msi1 could modulate the reprogramming efficiency of somatic cells. 
Moreover, in another study we would like to decipher the mechanism underlying the 
enhancement of somatic cell reprogramming by miR-302/367 along with OSKM genes. For 
this we established the miR-302/367 mediated reprogramming and we will generate 
mRNA-seq libraries form the time course of reprogramming. 
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6.3. Methods 
6.3.1 Cell culture 
Hek 293TN (System biosciences) and Platinum-E cells were cultured in GMEM (Sigma 
Aldrich), supplemented with 10% ESC specific FCS, 1X non-essential amino acids (Sigma 
Aldrich), 1X Pen/Strep antibiotics, 1mM sodium pyruvate (Sigma Aldrich) and 0.1mM 2-
mercaptoethanol (Gibco), 2mM L-glutamine (Sigma Aldrich) and 20ng/ml of LIF (from Kaji 
lab, SCRM, University of Edinburgh). This medium is hereafter denoted as “normal 
medium”. TNG-MEFs and WT MEFs were cultured with normal medium supplemented 
with FGF-2 (5ng/ml) and heparin (1ng/ml). Reprogramming medium was composed of 
normal medium with 1µg/ml doxycycline (Sigma Aldrich), 10µg/ml vitamin C (Sigma 
Aldrich) and 500nm Alk-5i (Tocris Bioscience). 
6.3.2 Viral vectors and transductions 
A doxycycline inducible lentiviral expression vector pTetO-Fuw-OSKM (addgene ID: 20321) 
was modified as per requirement. The EcoRI flanked OSKM cassette was replaced with the 
respective mouse cDNAs of Esrp1, Esrp2, Msi1, primary miR-302/367 and Renilla 
luciferase gene using the blunt end cloning method. All four modified lentivectors are 
hereby denoted as pTetO-Fuw-cDNA. Esrp1 and Esrp2 cDNAs were PCR amplified from a 
mouse mammary gland “NMuMGg” epithelial cell line [286], primary miR-302/367 was 
PCR amplified from pCuo-302/367 vector (Biocat), and Msi1 cDNA was commercially 
synthesized by Eurofins Scientific AG. Renilla luciferase gene was PCR amplified from 
psiCHECK-2 vector (Promega AG). pTetO-Fuw-OSKM vector with OSKM insert was used as 
an empty vector infection control for few optimization experiments. The blunt end cloning 
approach is briefly described separately in this methods section. Second-generation 
lentiviral packaging plasmids were used to generate pseudo-lentiviral particles in a 
producer HEK293 cell line (System Biosciences). The packaging plasmids used were 
pCMVR8.74 (addgene ID: 22036) and pMD2.G (addgene ID: 12259). To generate pseudo-
lentiviral particles, 2*10^6 HEK293 cells were seeded in 10cm culture dishes and the 
following day, pTetO-Fuw-cDNA, pCMVR8.74 and pMD2.G were co-transfected in a ratio 
of 5:3:2μg of plasmid DNA using 25μl of Lipofecatmine 2000 (Invitrogen). 8 hrs. after 
transfection, normal medium was replaced with fresh normal medium and 48 hrs. after 
transfection, culture medium containing pseudo-lentiviral particles was harvested, filtered 
using 0.45 micron filters. Polybrene (8μg/ml, Merck Millipore AG) was added to the 
filtered lentiviral medium to facilitate transduction. 2ml of such filtered viruses were 
transduced in TNG-MEFs/WT MEFs seeded on a 0.1% gelatinized one well of a six well 
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plate. After 4 hrs. of transduction, medium containing pseudo-viral particles was replaced 
with fresh medium of interest. 
Retroviral vectors were constructed using attR1 R2 gateway cloning cassette (Invitrogen). 
Mouse cDNAs of Esrp1, Esrp2, Msi1 and Renilla luciferase gene were cloned into an entry 
pENTR2B vector (Life technologies) using EcoRI sites. After confirming the inserts free of 
mutations by sequencing (Microsynth), these inserts were gateway cloned into a pMXs 
retro-vector using LR clonase (Life technologies). To produce pseudo-retroviral particles, 
2*10^6 platinum-E cells were seeded in 10 cm culture dish and the next day 10μg of pMXs 
retro-vector with transgenes were transfected with 25μl of lipofectamine 2000. 8 hrs. 
after transfection, the medium was replaced with fresh medium. After 48 hrs. of 
transfection, culture medium containing retroviral particles was harvested, filtered 
through 0.45 micron filters. Thus filtered medium with viruses was mixed with polybrene 
(final concentration 8μg/ml) and transduced in TNG-MEFs. 4hrs after transduction, 
medium was replaced with fresh medium of interest. The primers used for cloning splicing 
factors, Renilla luciferase and miR-302/367 are listed in table7. 
6.3.3 Generation of secondary mouse embryonic fibroblasts (TNG-MEFs) 
and reprogramming method 
Most of the TNG-MEFs and WT MEFs used in this study were kindly provided by Dr. 
Keisuke Kaji. Some batches of TNG-MEFs used to optimize lentiviral transductions and 
some preliminary experiments were done in the Zavolan lab at the Biozentrum, University 
of Basel. To obtain TNG-MEFs, a transgenic Nanog-GFP embryonic stem cell line (made in 
the Kaji lab, Figure 15A) was gene targeted in the Sp3 locus with a targeting plasmid 
containing a polycistronic cassette of reprogramming genes (Vector backbone 
represented in the Figure 15B), followed by IRES-mOrange, inducibly expressing from a 
single tetO2 promoter. The construct was used by the transgenic mouse core facility, 
Biozentrum, University of Basel to obtain chimaeric embryos by blastocyst injections. 
Embryos were collected at 12.5 days post coitum (d.p.c), decapitated, eviscerated and 
individually dissociated in 0.25% trypsin-EDTA, then cultured in normal medium. One 
tenth of the cells were treated with 1µg/ml doxycycline for two days. To estimate the 
percentage of transgenic MEFs, a FACS analysis was performed based on mOrange 
expression. A schema of the method is represented in the Figure 15C 
6.3.4 Quantitative real-time PCR 
MEFs that were transduced with retroviruses or lentiviruses were harvested 4 days after 
induction of reprogramming. Total RNA was extracted using TRI reagent (Sigma Aldrich) as 
per the manufacturer’s protocol, 10µg of total RNA was subjected to DNase digestion with 
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RQ1DNase (Promega), followed by phenol-chloroform purification. 1µg of total RNA was 
used for cDNA synthesis using SuperScriptIII (invitrogen) reverse transcriptase according 
to the manufacturer’s protocol. 10ng of cDNA per sample was used to in the qRT-PCR 
reaction using Power SYBR Green PCR Master Mix (Applied Biosystems) in triplicates. 
GAPDH levels were used as internal control and the samples from non-infected controls 
were used as external controls. mRNA levels of the transgenes were measured  by Step 
One Plus real time PCR system (Applied Biosystems). Relative fold change values were 
calculated as 2−ΔΔCT [287]. Small RNA Northern was performed as described in the first part 
of this thesis. 
6.3.5 Blunt end cloning 
Since the pTetO Fuw lentivector and the entry vector pENTR used for gateway cloning had 
only EcoRI restriction site for cloning the inserts and because this restriction site was 
encoded in all of the splicing factors, we adopted the blunt end cloning approach. 2µg of 
vector was digested for two hours with EcoRI restriction enzyme, gel purified using QIAEX 
II beads (from Qiagen) and made blunt by T4 DNA polymerase and Klenow DNA 
polymerase for 30 minutes at 200C. The vector was column purified by QIAquick PCR 
purification kit (from Qiagen) followed by the dephosphorylation of the blunted end of the 
vectors by FastAP (Thermo Fisher Scientific) for 30 minutes at 370C, then at 700C for 10 
mins to deactivate the enzyme. This was followed by the column purification of the 
reaction to elute blunted-dephosphorylated vector free of reaction components. On the 
other hand, PCR products were gel purified using QIAEX beads and phosphorylated by PNK 
(New England Biolabs) in presence of 10mM ATP for 1 hour at 370C, followed by column 
purification. The column-purified blunt vector and PCR products were ligated in 1:1 ratio, 
followed by the bacterial transformation. Positive clones were screened by sequencing. 
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Figure 15: Experimental model used to study the impact of tissue specific splicing factors on OSKM mediated 
somatic cell reprogramming. (A) A Nanog-GFP embryonic stem cell line was gene targeted in Sp3 locus with 
a (B) targeting vector containing an inducible polycistronic cassette expressing MKOS genes tagged with 
mOrange and constitutively expressing reverse tetracycline transactivator protein. (C) These ES cells were 
further injected in blastocysts or formed aggregates with morula.  These transformed blastocysts or morula 
aggregated were implanted in the uterus of foster mice to obtain chimeric embryos. 12.5 dpc embryos were 
harvested and enzymatically digested to derive embryonic fibroblasts. Thus obtained transgenic mouse 
embryonic fibroblasts cells can be induced with doxycycline to express MKOS factors, which eventually 
reprogram MEFs to iPSCs. Image B was kindly provided by Dr. Keisuke Kaji. 
6.4. Results 
6.4.1 Reprogramming of TNG-MEFs 
To maintain optimal conditions of reprogramming, 3% of TNG-MEFs were seeded with 
97% 129-WT MEFs constituting up to 1*10^5 cells for each 0.1% gelatinized well of a six 
well plate. TNG-MEFs were cultured in presence of reprogramming medium for 15 days. A 
general outline of the reprogramming experiment performed in this study is shown in 
Figure 16. A day after the induction with doxycycline, mOrange expression is observed, 
which indicates the expression of MKOS genes. By day 4 TNG-MEFs are seen with high 
proliferation, transiting through MET stage. By day 8, nice colonies are seen and some of 
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them start to express GFP, which indicates de novo expression of Nanog, a pluripotency 
marker. While the GFP expression becomes apparent, simultaneous silencing of mOrange 
expression is also observed.  By day 12 most of the colonies are seen expressing GFP. 
Images of the TNG-MEFs undergoing transition into iPSCs are shown in Figure 17. By day 
15, based on the number of Nanog-GFP colonies from the experimental condition are 
compared with the number of Nanog-GFP colonies observed in the controls to determine 
the reprogramming efficiency. 
Figure 16: A schematic representation of the reprogramming experiments performed in this study.  TNG-
MEFs are seeded with WT-MEFs and are infected with viruses containing transgenes. Expression of MKOS is 
then induced with doxycycline. After induction, TNG-MEFs are grown in reprogramming medium, which is 
changed every two days. After 15 days, the reprogramming efficiency is estimated by GFP-colony counting.  
Figure 17: Microscopic images taken during the time course of reprogramming. Top panel shows the images 
for the first six days where mOrange expression was tracked. Bottom panel shows the images taken until 
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day 15, wherein expression of GFP was monitored. After the induction with doxycycline, mOrange 
expression is observed and formation of colonies begins with high proliferation. By day 8 few colonies start 
to express GFP, indicating the expression of Nanog. By day 15 stable GFP colonies are observed which can be 
counted to estimate the reprogramming efficiency between different conditions. Scale bar represents 
100µm 
6.4.2 Tissue specific splicing factors promote reprogramming 
6.4.2.1 With retroviral top ups 
To address the hypothesis that the splicing factors, whose expression levels were 
drastically changed during reprogramming, may promote the reprogramming process, we 
have overexpressed the Esrp1, Esrp2 and Msi1 in TNG-MEFs. These splicing factors were 
cloned in the retroviral vectors. TNG-MEFs and 129 WT MEFs were seeded as described in 
the above section in a well of a six well plate. The next day, TNG-MEFs were infected with 
2ml of retroviruses encoding Esrp1, Esrp2, and Msi1 genes for 4 hours, followed by the 
medium change with reprogramming medium. For all the experiments, infection of 
retroviruses with Renilla luciferase gene was used as a negative control along with non-
infection control. For each splicing factor and controls, three such wells were considered 
in the experiment, wherein cells from one well were harvested after 4days of infection to 
check the transgene overexpression by qRT-PCR, and the rest of the two wells were 
considered in the actual experiment. Transgene overexpression was observed more than 
30 fold for all the splicing factors and luciferase (Figure 18A), when compared to the 
endogenous levels of the non-infection control and GAPDH gene was used an internal 
control. Expression of mOrange and GFP were monitored throughout the reprogramming 
experiment, and at day 15, total number of Nanog-GFP colonies was counted. The average 
taken over two independent experiments conducted in two different labs showed an 
increase in the reprogramming efficiency by splicing factors. Esrp1 and Msi1 showed ~1.6 
fold, whereas Esrp2 showed ~1.9 fold increase in the number of Nanog-GFP colonies 
compared to the infected Renilla luciferase and non-infected controls (Figure 18B). No 
increase was seen with Renilla luciferase gene compared to non-infected control. This 
indicates that the tissue specific factors promote reprogramming along with cognate 
reprogramming genes MKOS. Colonies were counted manually either from the images 
taken by Celigo cell imaging cytometer or under the microscope with GFP filter. 
Representative images of Nanog-GFP colonies of a single well of a six well plate taken by 
Celigo cell imaging cytometer are shown in Figure 18C.  
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Figure 18: Tissue specific splicing factors enhance reprogramming efficiency.  TNG-MEFs infected with 
retroviruses containing Esrp1, Esrp2, Msi1 showed increased in the Nanog-GFP colony number compared to 
infected Renilla luciferase and non-infected controls. (A) Transgene overexpression was measured by qRT-
PCR from the cells with 4 days of infection with retroviruses encoding different transgenes. An 
overexpression of over 30 fold of the splicing factors and luciferase gene compared to the endogenous 
levels from non-infected controls was observed. GAPDH gene was used as an internal control and error bars 
represent ± standard deviation of the three technical replicates.  (B) Total Nanog-GFP colonies counted from 
two independent experiments of the splicing factors showed an increase of more than ~1.6 fold compared 
infected Renilla luciferase gene and non-infected controls. Error bars represent ± standard deviation of two 
biological replicates. (C) Images of single wells infected with transgenes along with non-infected controls 
taken by Celigo imaging cell cytometer showing the total number of Nanog-GFP colonies per well. 
6.4.2.2 miR-302/367 and tissue specific splicing factors promote 
reprogramming with lentiviral top ups 
An efficient way to deliver the transgenes in primary cells is through lentiviruses. 
Assuming that increasing the transgene overexpression could increase the efficiency of 
splicing factors in promoting somatic cell reprogramming, an inducible lentiviral system 
was used. To validate the lentivectors containing Esrp1, Esrp2, Msi1, and miR-302/367, 
TNG-MEFs seeded as described above were infected with these lentiviruses. TNG-MEFs 
were harvested after 4 days of induction with 1µg/ml of doxycycline for further analysis of 
transgene expression. miR-302/367 expression was validated by small RNA Northern 
(Figure 19A), whereas the relative expression levels of Esrp1, Esrp2 and Msi1 were 
measured with qRT-PCR (Figure 19B). Transgene overexpression was higher than what 
was observed with retroviruses. Lentiviruses containing splicing factors and miR-302/367 
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were transduced in the same experimental set up as described above for the 
reprogramming experiment. Lentiviruses expressing Renilla luciferase gene and non-
infected cells were used as negative controls and viruses that expressed Nanog gene were 
considered as a positive control. With miR-302/367 lentiviruses we observed ~3 fold 
increase and with Nanog about ~2.5 fold increase in the number of Nanog-GFP colonies. 
With Esrp1, there was ~1.4 fold increase in the number of Nanog-GFP colonies while with 
Msi1 ~1.6 fold increase in the number of Nanog-GFP colonies. These numbers were similar 
to what was observed with retroviruses. Esrp2 showed up to 2-fold increase in the 
increase in the number of Nanog-GFP colonies, which is slightly greater than what was 
observed with retroviruses. Graphical representation of the number of Nanog-GFP 
colonies is shown in the Figure 19C and the images taken by Celigo imaging cell cytometer 
are shown in Figure 19D.  To confirm and improve the results a better setup of lentiviral 
packaging and further repetitions of the experiment are needed. 
Figure 19: Reprogramming experiment with lentiviruses expressing splicing factors and miR-302/367. 
Transgene expression from the lentiviruses was validated from TNG-MEFs-WT MEFs infected with 
87
lentiviruses. 4 days after doxycycline induction in the TNG-MEFs infected with lentiviruses expressing miR-
302/367 were harvested and its expression was confirmed with small RNA Northern. (A) Northern blot 
showing miR-302/367 cluster expression. Lane 1 and 4 were probed with the probes specific to miR-302b 
and miR-367, lanes 2 and 3 were loaded with total RNA from the cells without induction with doxycycline. 
Top panel blot shows the expression of U6 snRNA used as loading control and bottom panel shows miR-
302b and miR-367 expression. (B) Relative expression levels of splicing factors from the TNG-MEFs infected 
with lentiviruses containing splicing factors as transgenes were measured with qRT-PCR. Relative expression 
values are represented in log2 values, GAPDH gene was used an internal control. Error bars represent the 
±standard deviation of three technical replicates (C) Total Nanog-GFP colony number counted at day 15 of 
the reprogramming experiment observed from the splicing factors and miR-302/367 along infected and non-
infected controls. Error bars represent the ±standard deviation from two technical replicates. (D) Images of 
the reprogramming experiment with splicing factors and miR-302/367 taken with Celigo imaging and cell 
cytometer. 
6.5.  Discussion 
The differential gene expression analysis of 21 human iPSCs and 7 parental fibroblasts 
mRNA-seq libraries [279] revealed that 24% of all genes and 54% of splicing factors were 
differentially expressed between iPSCs and their parental fibroblasts. Among the splicing 
factors, tissue specific splicing factors showed a striking change in their expression levels. 
Esrp1, and Msi1 were the two splicing factors which were upregulated in iPSCs with high 
expression fold changes .In contrast, muscle blind like proteins MBNL1 and MBNL2 were 
downregulated with high expression fold changes. Just after our analysis, Blencowe and 
colleagues reported that MBNL proteins are negative regulators of alternative splicing 
events that are differentially expressed between ES cells and other differentiated cells 
types, and further showed that knockdown of these proteins in secondary MEFs enhanced 
the reprogramming efficiency [276]. Given the role of Esrp1/2 and Msi1 in the EMT 
process, their association with several pluripotency genes [67, 281, 283-285], the evidence 
showing the role of splicing factors in regulating pluripotency and reprogramming [275, 
276], and our own analysis of mRNA-seq data sets, we sought to investigate the role of 
Esrp1/2 and Msi1 in reprogramming. 
To address the role of Espr1/2 and Msi1 in the reprogramming of somatic cells we first 
asked whether these factors have an impact on somatic cell reprogramming. To look into 
this aspect, we chose a secondary reprogramming model to estimate the reprogramming 
efficiency after the overexpression these splicing factors in TNG-MEFs with cognate 
reprogramming genes MKOS. Splicing factors were overexpressed using retroviruses or 
lentiviruses in TNG-MEFs and the induction of MKOS was induced with doxycycline. The 
number of Nanog-GFP colonies with Esrp1 and Msi1 was more than 1.6 fold higher 
compared to controls and with Esrp2 it was up to 1.9 fold, indicating the role of tissue 
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specific splicing factors in somatic cell reprogramming. This was confirmed from two 
independent experiments 
Since the observed difference in the expression fold changes with Esrp1 and Msi1 from 
our differential gene expression analysis was more than 1000 fold, we assumed that 
increasing overexpression efficiency of the transgenes in TNG-MEFs, would probably be a 
better experimental design. For this we tried a lentiviral system, lentiviruses being known 
to be efficient in infecting both dividing and non-dividing cells. Our preliminary 
experiments with lentiviruses were problematic due to the toxicity of the constructs for 
cells [288], which thereby showed inconsistency in the number of Nanog-GFP colonies in 
infected controls of dsRED and empty vector controls.  Further Optimization of the 
lentiviral system was carried out and reducing the infection time lead to consistent 
numbers of Nanog-GFP colonies with infected and non-infected controls. With no 
difference in the Nanog-GFP colony number between infected with Renilla luciferase and 
non-infected controls, Msi1 showed similar difference as observed with retroviruses. 
Esrp2 increased the number of Nanog-GFP colonies up to 2 fold, which is slightly more 
than 1.9 fold as observed with retroviruses. Esrp1 also showed almost similar difference 
compared to what has been seen with retroviruses. Transgene expression was not verified 
with qRT-PCR in this particular experiment and thus additional experiments with 
lentiviruses are needed. 
With the knockdown of MBNL proteins, it was shown that the reprogramming efficiency 
could be increased up to 2 fold in the secondary reprogramming system [276], supporting 
our computational analysis in which MBNL proteins were the most downregulated splicing 
factors. Thus, we believe that our data indicates that splicing factors with epithelial 
pattern of expression can improve the reprogramming efficiency, probably because they 
regulate splicing events specific to pluripotency. 
Overexpression of miR-302/367 cluster alone in MEFs was reported to reprogram MEFs to 
iPSCs with an efficiency of two orders of magnitude compared to the reprogramming with 
OSKM alone [224]. In an attempt to decipher the underlying mechanisms of miRNA 
mediated reprogramming using a time series mRNA-seq data, we tried to re-establish this 
reprogramming method in the lab, but as reported by other labs [265, 266], we also failed 
to reprogram MEFs with miR-302/367 alone. Instead, overexpressing miR-302/367 along 
with OSKM genes enhanced reprogramming efficiency as reported by others [223]. Using 
this as experimental model we aim to uncover the role of miR-302/367 in somatic cell 
reprogramming by generating and analyzing a time series of mRNA expression. 
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One of the important observations during the preliminary optimization experiments with 
lentiviruses was the bigger size of the iPSC colony with upon overexpression of Msi1 as 
shown in Figure 20. Msi1, which is also known as a self-renewing gene in neural stem cells 
[289], has the ability to increase the self-renewal ability during reprogramming of TNG-
MEFs that eventually showed the colonies with bigger size. Quantification of the number 
of cells based on pluripotency marker expression at the end of the reprogramming 
experiment would most likely indicate an even higher reprogramming efficiency with 
Msi1. This is another aspect we would like to follow up in further studies.  
Figure 20: Overexpression with Msi1 leads to a phenotype of bigger Nanog-GFP colonies. Microscopic 
images of iPSC colonies with Nanog-GFP of infected control, Esrp1 and Msi1. Lentiviruses encoding Esrp1, 
empty vector control and Msi1 were transduced in TNG-MEFs and images were taken on day 15 of the 
reprogramming experiment. Top panel shows the images taken with bright field and bottom panel shows 
the images taken with GFP filter. Scale bar represents 100µm. 
6.6.  Conclusion and future prospects 
In this study we have experimentally investigated our hypothesis that we formulated 
based on a bioinformatics analysis of mRNA-seq data obtained from iPSCs and their 
parental fibroblasts. The hypothesis that tissue specific splicing factors promote somatic 
cell reprogramming has been validated. We have used inducible secondary MEFs as our 
basic reprogramming model, and the tissue specific splicing factors were delivered via 
lentiviruses or retroviruses for their overexpression. With retroviral vectors, tissue specific 
splicing factors Esrp1, Esrp2 and Msi1 were able to promote the efficiency of TNG-MEFs 
reprogramming by over 1.6 fold and the highest improvement in efficiency, of 1.9 fold, 
was observed with Esrp2. With lentiviruses as well, Esrp2 showed the highest 2-fold 
increase, whereas Msi1 and Esrp1 showed changes similar to retroviruses of 1.6 and 1.4 
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fold. The experiments with lentiviruses will be repeated to validate the increase in 
reprogramming efficiency and to further characterize the mechanism.  
As a follow up of these preliminary results, I would like to decipher the mechanisms 
involved in the facilitation of reprogramming by tissue specific splicing factors by 
preparing the mRNA-seq libraries of the early and late time series of the reprogramming 
and analyzing this data computationally. Following the kinetics of the reprogramming 
mediated by tissue specific splicing factors with the reprogramming associated cell surface 
markers [235] would also open new avenues to splicing and reprogramming field. I also 
intend to functionally characterize the iPSCs obtained with splicing factors and OSKM 
genes by in vitro and in vivo assays. In vitro assays include alkaline phosphatase assay of 
iPSC colonies and differentiation of these iPSCs into cells of three germ layers and in vivo 
assays include teratomas assay and checking the ability of these iPSCs to form chimeric 
mice by blastocyst injections. 
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Table 7: List of primers used to clone the splicing factors, Renilla luciferase and miR-302/367 cluster in pTetO FUW 
and pMXs vectors. qRT-PCR primers used for to check the transgene overexpression. DNA probes used for miR-
302b and 367 Northern. 
Primers used for cloning into pTetO Fuw and PMXs vectors 
Gene 
Symbol 






























Primers used for qRT-PCR 
Esrp1 CCCCAGGTTCGCCTAATAGT AGTCCATCCTCGGTTGCATA 
Esrp2 TCCTACTGCCTTGGCCTCTA AGGGGCTTGTAACACAGTGC 
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